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Abstract 
Multidrug efflux pump P-glycoprotein (P-gp) has been the subject of significant 
research interest since the discovery of the protein in multi-drug resistant cancer cells 40 
years ago. Overexpression of P-gp can confer resistance to a broad range of structurally 
and functionally distinct drugs. The mechanism of this polyspecificity is poorly 
understood, yet the mechanism is known to involve a complex series of binding, 
hydrolysis and dissociation events that are coupled to an array of conformational 
changes. A wealth of biochemical data implicates TM6 & 12 as mediators of 
bioenergetic coupling in P-gp. A major issue in attempts to determine the molecular 
mechanism is the lack of a high-resolution structure of human P-gp in the basal, inward-
facing state. Several crystal structures of murine P-gp in the basal state are available, 
and molecular dynamics have been used to simulate the structure of human P-gp. Both 
of these structural models are subject to controversy. Crystallisation requires 
solubilisation of P-gp into a detergent micelle, an environment in which the protein has 
been demonstrated to be inactive; the crystal structures published to date also differ 
significantly. MD simulations are an increasingly powerful tool for predicting protein 
structure; however, these must be treated with caution when not supported by 
experimental data. 
 The present investigation determined the relative position of two transmembrane 
helices, six and twelve (TM6 & 12), by measuring the distances between residues. Site 
directed mutagenesis was used to generate nine double mutants, each containing one 
cysteine on TM6 and one on TM12. Double mutants were expressed using the 
baculovirus/insect cell expression system. Crude membranes containing P-gp were 
isolated, followed by purification by affinity chromatography. P-gp mutants were 
reconstituted into proteoliposomes; retention of function in the P-gp double mutants was 
confirmed using ATP hydrolysis assays. Inter-residue distance measurements were 
performed using intramolecular cross-linking with homobifunctional reagents and 
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double resonance EPR. Further ATP hydrolysis assays were used to determine the effect 
of intramolecular cross-linking between TM6 & 12 on the activity of P-gp. 
All the double mutants were functional, and most inter-residue distances were 
measured successfully by both techniques. The topographical map generated was 
compared to distance measurements in the crystal structures and MD simulations to 
judge whether either of these models are a good representation of human P-gp in a lipid 
bilayer. It was found that the 4M1M structure of murine P-gp is the most accurate 
representation among models derived by crystallography, while MD simulations based 
on this are closer still to experimental observations. The experimental results strongly 
suggest that the side chain orientations are accurate in the models in the membrane 
embedded portion of TM6 & 12. This investigation therefore demonstrated that 4M1M-
based structural models can be relied upon in the important membrane-integral region, 
which has been shown to be the site of drug binding. This can give greater weight to in 
silico methods for predicting molecular interactions with P-gp. Further details of the 
role of the two helices in the P-gp mechanism were added by analysis of functional 
changes in P-gp containing intramolecular cross-links between TM6 & 12. Specifically, 
the results presented here indicate that different parts of the helices require relative 
movement during drug-stimulated ATP hydrolysis in comparison to basal hydrolysis, 
suggesting that the conformational transitions of P-gp may be different in the two cases. 
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1.1 Cancer  
Worldwide there were 14.1 million new cases of cancer in 2012 and 8.2 million 
deaths from the disease. Cancer has a roughly equal prevalence in regions of high and 
low human development index, although rates for different forms of the disease vary 
(Ferlay et al. 2015). A complex array of genetic, viral, lifestyle and environmental 
influences are thought to be the aetiological factors in cancer (Hamilton and Mack 
2003; Song, Pitot, and Lambert 1999; Hisada et al. 1998). Despite the efforts of the 
scientific community, cancer remains one of the most difficult public health problems to 
prevent or treat. Mortality rates from heart disease decreased by 51% in the UK between 
2004 and 2014 (Nichols et al. 2014) which is in stark contrast to the minor changes in 
cancer. Changes in the mortality rates for cancers are complex and give rise to 
observations such as decreases for some tumour types with concomitant increases for 
some forms of the disease (Figure 1.1). The importance placed on increasing 
understanding of cancer and developing treatments means that more than $10bn US 
dollars is spent on research across public bodies and pharmaceutical companies 
annually (Jonsson and Wilking 2007).  
The main factor leading to the slow decline in mortality rates from cancer is the 
difficulty associated with treating it. There are three main types of cancer treatment 
available today, surgery, radiotherapy and chemotherapy. One strategy to reduce cancer 
mortality currently pursued by governments is increasing screening for cancer for 
certain ‘at risk’ groups, so that cancer can be treated by surgery at an early stage of 
development of the disease (Berry et al. 2005). Surgery is limited as a cancer treatment 
by the need to invasively access the site of the tumour, which can cause severe damage 
to internal organs, such as the brain or lungs; however common forms of the disease 
such as breast or prostate cancer are relatively accessible. The surgical excision of 
prostate tumours before metastasis has been shown to reduce 10 year mortality rates by 
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63% (p<0.05) compared to those not undergoing surgery (Bill-Axelson et al. 2014). 
However, the results of this study have 
 
Figure 1.1 Changes in mortality rates for the 20 most common causes of cancer death for 
Males in the UK. Percentage Change in European Age-Standardised Three-Year Average 
Mortality Rates, 2001-2003 and 2010-2012. From Cancer research UK, 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-
cancers-compared#heading-Three, accessed 02/16. 
been questioned due to hormone treatments being applied or withheld from the two 
groups (Benjamin 2014). Statistically, the increased identification and early treatment of 
breast cancers in the USA and Europe has not resulted in a decreased proportion of the 
total population dying from breast cancer (Autier et al. 2011; Fox 1979; Jorgensen, 
Zahl, and Gotzsche 2010). There are two possible explanations for this, either that many 
of the additional early stage cancers identified and treated by surgery were not life 
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threatening and would have disappeared without treatment (Morrell et al. 2010), or that 
increased medical observation and understanding of causes of death since the mid-20th 
century has led to more incidences of mortality from breast cancer being identified, and 
this is balanced out by improved survival rates. There is relative consensus between 
researchers that once cancer has metastasised surgery alone is not sufficient to reduce 
mortality, indeed some researchers have theorised that surgery promotes the growth of 
secondary tumours (Demicheli et al. 2008; Kinsey 1961).  
 Radiotherapy is defined as the use of ionising radiation to treat disease. In the 
treatment of cancer, radiation is directed to the locality of the tumour. This damages the 
DNA of cancer cells directly by ionisation, or indirectly by generating free radicals or 
reactive oxygen species which subsequently damage DNA (Baskar et al. 2014). Cancer 
cells are thought to be more sensitive than normal cells to DNA damage due to their 
rapid proliferation leaving insufficient time for DNA repair before mitosis (Baskar et al. 
2014; Bernier, Hall, and Giaccia 2004; Elkind et al. 1965). Radiotherapy is usually used 
in conjunction with surgery and/or chemotherapy; approximately 50% of patients with 
localised malignant tumours are treated with radiotherapy over the course of the disease 
(Liauw, Connell, and Weichselbaum 2013). A Randomised trial demonstrated that a 
combination of radiotherapy and insulin-like growth factor 1 receptor inhibitor 
cetuximab (monoclonal antibody), improved locoregionally advanced head and neck 
cancer 5-year survival rates to 45% in comparison to 36% with radiotherapy alone 
(Bonner et al. 2010). While radiotherapy is a useful weapon in the arsenal of 
oncologists, like surgery, it is primarily useful for treating localised cancers because the 
radiation dose is applied locally.  
1.2 Chemotherapy as a cancer treatment  
Chemotherapy is defined as the treatment of disease by chemical substances, usually 
called drugs. The key advantage of the use of chemotherapy in cancer treatment is that 
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the effect is not localised, so drugs can be used to treat systemic cancers such as 
leukaemia, or advanced metastasised cancers. There are two major types of 
chemotherapy drugs; cytotoxic compounds have been defined as agents that possess 
specific destructive action on certain cells, or that may be genotoxic, oncogenic, 
mutagenic, teratogenic or hazardous to cells in any way (Easty et al. 2015). 
Alternatively, chemotherapy drugs may be defined as cytostatic, if the drug prevents 
rapid mitosis but does not kill cancer cells directly (Rixe and Fojo 2007). All types of 
chemotherapy can be harmful to healthy cells in high doses (Corrie 2011). 
Chemotherapy often exploits the differences in cellular processes on which cancer cells 
are more reliant, and disrupt these to create a ‘therapeutic window’ permitting a dose 
which is significantly more harmful to the cancer than to the healthy cells (Corrie 2011; 
Felici, Verweij, and Sparreboom 2002). Chemotherapy is often used to exploit the 
differences between cancer cells and healthy cells relating to the rapid proliferation of 
cancer cells (Blagosklonny 2006).  
The efficacy of chemotherapy varies with the type of tumour. In some tumour 
types chemotherapy results in a large increase in survival rates; for example, patients 
with diffuse large B-cell lymphoma who undergo no treatment have a median survival 
rate of less than one year compared with greater than 5 years under a range of 
chemotherapy treatments (Flowers, Sinha, and Vose 2010). Conversely chemotherapy 
treatment is usually ineffective against non-small cell lung cancer, where decades of 
high investment in new treatments has only yielded an increase in average survival time 
from roughly 12 to 24 months (Quan et al. 2016). The stage at which tumours are 
identified also influences survival rates; average survival times for advanced cancers 
such as ovarian, lung and colorectal are approximately 1-3 years with current treatment 
options (Yoshihama et al. 2015; Pilkington et al. 2015; Gamelin et al. 2008). A major 
factor in these poor prognoses for patients is chemotherapy resistance. 
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1.3 Mechanisms of chemotherapy resistance  
 
Chemotherapy resistance can either be an intrinsic property of a specific type of cancer 
or acquired after treatment. Cancers such as colorectal carcinoma or malignant 
melanoma are intrinsically resistant to most classes of drugs, whereas breast cancers 
often go into remission early in treatment, before returning to growth (Selby 1984; 
Hammond, Swaika, and Mody 2016). The possibility for cancer cells to have intrinsic 
or acquired resistance has long been documented and studied, and over the years a 
number of mechanisms by which drug resistance functions have been identified (Shen 
et al. 1986; Kessel, Botterill, and Wodinsky 1968; Housman et al. 2014). The 
underlying reason resistance is likely to develop is that in many tumours the pathways 
for DNA quality control have been compromised, such as down-regulation or mutation 
of tumour suppressor gene p53 (Goh, Coffill, and Lane 2011). For example, targets of 
drugs may become altered by genetic mutations to reduce efficacy of anti-cancer agents. 
Paclitaxel has been shown to prevent mitosis by binding to the βIII-tubulin isotype and 
causing stabilisation of the microtubules; however, resistance can occur if βIII-tubulin is 
overexpressed or mutated to reduce affinity for the drug. This in turn renders the 
effective concentration of paclitaxel insufficient to prevent progression of the cell cycle 
(Schiff and Horwitz 1980; Lowe et al. 2001; Kamath et al. 2005). Resistance can also 
occur due to inactivation of drugs in vivo, one example of this is the acute myelogenous 
leukaemia drug cytarabine (AraC). AraC requires multiple phosphorylation events 
catalysed by deoxycytidine kinase to become activated (Sampath et al. 2006). 
Deoxycytidine kinase expression is down-regulated in several cancer types (Sampath et 
al. 2006; Stegmann et al. 1995), and this is associated with a resistance phenotype.  
Chemotherapy drug cisplatin cross-links to DNA, specifically by attachment to the 
N7 reactive centre of purine residues (Dasari and Tchounwou 2014). Cisplatin in 
solution is tetravalent with two H2O ligands which can be replaced in favour of cross-
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links to purine, thus it can cause intramolecular links between two strands of DNA, or 
intermolecular links between two adjacent purine residues; leading to disruption of 
mitosis an subsequent apoptosis (Beck and Brubaker 1973; Horacek and Drobnik 1971; 
Eastman 1987). A key resistance phenotype which has been observed is recognition of 
DNA damage by quality control enzymes such as the excision repair cross-
complementation group 1, this can become up-regulated, leading to a removal of the 
harmful cross-links (Pinto and Lippard 1985; Sherman et al. 1985; Olaussen et al. 
2006). Other forms of cisplatin resistance have also been investigated including 
selective arrest of the cell cycle to repair DNA, inhibition of apoptosis pathways and 
drug efflux (Rosell et al. 2004; Shen et al. 2012; Youn et al. 2004).  
Tumours can become resistant to dozens of structurally unrelated compounds by 
acquiring a multi-drug resistance (MDR) phenotype. MDR was defined in 1993 as the 
insensitivity or cross-resistance of cancer cells to the cytotoxic or cytostatic actions of 
structurally distinct drugs that have differing molecular targets (Gottesman 1993). 
Phenotypes discussed above such as increased DNA repair or inhibition of apoptosis 
pathways render tumour cells resistant to many drugs by preventing cell death (Gillet 
and Gottesman 2010). Another way tumours acquire MDR is overexpression of multi-
drug efflux pumps, which cause resistance by preventing drugs from accumulating to 
therapeutic levels in cancer cells (Ling et al. 1983). Three key mediators of this 
phenotype are primary active transporters of the ABC transporter superfamily, P-
glycoprotein (P-gp/ABCB1), BCRP (ABCG2) and MRP (ABCC1) (Trock, Leonessa, 
and Clarke 1997; Cole et al. 1992; Robey et al. 2001). 
1.4 Multidrug efflux and the discovery of P-glycoprotein 
 
The initial investigations of chemotherapy resistance involved exposing cancer cell 
lines to increasing concentrations of chemotherapy drugs and isolating the colonies that 
survived (Ling and Thompson 1974). Chinese hamster ovary (CHO) cells were 
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rendered resistant to colchicine using this strategy, with the expectation that the 
resistance phenotype would be due to altered binding of colchicine to its target, tubulin. 
In drug sensitive cells line, colchicine would prevent microtubule formation by binding 
to tubulin (Borisy and Taylor 1967; Brinkley, Stubblefield, and Hsu 1967). However, it 
was shown by binding of radio-labelled colchicine to protein in a cytoplasmic extract 
that the affinity of this interaction was unaffected in the resistant cell line. The 
mechanism by which these CHO cells had become resistant to colchicine was revealed 
by measuring the accumulation of the drug; [3H]-colchicine accumulated to a 30-fold 
lower concentration in resistant cell lines compared to the sensitive CHO cells.  
It was thought that the reduced colchicine accumulation of resistant cells was 
caused by a large number of genetic mutations in the cell, or a change in the lipid 
composition of the membrane rendering it less permeable. In order to determine the 
composition of the CHO membrane a series of radio-labelling reagents were employed 
which modified membrane components. Surface polypeptides were labelled by 
pyridoxal phosphate-[3H]-borohydride, or lactoperoxidase to catalyse the attachment of 
131I to tyrosine residues. The carbohydrate groups of glycoproteins or glycolipids were 
also modified by [3H]-borohydride by galactose oxidase catalysed oxidation. Labelling 
was followed by SDS-electrophoresis and scintillation counting (Juliano and Behar-
Bannelier 1975). This process was then repeated on the resistant CHO cells, and a 
170kDa protein, not present in the sensitive cell lines, was found to be highly expressed; 
it was also noted that the level of expression was strongly correlated with the degree of 
resistance across multiple lines of resistant cells (Ling and Thompson 1974; Juliano and 
Ling 1976). The resistant cells were also shown to have a reduced response to 
vinblastine and actinomycin, both of which are structurally distinct drugs with differing 
molecular targets in comparison to colchicine.    
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Membranes were isolated from resistant and sensitive cells grown in the presence 
of isotopically labelled protein and carbohydrate precursors, they were then subjected to 
electrophoresis and the radioactivity levels were analysed (Juliano 1976). The co-
localisation of isotopes introduced into the peptide and glucosamine precursors in a 
170kDa band in the resistant cells demonstrated that the newly identified protein was a 
glycoprotein. Due the specific role of this glycoprotein in preventing accumulation of 
drugs within the resistant cells it was given the name ‘permeability glycoprotein’ or P-
glycoprotein (P-gp/ABCB1). 
In 1979 P-gp was identified in human cancer cells displaying the multi-drug 
resistance (MDR) phenotype for the first time; human leukemic lymphoblasts were 
grown in the presence of vinblastine, a drug previously shown to have reduced efficacy 
in P-gp expressing cells, and again a 170 kDa glycoprotein was detected by Beck et., al 
(Ling et al. 1983; Beck, Mueller, and Tanzer 1979). It was demonstrated that there was 
a strong correlation between the degree of vinblastine resistance and the expression 
level of P-gp. A later investigation by Ling et. al. used western blotting analysis to show 
that the expression of P-gp was proportional to the degree of resistance present in cell 
lines from hamster, mouse and human sources (Kartner, Riordan, and Ling 1983).  It 
was also noted in this study that although each cell line was selected on the basis of 
resistance to a single drug, the P-gp expressing cells subsequently displayed resistance 
to a range of compounds with distinct structures (Figure 1.4) (Beck and Cirtain 1982). 
The results of this investigation made clear that the resistance phenotype caused by P-gp 
expression affects drugs with distinct molecular targets. For example reduced efficacy 
was observed after treatment with vinblastine, which prevents mitosis by reducing 
microtubule polymer mass (Jordan and Wilson 2004), Puromycin, an antibiotic which 
kills cancer cells by disrupting peptide transfer on ribosomes (Azzam and Algranati 
1973), daunorubicin, a DNA intercalating agent(Kessel, Botterill, and Wodinsky 1968; 
Kartner et al. 1983) and emetine the vomit-inducing compound which gave its name to  
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Figure 1.2: Structures of drugs to which resistance was conferred in human leukemic 
lymphoblast cells by P-gp. After generation of resistant cell lines by exposure to vinblastine (A), 
the human leukemic lymphoblast cells were also shown to be resistant to: Puromycin (B), 
daunorubicin (C), and (D) Emetine. Cells also showed resistance to further microtubule 
targeting drugs, vincristine and colchicine (structures not shown). 
emetics,and shows anticancer activity due to a variety of effects on DNA and protein 
synthesis (Cornet-Masana et al. 2016). It was therefore becoming clear that the poly-
specific property of P-gp plays a significant role in the failure of many anti-cancer 
agents. 
1.4.1 Clinical implications of P-gp expression 
 
Detection of P-gp was measured in tumour biopsies to assess its clinical 
importance. Western blot analysis was done on samples from five patients with 
A 
 
B 
C 
 
D 
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advanced ovarian cancer; two were shown to have high levels of expression of P-gp, 
and this was hypothesised to be a major contributor to failure of chemotherapy in 
ovarian cancer patients displaying a multidrug resistance phenotype (Bell et al. 1985). 
In a separate study, a DNA fragment (MDR1) cloned from resistant human KB 
carcinoma cells was independently shown to correlate with multidrug resistance 
(Roninson et al. 1986; Gros, Croop, and Housman 1986). It was subsequently 
demonstrated that cells carrying the MDR1 gene express P-gp, and that cDNAs 
encoding P-gp are able to cross-hybridize with MDR1 cDNAs. This evidence was used 
to conclude that the MDR1 gene encodes P-gp (Shen et al. 1986; Chen et al. 1986; 
Roninson et al. 1986).  
This discovery introduced the idea that chemotherapy treatment could be tailored 
based on the presence or absence of the MDR1 gene in clinical samples. In another 
early study, RNA was extracted from a variety of human tissues, tumour cell lines and 
clinical samples from patients displaying the multidrug resistance phenotype. The 
samples were analysed by western blotting to determine the P-gp expression pattern in 
healthy and cancerous tissues (Fojo, Shen, et al. 1987; Fojo, Ueda, et al. 1987; 
Thorgeirsson et al. 1987). Results of the analysis confirmed the normal physiological 
presence of P-glycoprotein in the kidneys, colon, lung, rectum and brain tissue; while 
samples from tumour biopsies demonstrated that MDR cells from Neuroblastoma, 
Pheochromocytoma, leukaemia, colon cancers and others showed expression of P-gp. 
These early investigations thus showed that P-gp is expressed in a range of healthy 
tissues, where its role was not yet defined, as well as in a range of drug-resistant 
cancers. The expression of P-gp has been correlated with significantly lower survival 
rates in acute myeloid leukaemia (AML) in patients aged over 60 treated with 
daunorubicin, a P-gp substrate (van der Holt et al. 2005). Use of P-gp inhibitors has also 
been shown to improve outcomes for younger patients with AML, when expression of 
P-gp is observed (Leith et al. 1999). A strong correlation has been drawn between 
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expression of P-gp and failure of paclitaxel treatment in ovarian cancer (Penson et al. 
2004).  
Two other proteins were discovered later which when overexpressed confer a 
similar resistance phenotype in cancer. In 1992 a gene was isolated from a doxorubicin-
selected lung cancer cell line, which was demonstrated to not express P-gp (Cole et al. 
1992). Overexpression 100-200 fold of this gene relative to the drug-sensitive parent 
cell-line was shown to result in resistance to anthracycline analogues as well as vinca 
alkaloids, as such it was designated Multidrug Resistance-associated Protein 1 
(MRP1/ABCC1) (Mirski, Gerlach, and Cole 1987; Cole et al. 1992). A further protein 
was found in anthracycline resistant breast cancer cells which did not express P-gp or 
MRP1; when transfected into sensitive cells the overexpression of this protein (termed 
Breast Cancer Resistance Protein/BCRP/ABCG2) was shown to result in a reduced 
accumulation of anticancer drug daunorubicin (Doyle et al. 1998).  
Less evidence is available in the literature for the effect of MRP1 and BCRP on 
patient prognoses. However, the presence of MRP has been established in drug resistant 
leukaemias (Legrand et al. 1998; Michieli et al. 1999; Damiani et al. 2002) and 
expression of this protein has been linked to reduced survival times in neuroblastoma 
(Goto et al. 2000). BCRP over-expression has been associated with poorer outcomes in 
AML, while patients expressing of both P-gp and BCRP having the worst chemotherapy 
outcomes when treated with drugs that are substrates of both transporters, such as 
daunorubicin and mitoxantrone (van den Heuvel-Eibrink et al. 2007; Benderra et al. 
2004). The three key mediators of multidrug resistance due to drug efflux, P-gp, BCRP 
and MRP are related not only in the resistance phenotype conferred when overexpressed 
in cancer cells, they are also members of the same family of proteins (Trock, Leonessa, 
and Clarke 1997; Cole et al. 1992; Robey et al. 2001). 
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1.4.2 Classification of P-gp as an ABC transporter 
 
The ABC superfamily was initially defined through the study of three ATP binding-
dependent protein transport systems in bacteria. In the Early 1980’s Higgins et. al. 
discovered similarities between the histidine transport system of Salmonella 
typhimurium, the E.coli maltose transporter and the oligopeptide permease of S. 
typhimurium (Gilson et al. 1982; Higgins et al. 1985; Higgins et al. 1986). Significant 
sequence identity was found between the hisP subunit of the histidine transporter, malK 
subunit of the maltose transporter, and oppD, one of the genes contributing to the 
oligopeptide permease. One region of the proteins displaying significant similarity 
included the sequence G-x(4)-GK-[TS], (now known as the Walker A motif) and the 
downstream [RK]-x(4)-G-x(4)-LhhhhD (Walker B) sequence, both of which had been 
implicated in ATP binding (Walker et al. 1982). The oppD protein was shown to have a 
functional ATP binding site by two methods: firstly it was demonstrated to bind to a 
Cibracon Blue affinity column and be eluted by ATP, an established protocol for 
purifying nucleotide binding proteins (Thompson, Cass, and Stellwagen 1975). 
Secondly oppD was shown to link to an ATP binding site specific probe 5'-p-
Fluorosulphonylbenzoyl-adenosine and it was demonstrated that this binding could be 
inhibited by the presence of ATP.  
Another conserved sequence (LSGGQ) was so common that it has been designated 
as the signature sequence of a burgeoning family of transporters. The collective was 
termed the ATP Binding Cassette (ABC) transporter superfamily (Gros, Croop, and 
Housman 1986). More than 1000 ABC proteins have now been identified by detection 
of LSGGQ sequence and the Walker A & B motifs in genes during genome sequencing 
(Decottignies and Goffeau 1997). Based on the sequence similarities, it was proposed 
that these bacterial transport systems shared a similar mechanism, coupling ATP 
hydrolysis directly to transport of substrates across a membrane (Higgins et al. 1985). 
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Sequencing of the MDR1 gene (discussed in Section 1.4.1) revealed that it contains the 
walker A & B motifs, as well as the ‘signature’ sequence of the ABC transporter 
superfamily LSGGQ (Gros, Croop, and Housman 1986). This demonstrated that P-gp 
was a member of the ABC transporter superfamily, which decreases accumulation of 
drugs by actively transporting them out of cells. A series of attempts have been made to 
find clinically viable P-gp inhibitors which can arrest the transport activity of the 
protein, in order to restore drug accumulation and thus make MDR cancers treatable.  
1.4.3 Attempts to overcome P-gp mediated drug resistance   
 
The first generation of P-gp inhibitors exploited the poly-specificity of the 
pump. These inhibitors were established drugs, perhaps the most famous were the L-
type calcium channel blocker verapamil and the immunosuppressant cyclosporine A. 
Verapamil is known as a ‘calcium antagonist’ and has been shown to blockade the 
movement of calcium and potassium ions associated with membrane polarisation in 
guinea pig heart cells (Lee and Tsien 1983). Using P-gp overexpressing K562/ADM 
(human hemo-lymphocytic) cells it has been demonstrated by photolabelling and the 
cellular accumulation of verapamil that the drug is a competitive inhibitor of P-gp 
mediated drug efflux (Yusa and Tsuruo 1989). Cyclosporine A acts as an immune 
suppressant by binding to the cytosolic protein cyclophilin, this complex in turn inhibits 
a transcription factor activator necessary for T-cell activation (Matsuda and Koyasu 
2000). Like verapamil, cyclosporine A is a competitive inhibitor of P-gp transport 
activity (Saeki et al. 1993). Despite overcoming P-gp mediated MDR, first generation 
inhibitors were limited by poor potency; doses required to inhibit P-gp caused severe 
side effects related to the original function of the drugs.  
The design of the second generation of inhibitors was a direct logical response to 
the failure of the first; namely to modify the first generation to remove the original 
cellular activity but retain the ability to inhibit P-gp (Hollt et al. 1992). PSC-833 and 
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dexverapamil were derivatives of cyclosporine A and verapamil respectively, without 
the immunosuppressant or channel blocking potency of their parent compounds 
(Palmeira et al. 2012). While the second generation compounds provided promising 
results in vitro, results of clinical trials included unpredictable pharmacokinetic 
interactions and unacceptable toxicity (Baer et al. 2002). Removal of the original 
function enabled the administration of higher doses of the inhibitors, but these 
compounds proved to have unexpected off target effects due to lack of specificity for P-
gp, and the poor-potency of the inhibitors. There were also problems related to the 
clearance and metabolism of drugs under co-administration of second generation 
inhibitors with anti-cancer agents. For example, CYP450 is involved in clearance and 
metabolism of PSC-833 as well as many chemotherapy drugs, meaning drugs were not 
cleared effectively from the patient’s system under combination therapy, leading to 
toxicity (Fischer et al. 1998; Gottesman, Fojo, and Bates 2002).  
The third generation used quantitative structure-activity relationships and 
combinatorial chemistry to develop specific and potent P-gp inhibitors (Goldman 2003; 
Krishna and Mayer 2000). One well studied third generation inhibitor is tariquidar, 
which is based on anthranilic acid (Fox and Bates 2007). This was shown to increase 
potency of P-gp substrate anticancer agents in a range of tumour types in vitro, and in 
vivo (Mistry et al. 2001). Phase I trials were promising, showing extended overcoming 
of P-gp activity, without pharmacokinetic effects but ultimately these too were 
abandoned after phase II (Stewart et al. 2000; Pusztai et al. 2005). Ultimately tariquidar, 
like other P-gp inhibitors caused toxicity and while it was able to increase the uptake of 
a P-gp substrate into tumours, this did not lead to an increased response to 
chemotherapy in most patients (Pusztai et al. 2005).  
The challenges detailed in this section emphasise the need for new indirect 
strategies for overcoming MDR caused by P-gp. Attempts are underway to exploit 
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differences in expression pathways between P-gp in the barrier tissues and in cancers in 
order to selectively knock-down expression of the transporter in tumours (Kang et al. 
2004). Other researchers are looking to exploit ‘Collateral Sensitivity’ (CS) of MDR 
cells, i.e. develop drugs which are selectively toxic to MDR cells (Hall, Handley, and 
Gottesman 2009). CS agents target processes related to the development of MDR, 
turning a resistance phenotype into a weakness (Szybalski and Bryson 1952). For 
example, P-gp expression can exploited to kill MDR cells using CS agents which are P-
gp substrates, these can lead to ‘futile cycling’ as the CS agent continually diffuses into 
the cell and is pumped out by P-gp, requiring large quantities of ATP. The cellular rate 
of oxidative phosphorylation is increased to replace ATP, generating larger amounts of 
cytotoxic reactive oxygen species, leading to cell death (Karwatsky, Lincoln, and 
Georges 2003). Another potential route is to prioritise the design of new chemotherapy 
drugs which are not substrates of P-gp, or to modify existing anti-cancer drugs which 
are P-gp substrates, to reduce transport by P-gp (Perego et al. 2001). In silico methods 
have been used to predict which compounds will be substrates of P-gp (Seelig 1998b, 
1998a). In order to enhance these predictions a high resolution structure is needed, 
which accurately represents which residues are involved in drug binding (Srivalli and 
Lakshmi 2012).  
1.5 Landmarks in the study of P-gp structure 
 
As described in Section 1.4.1, The MDR1 gene was cloned into sensitive cells to show 
that this gene encodes P-gp (Ueda et al. 1987), and as mentioned in Section 1.4.2, 
comparison of this gene to bacterial proteins identified P-gp as a member of the ABC 
superfamily (Gros, Croop, and Housman 1986). Gros et. al. also demonstrated that P-gp 
contained 12 hydrophobic domains, presumed to be transmembrane helices (TMs) 
(MacLennan et al. 1985; Paul and Rosenbusch 1985; Chen et al. 1986). These TMs 
were observed to be closely clustered in the primary sequence into two groups of six, so 
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these were postulated to be arranged as two transmembrane domains (TMDs) each 
containing six helices (six-plus-six). Internal duplication in the sequence of the MDR1 
gene, of regions containing the Walker motifs, indicated that the protein contained two 
nucleotide binding domains. These predictions, together with the order of the predicted 
domains in the sequence (and the later confirmed assumption that the nucleotide 
binding domains would be located on the intracellular side of the membrane) meant that 
a basic topographical map for P-gp could be made (see figure 1.3). This model also 
contained possible sites (N-x-T/S) for the glycosylation originally shown by Ling et. al.; 
the functional number of these and the putative orientation of the ATP binding sites 
within the NBDs were altered by subsequent investigations. 
 
  
 
 
 
 
 
 
 
1.5.1 The topology of P-gp 
 
The prediction of P-gp topology (Figure 1.3) was eventually shown to be remarkably 
accurate by the crystal structures of ABC transporters, and topographical studies using 
P-gp mutants. Initially there was controversy over whether all the regions originally 
TMD 1-6 TMD 7-12 
NH2 
COOH 
ATP 
Figure 1.3: Basic topological map of P-gp. Adapted from Gros et. al. 1986 (Gros, Croop, and 
Housman 1986). Transmembrane domains (TMDs) are numbered, possible sites of N-Glycosylation 
shown with filled circles. The labels ‘OUT’ and ‘IN’ denote the extracellular and intracellular leaflets 
of the plasma membrane, respectively. 
OUT 
IN 
ATP 
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identified as potential transmembrane helices (Gros, Croop, and Housman 1986; 
Gerlach et al. 1986; Chen et al. 1986) were actually inserted into the membrane and 
whether all the potential glycosylation sites were actually glycosylated. In order to 
determine which N-x-T/S sequences for potential N-linked glycosylation were 
glycosylated in P-gp expressed in a human cancer cell line, P-gp mutants were 
expressed with glutamine introduced in the place of asparagine in the potential 
glycosylation sequences (Schinkel et al. 1993). This showed that three sites in the first 
extracellular loop (between TM1 and TM2), N91, N94 and N99 were glycosylated, as 
mutation of each lead to a subsequent increase in electrophoretic migration of the 
denatured protein. It was also shown that treatment of the N91Q-N94Q-N99Q triple 
mutant with a N-glycanase (a mixture of glycosylation-cleaving enzymes) did not result 
in any greater increase in the rate of electrophoretic migration, and therefore that N91, 
N94 and N99 are the only sites glycosylated in full length P-gp expressed in a human 
cell line (Schinkel et al. 1993), This is depicted in Figure 1.4 Panel A. 
This result was contradicted by studies using P-gp generated by in vitro 
translation and expression in Xenopus oocytes. Full length mouse P-gp, alongside N-
terminal and C-terminal ‘halves’ were constructed by in vitro translation, and inserted 
into canine pancreatic microsomal membranes in one study (Zhang and Ling 1991). 
Protease K was used to digest P-gp and glycosylated fragments were identified by their 
protection from digestion, this study identified that there was glycosylation of the 
TM1/TM2 extracellular loop and an additional glycosylation site at N807, in the 
extracellular loop between TM8 and TM9 (Zhang and Ling 1991). A similar 
investigation using only the N-terminal half of hamster P-gp suggested a different 
organisation of predicted transmembrane helices, and a further glycosylation site on the 
N-terminal side of TM5 (Zhang, Duthie, and Ling 1993). Another study which 
expressed P-gp fragments in Xenopus oocytes and used the digestion strategy, also 
reported glycosylation between TM8 & 9 (Skach, Calayag, and Lingappa 1993).  
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These studies which identified differing N-glycosylation patterns also proposed 
a differing number of transmembrane helices (the four-plus-four model, Figure 1.4 
Panel B) (Zhang and Ling 1991; Zhang, Duthie, and Ling 1993). Glycosylation occurs 
while membrane proteins are in the membrane of the endoplasmic reticulum (ER), 
while in the ER membrane proteins are oriented in the same way as their final 
orientation on the cell membrane, with the NBDs on the cytoplasmic side while 
extracellular portions of the protein are located in the ER lumen. Glycosylation only 
occurs in the lumen of the ER, therefore only the portions of the protein which are 
extracellular in the final configuration can be glycosylated. The originally proposed 
topological configuration only exposes the potential glycosylation sites of the TM1-
TM2 loop to the extracellular side of the membrane, and thus the ER lumen (Figure 
1.3). An alternative glycosylation pattern requires more of the protein to be exposed to 
the ER lumen, meaning more of the protein would be on the extracellular side of the 
membrane in the final configuration.  
The four-plus-four model proposed that TM5 and TM8 would be on the 
extracellular side of the membrane rather than inserted into the bilayer, while TM3 and 
TM10 would be on the intracellular side (Zhang, Duthie, and Ling 1993; Zhang and 
Ling 1991). This in turn would mean that TM4 and TM9 would pass through the 
membrane in the opposite direction than that proposed in the six-plus-six model, thus 
making the TM4-5 and TM8-9 loops extracellular rather than intracellular and exposing 
these to glycosylation. A different four-helix insertion pattern was observed in the P-gp 
fragments expressed in Xenopus oocytes (Figure 1.4, Panel C), which proposed both 
TM8 & 9 to be located on the extracellular side of the membrane, also exposing the 
TM8-9 loop to the ER lumen (Skach, Calayag, and Lingappa 1993). However, this and 
two other investigations of the truncated N-terminal half of P-gp expressed in oocytes 
all supported a 6-TM helix first transmembrane domain (Skach, Calayag, and Lingappa 
1993; Skach and Lingappa 1993, 1994).  
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These topological controversies were solved by a highly influential study which 
also laid the groundwork for many future projects by using the cysless mutant form of 
P-gp (Loo and Clarke 1995). It was demonstrated that cysless P-gp retained the ability 
to confer resistance to P-gp substrates in murine NIH 3T3 cells. Mutants could therefore 
be generated by site-directed mutagenesis to contain a single cysteine and be tested for 
the retention of physiological function, unlike the previously used truncations, for which 
the relevance to human P-gp is questionable (Germann and Chambers 1998). Cysteine 
is reactive at physiological pH so a single mutant, which retains function, can be tested 
for its ability to bind thiol reactive probes. This strategy was used to confirm the 
Figure 1.4: Proposed alternative P-gp 
Topologies. The original arrangement, 
deduced from glycosylation patterns of full-
length mutant P-gp, is shown in Panel A 
(Gros, Croop, and Housman 1986). Panel B 
 
B 
C 
shows the alternative ‘four-plus-four’ topology derived from glycosylation of in-vitro 
translated P-gp halves (Zhang, Duthie, and Ling 1993). Panel C depicts a further variation of 
a four TM helix insertion pattern, restricted to TMD2, observed in P-gp fragments expressed in 
Xenopus oocytes (Skach, Calayag, and Lingappa 1993). Transmembrane helices are 
represented by black rectangles, numbered according to their order in the primary structure. 
Number labels have been flipped upside-down to indicate where a proposed topology requires 
a reversal of the direction of a TM helix relative to the original proposed model. Relevant 
potential glycosylation sites (N-x-T/S) are indicated by coloured circles, green being 
glycosylated in that model, and red being un-glycosylated. 
 
A 
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topology of the transporter. A series of positions in the predicted transmembrane 
helices, intracellular and extracellular loops were mutated to cysteine in order to 
determine their environment (Loo and Clarke 1995). The study used probes that were 
permeable or impermeable to the lipid bilayer and analysed the position of the residues 
relative to the membrane by the ability of the probes to displace labelling by biotin. 
Residues for which the membrane impermeable probes displaced binding of biotin were 
shown to be extracellular, while those still labelled with biotin were deduced to be 
intracellular. This identified that TM2-3, TM4-5, TM8-9 and TM10-11 loops were 
intracellular, while TM5-6, TM7-8 and TM11-12 loops were extracellular, consistent 
with predictions in the original six-plus-six model. Residues which were not labelled by 
biotin regardless of incubation with another probe were therefore inherently inaccessible 
so were said to be in the transmembrane region. In this way, residues in TM3, TM4, 
TM8 and TM9 were all demonstrated to be embedded in the membrane, contradicting 
the four-plus four model which predicted an intracellular TM3, and an extracellular 
TM8, and thereby confirming the original topology shown in Figure 1.4, Panel A (Loo 
and Clarke 1995; Zhang, Duthie, and Ling 1993). 
The six-plus-six model was further supported by studies using epitope insertion 
and immunofluorescence. The N-terminal half (Kast et al. 1995), or full length murine 
P-gp (Kast et al. 1996), were mutated to introduce linear epitopes, the position of these 
epitopes relative to the membrane was determined by measuring the attachment of a 
monoclonal antibody in intact or permeabilised cells. The first study to use this strategy 
determined that loops between TM1-2 and TM5-6 were extracellular using the N-
terminal half of P-gp, while TM2-3 was intracellular (Kast et al. 1995). The second 
investigation used full-length P-gp mutants which were characterised for retained ability 
to confer resistance. This study confirmed that TM4-5, TM6-NBD1, TM10-11 and 
TM12-NBD2 loops were intracellular and TM7-8, 9-10 and 11-12 were extracellular. 
All studies using full length P-gp which could be demonstrated to retain activity thus 
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produced results consistent with a six-plus TM helix organisation, not four plus four 
(Kast et al. 1996).  
1.5.2 Topography of the transporter 
 
The first images of the structure of P-gp, and the first of any ABC transporter, 
were made using electron microscopy (EM) of Chinese hamster P-gp in 1997 
(Rosenberg et al. 1997). The structure was determined at low-resolution (25 Å) using 
single particle image analysis of P-gp in detergent micelles and reconstituted into 
proteoliposomes. A central cavity of approximately 50Å diameter was observed 
between the transmembrane domains, open to the extracellular side of the membrane; 
also visible on the intracellular side were two lobes of 30 Å diameter, predicted to be 
the nucleotide binding domains. The structure exhibited six-fold symmetry in the 
transmembrane domains, consistent with the six-plus-six twelve TM-helix model. A 
further Cryo-EM investigation using two-dimensional crystals was able to improve 
resolution to approximately 10Å (Rosenberg et al. 2001). Structural changes during 
transport were also investigated, demonstrating large conformational transitions 
following ATP binding and hydrolysis. The basal state structure was similar to that 
determined by single particle analysis, with the central cavity open to the extracellular 
side of the membrane and the two NBDs located on the intracellular side. The volume 
of unit cells was indicative of P-gp crystallised as monomers and the area of a crystal 
cross-section at the TMDs was consistent with 12 TM helices. These results were 
corroborated by another investigation using Cryo-EM and 2D crystals of murine P-gp 
(Lee et al. 2002). This also observed monomeric P-gp and intracellular NBDs using P-
gp crystallised in a 2D lipid bilayer, more similar to the native environment of the 
protein. However the murine p-gp crystals appeared to show the NBDs in close contact 
in the basal state, in contrast to the studies using Chinese hamster P-gp and 
contemporaneous X-ray diffraction studies of the bacterial ABC transporter MsbA 
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(Chang and Roth 2001). These structures provided by the turn of the millennium some 
insight into the position of the two TMDs and two NBDs relative to each other and the 
lipid bilayer, but the resolution was as yet too low to determine the internal organisation 
of these large domains.  
1.5.3 Internal organisation of NBDs and TMDs  
 
As noted in Section 1.4.2, the Walker motifs and the signature sequence (LSGGQ), are 
conserved across all members of the ABC transporter superfamily. The study which 
first proposed a schematic of P-gp structure (discussed in Section 1.5) hypothesised that 
the set of Walker motifs and the signature sequence in each NBD formed two distinct 
‘nucleotide binding folds’ (Figure 1.3) (Gros, Croop, and Housman 1986). It was 
subsequently demonstrated that mutations within either or both sets of conserved 
sequences led to a loss of drug-exporter function (Azzaria, Schurr, and Gros 1989; 
Roninson 1992). Expression of P-gp as two half-molecules and the observation that 
these halves retained ATPase activity (Loo and Clarke 1994b), was interpreted as 
evidence that there were indeed two independently active nucleotide binding sites in the 
two NBDs, although this study did not determine whether the halves were active as 
monomers or dimers. These results taken together suggest that there are two 
catalytically active nucleotide binding sites, but both are required for the proper 
function of P-gp. This left the question as to why, if there were two independent 
catalytically active sites for ATP hydrolysis, both were required. Incubation of the 
transporter with equimolar vanadate was used to demonstrate that ATPase activity was 
completely abolished by trapping of one of the two sites of nucleotide hydrolysis 
(Urbatsch et al. 1995), meaning that while there were two catalytically active sites, they 
were not independent.  
With the publication of the first crystal structures of nucleotide binding domains of 
other ABC proteins such as the Rad50 ATPase (Hopfner et al. 2000), involved in 
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double-strand break repair, came a different interpretation of the functional composition 
of the nucleotide binding sites of ABC proteins. The NBDs were co-crystallised with 
non-hydrolysable ATP analogue AMP-PNP as a dimer (Figure 1.5). This showed ATP 
binding sites to be composed of the walker motifs of one NBD, together with the 
signature sequence of the other NBD, as had previously been predicted using MD 
simulations (Jones and George 1999). This structural basis of the inter-dependent 
activity of the nucleotide binding domains was consistently observed with the 
emergence of further ABC transporter structures (Hopfner et al. 2000; Locher, Lee, and 
Rees 2002) and came to be termed the ‘sandwich dimer’ (Smith et al. 2002) 
 
Figure 1.5 ATP-Rad50 dimer. Above is the 1F2U structure of an ATP-bound Rad50 dimer. 
One monomer of Rad50 is coloured green, while another is coloured violet. The signature 
sequence of the left monomer is shown in VDW radii and coloured yellow. The signature 
sequence of the right monomer is shown in VDW radii and coloured red. ATP molecules bound 
at the dimer interface are represented as bonds. 
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In the absence of a high-resolution crystal structure of P-gp, biochemical 
techniques such as mutational analysis were used to investigate the relative position and 
role of helices within the TMDs. One early example of this strategy investigated 
similarities between the first transmembrane helix of the first TMD (TM1) and the first 
transmembrane helix of the second TMD (TM7) (Loo and Clarke 1996b). Point 
mutations of each residue in each helix to alanine determined which residues were 
necessary for the proper processing and expression of P-gp; similarities were found 
between the effects of mutations in TM1 and mutation of homologous residues in TM7. 
Chimeras of P-gp were made containing either the sequence of TM7 in place of TM1 or 
TM1 in the place of TM7. These chimeras retained the ability to confer resistance to P-
gp substrates and retained a considerable portion of the ATPase activity of the wild-type  
 
Figure 1.6: An aerial view of proposed models of transmembrane helix organisation within 
the TMDs. The linear model is depicted on the left and the cyclone model is depicted on the 
right. Transmembrane helices are represented by numbered circles. Adapted from (Loo and 
Clarke 1999). 
protein; indicating that TM1 and TM7 play a similar role in the function of the protein. 
It was not yet clear that there was a symmetrical arrangement of all TMDs however, as 
TM6/TM12 chimeras were found to be inactive. Introduction of cysteine residues to 
TM6 and TM12 was subsequently used to show via direct cross-linking that the final 
helices of each TMD are close in the tertiary structure (Loo and Clarke 1996a). This 
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observation was used by Loo & Clark to propose two possible configurations for 
symmetrical organisation of the TMDs, in either a linear or ‘cyclone’ mode (Figure 1.6) 
(Loo and Clarke 1999).  
These models were tested by generating further cysteine ‘double mutants’ 
containing pairs of point mutations, one in TM6 or TM12 and one in a transmembrane 
helix of the opposing TMD (Loo and Clarke 2000); i.e. a cysteine residue, P350C in 
TM6 (TMD1) was combined with residues in TM7, 8, 9, 10, 11 (TMD2). Cross-linking 
analysis was performed, which showed the TM6 residue P350C formed direct links with 
TM10 and TM11, while the TM12 residue S993C formed direct links with TM4 and 
TM5. These results were interpreted as supporting the cyclone model (Figure 1.6). As a 
strategy for discerning between the two models this approach seems flawed, as TM6 is 
predicted by both models to lie relatively close to TM10 & TM11, while TM12 is 
predicted to lie relatively close to TM4 & TM5. Furthermore, in the case of the cyclone 
model it is predicted that TM6 and TM12 are proximal to all helices of the opposing 
TMDs, so the results seem to more nearly represent the linear model. However, as only 
one residue in TM6 or TM12 was used, the cross-linking profile could be influenced by 
the orientation of the side chain of this residue. 
A subsequent investigation used a series of homobifunctional thiol-reactive 
methanethiosulphonate (MTS) reagents of varying lengths to quantify the distances 
between TM helices 4, 5, 6, 10, 11 and 12 (Loo and Clarke 2001c). This used more than 
one residue from a number of these helices, compensating for potential 
misinterpretation caused by side chain orientation. Broadly in line with both models 
these six helices were shown to be reasonably close together, although TM10 was 
shown to be closer to both TM4 and TM6 than TM6 was to TM12, suggesting a lack of 
symmetry. The seemingly obvious and decisive way of discriminating between cyclone 
and linear models, by determining whether helices only predicted to be close to one 
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another in one of the two models were in fact close (TM1 - TM7, TM2 - TM8) was 
taken over the following years (Loo, Bartlett, and Clarke 2006a, 2006b, 2004a, 2004b). 
This demonstrated that TM1 could form direct cross-links with TM12, TM5 with TM8 
and TM2 with TM11, and TM 7 with TM1, 6 & 5. These results in combination 
undermined both models, and led to the postulation of a ring of TM helices (Loo, 
Bartlett, and Clarke 2004a), although this too was to change with the publication of the 
first crystal structure of murine P-gp. 
1.5.4 X-ray crystallography determines the three-dimensional 
structure of murine P-gp 
 
The P-gp structure models most relevant to the study of human P-gp have been 
constructed by X-ray crystallography on the murine isoform, which has been shown to 
share a high degree of sequence identity (87%) with human P-gp (Chin et al. 1989; 
Bosch and Croop 1998). While a higher resolution (3.4Å) structure is available for 
Caenorhabditis elegans P-gp (Jin et al. 2012), this protein is less functionally similar to 
human P-gp (discussed in section 6.2.1). Mouse P-gp was crystallised in the presence of 
dodecyl-β-D-maltoside (DDM) in the ‘basal’ (inward-facing, nucleotide-unbound) state 
and crystals were obtained at a high enough quality for resolution of diffraction data to 
3.8Å (PDB code 3G5U) (Aller et al. 2009). This structure disagreed with some 
biochemical evidence on the orientation of TM3 and TM5, which were shown to have 
inverted hydrophilic and hydrophobic faces in the 3G5U crystal structure in comparison 
to experimental evidence from arginine mutagenesis in human P-gp (Loo, Bartlett, and 
Clarke 2009). The murine P-gp crystal structure was later refined after the publication 
of the C. elegans P-gp crystal structure, altering the orientation of transmembrane 
helices 3-5, 8, 9 and 12 in addition to three of four intracellular coupling helices (Li, 
Jaimes, and Aller 2014). This resulted in improved scores for statistical quality control 
methods Rfree and Rwork, and fewer Ramachandran outliers; this structure was given the 
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PDB code 4M1M (Figure 1.7) (Jin et al. 2012; Li, Jaimes, and Aller 2014). The refined 
structure was also found to be in closer agreement with the biochemical evidence noted 
above. 
 
Figure 1.7: Refined 4M1M structure of murine P-gp. NBDs are coloured orange, TM helices 
1-6 are coloured blue while TM helices 7-12 are coloured red. Image generated using VMD 
1.9.1. 
Both 3G5U and 4M1M structures show 12 TM helices in two TMDs following a 
six-plus-six organisation as expected (Section 1.5.1), however the two transmembrane 
domains are not composed of helices purely from their own half of the primary 
structure. TMD1 contains TM helices 1-3, 6, 10 & 11, while TMD2 contains TM 
helices 4, 5, 7-9 & 12 (Aller et al. 2009). This does not match any of the TMD 
orientations proposed prior to the publication of the crystal structures (Section 1.5.3) but 
offers an explanation as to why none of these attempts had been successful, as they 
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started from the assumption of two TMDs containing helices from the two halves of the 
primary structure. These nucleotide-unbound crystal structures also show a considerable 
(10-20Å) separation of the two NBDs. This suggests very large conformational changes 
are required for the formation of the sandwich dimer conformation described in Section 
1.5.3 and seen in the 3.4Å resolution nucleotide-bound structure of Staphylococcus 
aureus P-gp homolog Sav1866 (Dawson and Locher 2007). X-ray crystallography has 
also been used to show the large conformational flexibility of P-gp in the basal state 
(Ward et al. 2013) (discussed in Section 6.2.2), but as crystallography-derived structures 
are static, the dynamic elements of the structure have been more extensively 
investigated by computational techniques. 
1.5.5 Probing the dynamic structure of human P-gp with in silico 
simulations 
 
Molecular Dynamics (MD) simulations have been important for probing the structure of 
P-gp for two reasons. Firstly, MD simulations have allowed the effect on P-gp structure 
of a native-like environment to be predicted, while X-ray crystallography has used P-gp 
crystallised in detergent micelles. Secondly, simulations have been used to probe the 
dynamic structure of P-gp, of particular relevance given the large conformational 
changes undergone during ATP hydrolysis and substrate extrusion.  
MD simulations have shown the 3G5U structure rapidly deforms when 
simulated in an aqueous environment, however when introduced to a simulated lipid 
bilayer environment the simulated protein reached a comparatively stable equilibrium 
(O'Mara 2012). This study placed the 3G5U structure in a cholesterol-enriched 
phosphatidylcholine bilayer and measured changes over 60ns, determining that the 
resulting structure had numerous minor rearrangements in the TMDs resulting in a 
closer agreement with available cross-linking data, and a larger separation of the NBDs. 
Biochemical investigations have demonstrated that P-gp has a higher rate of ATPase 
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activity when reconstituted into a lipid bilayer, in comparison to protein in a detergent 
micelle, suggesting the changes in the structure upon introduction to the simulated 
bilayer may be a better representation of physiological P-gp (Callaghan et al. 1997), as 
was indicated by the closer alignment of the simulated structure with existing 
crosslinking data (O'Mara 2012). 
Simulations of P-gp structure have consistently observed that the protein is highly 
flexible, typically displaying a Root Mean Squared Deviation (RMSD) of greater than 
4Å (O'Mara 2012; O'Mara and Mark 2014). The span between the NBDs has been 
observed in MD simulations to vary in excess of 20Å (Wen et al. 2013), this study 
observed similar variability with EPR spectroscopy, and another showed broad changes 
in the inter-NBD distance on varying crystallisation conditions (Ward et al. 2013). MD 
simulations are used to predict the process of conformational rearrangement, so can 
identify the origin of large transitions, unlike the single snapshot provided by a crystal 
structure. For example, the variability of inter-NBD distance has been hypothesised to 
be the result of kinking or unwinding of helices within the TMDs (Wen et al. 2013). 
This study observed deformation of TM1, TM2, TM6 (NBD1) and TM7, TM8, TM12 
(NBD2) at the centre of the membrane spanning portion of these helices, this was 
interpreted to show a hinge in both TMDs, with changes at this point directing 
movement of the intracellular portions of the transporter. MD simulations thus offer a 
powerful tool for exploring the transient intermediate conformations between points of 
the ATP hydrolysis/drug translocation cycle. 
1.6 What is the molecular mechanism of P-gp? 
 
As noted in Section 1.4.2, P-gp is a member of the ABC transporter superfamily, which 
couple the hydrolysis of ATP to transport of molecules across lipid bilayers. Decades of 
research have been focused on determining the molecular basis of ATP and drug 
binding, nucleotide hydrolysis and dissociation of transported substrates and hydrolysed 
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products. This section will describe the discoveries which led to the current 
understanding of the molecular mechanism of P-gp. 
Biochemical studies done in the 1980s and 1990s confirmed the fundamental 
constituents of the P-gp mechanism which lead to decreased accumulation of drugs in 
P-gp expressing cells. The ATPase activity of P-gp was confirmed in 1988 after 
purification by immunoaffinity chromatography, incubation with ATP, and isolation of 
liberated inorganic phosphate (Hamada and Tsuruo 1988). A study published in the 
same year used inside-out vesicles, isolated from drug resistant cells expressing P-gp, 
these were shown to accumulate tritiated vinblastine in an ATP dependent manner, 
demonstrating that P-gp actively transports drugs out of cells (Horio, Gottesman, and 
Pastan 1988). It was also demonstrated that inhibition of ATP hydrolysis by vanadate 
trapping or presence of non-hydrolysable nucleotide analogue AdoPP[NH]P lead to 
potent inhibition of the transport of vinblastine across the membrane. Purified P-gp, 
reconstituted into proteoliposomes, was used to show that the ATPase activity is 
stimulated in the presence of vinblastine (Ambudkar et al. 1992), taken together these 
studies showed that ATP hydrolysis and drug translocation were coupled. 
Starting from P-gp present in the ‘basal’ unloaded state in the plasma membrane, 
logically the first steps which must occur in a coupled hydrolysis/translocation 
mechanism is the association of ATP and drug(s) (Figure 1.8, Panel A) (Callaghan, 
Ford, and Kerr 2006). Given the presence of a basal rate of hydrolysis (Taylor et al. 
2001) it seems ATP is able to bind to the NBDs in the absence of a transported 
substrate, followed by a slow transition from the ‘open’ to ‘closed’ conformations 
(Figure 1.8). Thiol-reactive fluorescencent probes have been used to show that 
conserved cysteine residues in the NBDs are susceptible to covalent modification in the 
absence of nucleotide, but the presence of ATP alone is sufficient to hinder accessibility 
of these residues (Liu and Sharom 1996). This study showed that ATP binding occurs in 
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the absence of drugs, although the affinity for ATP was increased in the presence of 
vinblastine or colchicine. There is extensive evidence for an association of the NBDs 
after nucleotide binding, including the structures determined of other ABC transporters 
in a nucleotide bound state (Dawson and Locher 2007; Smith et al. 2002) in addition to 
the recent nucleotide bound structure of human P-gp (Kim and Chen 2018), and cross-
linking evidence that demonstrates nucleotide hydrolysis takes place in the closed 
sandwich dimer conformation described in Section 1.5.3 (Liu and Sharom 1997; Smith 
et al. 2002; Dawson and Locher 2007; Loo, Bartlett, and Clarke 2010). Analysis of P-gp 
activity after trapping intracellular portions of the TMDs in close proximity has 
provided additional evidence for ATP hydrolysis occurring in a closed conformation. 
When intracellular portions of TM3 and TM9, which were predicted to be in close 
proximity only in the closed conformation (Figure 1.8, panel B), were covalently 
crosslinked the basal and drug-stimulated rates of ATPase activity were increased (Loo, 
Bartlett, and Clarke 2010). 
Significant controversy remains regarding the stoichiometry of ATPase-coupled 
drug transport by P-gp. Both ATP binding sites are catalytically active (al-Shawi and 
Senior 1993; Urbatsch et al. 1995; Beaudet, Urbatsch, and Gros 1998), and mutations in 
the Walker A or Walker B motif of either NBD is sufficient to abrogate the ATPase 
activity of the transporter (Urbatsch et al. 1998). It is not clear whether both hydrolyse a 
molecule of ATP during a single export cycle (Ambudkar et al. 1997; Eytan, Regev, and 
Assaraf 1996; Shapiro and Ling 1998; Callaghan, Ford, and Kerr 2006). Measurement 
of ATPase activity and substrate transport has shown that the molar ratio of substrate 
transport to ATP hydrolysis is 0.5-0.8, but basal hydrolysis may lead to an 
overestimation of the number of ATP molecules required per transport event (Eytan, 
Regev, and Assaraf 1996). Strong evidence suggests though that NBD dimerisation is 
asymmetric, and there is a higher affinity for ATP at one site (Siarheyeva, Liu, and 
Sharom 2010; O'Mara and Mark 2014; Rosenberg et al. 2005; Delannoy et al. 2005). 
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One study, using native, catalytically active human P-gp (Siarheyeva, Liu, and Sharom 
2010) made use of the intrinsic fluorescence of tryptophan residues in P-gp, which is 
quenched upon nucleotide binding (Liu, Siemiarczuk, and Sharom 2000). Quenching of 
tryptophan fluorescence was biphasic in the presence of the non-hydrolysable 
nucleotide analogue adenosine 5′-(γ-thio)triphosphate (ATPγS), revealing low (Kd 0.74 
mM) and high (Kd 6 μM) affinity binding sites (Siarheyeva, Liu, and Sharom 2010), it 
was postulated that ATP hydrolysis occurs only at the high affinity site. Asymmetric 
structures of ATP-bound murine P-gp (4M1M) have been predicted using MD 
simulations (O'Mara and Mark 2014). However, other researchers propose that there are 
two ATP hydrolysis events per molecule transported, occurring at different stages of the 
mechanism (Sauna and Ambudkar 2000) affecting different outcomes (Sauna and 
Ambudkar 2001), which would be consistent with an asymmetric binding at the two 
sites. 
The traditional concept of active transport envisages that ATP hydrolysis provides 
the impetus for conformational changes leading to the translocation of a substrate. 
However, P-gp has been shown to bind tritiated vinblastine at high affinity in the 
absence of nucleotide, while the vinblastine binding capacity was significantly reduced 
in the presence of ATPγS (Martin, Berridge, Mistry, et al. 2000) indicating that 
nucleotide binding is sufficient to affect dissociation of the substrate (Figure 1.8, Panel 
B). A subsequent study, also using tritiated vinblastine (Martin, Higgins, and Callaghan 
2001) revealed that association of the drug was monophasic, demonstrating a single 
binding site and thus single molecule of vinblastine transported per hydrolysis event. 
This study showed that the vinblastine binding affinity at this site was principally 
reduced after the binding of non-hydrolysable nucleotide analogue AMP-PNP, 
remained low after hydrolysis, and was restored by the dissociation of phosphate 
(Martin, Higgins, and Callaghan 2001). Site directed mutagenesis has been used to 
show that the cross-linking profile of cysteines introduced into the drug binding region 
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is significantly altered upon nucleotide binding (Loo and Clarke 2002). This is 
supported by the extant structures for ABC transporters in the ‘closed’ conformation, 
which show significant conformational changes and reorientation toward the 
extracellular face of the membrane (Dawson and Locher 2007; Korkhov, Mireku, and 
Locher 2012; Smith et al. 2002). The recent nucleotide bound structure of human P-gp 
was obtained in the presence of vinblastine, but no electron density corresponding to 
vinblastine was located, this was interpreted to confirm that vinblastine had been 
dissociated from P-gp in this conformation (Kim and Chen 2018). The dissociation of 
drug from the TMDs seems to occur due to a drop in affinity associated with 
conformational changes involving the rotation of transmembrane helices (Loo and 
Clarke 2001a; Rosenberg et al. 2001; Loo and Clarke 2002).  
The mechanism of ATP hydrolysis at ABC NBDs has been studied in great detail. 
In the sandwich dimer conformation, each ATP molecule is bound by a complex system 
of hydrogen bonds with the Walker motifs of one NBD and LSGGQ sequence of the 
opposing NBD (Smith et al. 2002). Hydrolysis of ATP is mediated by glutamate 
residues at the terminus of the Walker B motifs (Walker et al. 1982), these residues 
immobilise, polarise and orient a water molecule for a nucleophilic attack on the g-
phosphate of the nucleotide (Mildvan 1997). Mutation of these residues to remove the 
charge has demonstrated them to be necessary for ATP hydrolysis by P-gp, and the drug 
resistance phenotype (Urbatsch, Julien, et al. 2000). ATP hydrolysis is followed by 
transition to a further, distinct, conformation (Figure 1.8, Panel C). Studies employing 
conformation-specific antibodies, such as UIC2, which binds to an intracellular loop 
accessible in the inward-open basal conformation showed that the vanadate trapped 
conformation is significantly different to those adopted at the other stages of the 
translocation cycle (Ritchie, Kwon, and Atkins 2011).  
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Figure 1.8: Schematic of the translocation mechanism of P-glycoprotein. Panel A: The first stage of the mechanism involves association of ATP 
from the cytoplasm to the intracellular NBDs and the substrate from the intracellular leaflet of the membrane to a binding site with inherent or 
induced high affinity. Panel B: Association of transported substrate and nucleotide then results in dimerisation of the NBDs and a drop in affinity for 
the substrate, due to rotation of the TMDs obscuring those residues involved in high affinity binding. Panel C: This is followed by ATP hydrolysis, 
which leads to another distinct conformation of the protein, with a lower affinity for phosphate than ADP, and retains low affinity for drug. Panel D: 
Finally release of phosphate and dinucleotide leads to a reversion to the original conformation. Purple squares with red semicircles attached 
represent ATP, while after hydrolysis ADP is represented by the purple square and inorganic phosphate by the red semicircle. The P-gp substrate is 
represented by the blue pentagon, and the pink areas on the TMDs denote the residues involved in high affinity substrate binding. 
A B
 
C
 
D
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Trapping with vanadate in the post hydrolysis state, which stabilises the P-gp-ADP g 
complex, has been shown to inhibit ATPase activity, whereas only the presence of very 
high concentrations of inorganic phosphate affected activity (Urbatsch et al. 1995). 
These results show that phosphate has low affinity for the post-hydrolytic state, 
indicating that it is dissociated before ADP. Low-resolution cryo-EM images of human 
P-gp in the post-hydrolytic, ADP.Vi-trapped state, show that is this a ‘closed’ 
conformation, in which the NBDs remain dimerised (Frank et al. 2016), as has 
previously been deduced in biochemical investigations (Urbatsch et al. 2003). However, 
incubation of unloaded P-gp with ADP was insufficient to promote dimerisation. Taken 
together, these results suggest that the release of phosphate leads to the transition back 
to the open state, at which point ADP is dissociated (Figure 1.8, Panel D).  
In summary, the mechanism of P-gp is complex, and involves multiple 
conformational rearrangements. Drugs and ATP bind readily to P-gp in the basal 
conformation; ATP binding is well understood and is known to lead to conformational 
change and the dissociation of transported substrates. This in turn is followed by ATP 
hydrolysis, and a less well understood process of dissociation of hydrolysis products 
and return to the basal state. Even more complex propositions have been made for a 
complete mechanism of the transporter, based on the observation that both ATP binding 
sites are required to be catalytically competent, and display cooperativity (Senior and 
Bhagat 1998). It has been proposed that the two NBDs alternate in hydrolysing ATP, 
over two translocation events, conventionally known as the ‘Alternating Catalytic 
Mechanism’ (Senior 1998; Lugo and Sharom 2014). Under this scheme, Figure 1.8 
represents one half of a complete reaction scheme which couples the separate transport 
of two substrate molecules to the hydrolysis of two nucleotides. A further area of 
intense research interest in P-gp has been the attempt to discern the molecular basis for 
the broad substrate specificity of the transporter 
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1.6.1 How does P-gp interact with so many different molecules? 
 
P-gp has been shown to interact with over 300 molecules (Callaghan 2015), and has 
been implicated in the reduced efficacy of multiple classes of anti-cancer drugs (ACDs) 
(Section 1.4). This includes vinca alkaloids, anthracyclines, taxanes, camptothecins and 
others, as well as biological molecules such as cortisol and hormones (Horio, 
Gottesman, and Pastan 1988; Cole et al. 1992; Ambudkar et al. 1999; Szakacs et al. 
2006; Luo et al. 2002; Ueda et al. 1992; Bello-Reuss et al. 2000). Inhibitors of P-gp are 
also structurally distinct (Figure 1.9). Understanding the binding promiscuity of P-gp 
has been a key goal to enable the design of novel inhibitors and ACDs which evade P-
gp mediated MDR (Wang et al. 2005). 
 
 
Figure 1.9 Structural diversity of P-gp inhibitors. The structure labelled ‘A’ is the first-
generation, competitive inhibitor verapamil (Sharom 2011). ‘B’ is the second-generation 
competitive inhibitor psc833, a derivative of cyclosporine D (Uchiyama-Kokubu, Watanabe, 
and Cohen 2001). ‘C’ is the third generation competitive inhibitor zosuquidar (Rubin et al. 
2002). 
As shown in Figures 1.2 and 1.9, the structures of substrates and inhibitors are 
highly variegated, but there are recurring physiochemical properties in compounds 
A B 
C 
  
49 
 
which interact with P-gp. All are hydrophobic, and many contain a positively charged 
nitrogen atom at physiological pH (Sharom et al. 1999). Most contain aromatic rings of 
some form, which may intercalate with aromatic amino acids in P-gp TMDs to stabilise 
the protein-substrate interaction (Pawagi et al. 1994), however this is not essential, as 
demonstrated by the structure of cyclosporines and derivatives (Figure 1.9, panel B). 
Computational techniques have identified groups of characteristics, which can be 
ascribed to different clusters of P-gp modulators (Poongavanam, Haider, and Ecker 
2012). However, it is clear that no one classic ‘lock and key’ style binding site could 
accommodate such diversity in structure and character. 
The crystal structure of P-gp shows it has a large central cavity (Aller et al. 
2009). Even at 2000Å3 the cavity is not large enough to contain 300 separate high 
affinity lock and key sites. The data currently available provide strong evidence that 
there are several binding sites each capable of binding a variety of drugs (Sauna and 
Ambudkar 2000; Hrycyna et al. 1999; Shapiro and Ling 1997; Martin, Berridge, 
Higgins, et al. 2000), other investigations suggest that the polyspecificity of these sites 
may be due to an induced fit mechanism of drug binding (Loo, Bartlett, and Clarke 
2003). The first study to propose distinct binding sites in P-gp monitored the uptake 
fluorescent substrates rhodamine 123 and Hoechst 33342 into P-gp containing vesicles 
(Shapiro and Ling 1997). Transport rates of each compound was increased in the 
presence of both compounds, this was interpreted to demonstrate the presence of two 
positively cooperative binding sites, named ‘H’ and ‘R’ sites for Hoechst 33342 and 
rhodamine 123 respectively. Measurements of ATPase activity stimulation in the 
presence of combinations of drugs also demonstrated a non-competitive interaction 
between distinct nicardipine and verapamil binding sites (Pascaud, Garrigos, and 
Orlowski 1998). A further investigation, using tritiated vinblastine, demonstrated that 
the presence of cyclosporin A, vincristine and actinomycin D did not alter the affinity of 
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P-gp for vinblastine, indicating that these drugs did not share a common binding site 
(Ferry, Russell, and Cullen 1992). However, the dissociation rate of vinblastine was 
increased in the presence of a series of 1,4-dihydropyridines, showing that this class of 
drugs possesses a further binding site, which has a non-competitive allosteric interaction 
with the vinblastine binding site. Another study using radiolabelled modulators (Martin, 
Berridge, Higgins, et al. 2000) identified at least four allosterically communicating drug 
binding sites, three for transported substrates, and one ‘regulatory’ site for non-
transported modulators. 
Numerous studies have reported conformational changes in the TMDs in the 
presence of P-gp substrates (Loo and Clarke 2001b), and it has been proposed that this 
reveals a substrate induced fit mechanism of drug binding (Loo, Bartlett, and Clarke 
2003; Prajapati and Sangamwar 2014). A cross-linking study demonstrated that the 
presence of cyclosporine A, progesterone, colchicine or demecolcine lead to a decrease 
in the distance between TM6 and TM12 (Loo, Bartlett, and Clarke 2003). Multi-
targeted MD simulations have also predicted similar changes in response to the binding 
of a variety of anthracyclines (Prajapati and Sangamwar 2014). Another study measured 
changes in intrinsic tryptophan fluorescence upon drug binding (Mittra et al. 2016), 
divergent forms of quenching and spectral shifts were observed in response to different 
drugs. This suggests that there are different conformational changes in response to the 
binding of different modulators. 
Recently a Cryo-EM structure of human-mouse chimeric P-gp, bound to the 
antibody UIC2 and two molecules of the inhibitor zosuquidar, was determined at a 
resolution of 3.6Å (Alam et al. 2018). This showed a structure in which NBDs were 
partially dimerised (Figure 1.10, Panels A&B) and the central cavity was fully enclosed, 
containing two molecules of inhibitor and involving significant rearrangements of the  
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Figure 1.10: Modulator-induced conformational rearrangements in P-gp. Panel A shows the 
basal state 4M1M structure of murine P-gp. Panel B shows the zosuquidar-bound 6FN1 
structure of human-mouse chimeric P-gp, from which the extracellularly associated UIC2 
antibody has been excluded. Panel C shows the arrangement of the TMDs in the basal state. 
Panel D shows the arrangement of the TMDs after association of two molecules of zosuquidar. 
4M1M is shown in gold, 6FN1 is shown in green, the VDW radii of zosuquidar is shown in red. 
TM1 is indicated by 1, TM2 is indicated by 2, etc. 
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TMDs (Figure 1.10, Panels C&D). The enclosed cavity is formed by the envelopment 
of TM4 and TM10 at the intracellular leaflet, and movement of TM1 and TM7 toward 
the centre of the cavity at the mid-point of the membrane spanning portion of the 
helices. These observations suggest that modulator binding contributes to the formation 
of the sandwich dimer, as well as inducing rearrangement of the TMDs to form a high-
affinity binding site. However, the 6FN1 structure was generated from a mutant 
containing two cysteines, one introduced at each NBD, which are cross-linked. This and 
the chimeric nature of the construct and the association of the UIC2 antibody, may have 
influenced the changes relative to the basal structure. It is also essential to note that 
zosuquidar elicits a depression of the basal rate of reconstituted P-gp ATPase activity 
(Shukla et al. 2017), in contrast to transported substrates, so the structural changes 
likely differ in these cases, as indicated by MD simulations (Prajapati and Sangamwar 
2014). 
In summary, the polyspecificity of P-gp is explained by the presence of distinct 
binding sites, each of which may form high affinity interactions with a selection of 
modulators via local conformational changes. Conformational changes associated with 
modulator binding subsequently promote ATP binding (Tombline and Senior 2005), 
which in turn leads to dissociation of drugs, followed by ATP hydrolysis (Section 1.6). 
What is less well understood is the pathway by which events at the TMDs are 
communicated to the NBDs, and vice-versa. 
1.7 Structural features of P-gp mediating coupling of ATP hydrolysis 
and drug transport 
 
The mechanism of P-gp involves two processes that are coupled; nucleotide hydrolysis 
and drug transport. A key issue to address is which residues or domains communicate a 
binding, dissociation or hydrolysis event in one region to the other via conformational 
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change. P-gp binds a large number of drugs at different binding sites, via an induced fit 
mechanism, therefore this may suggest multiple pathways to communicate events at the 
TMDs to the NBDs. Inter-domain communication must be bidirectional, and the 
observation of a basal rate of hydrolysis suggests it is a loose coupling. Two parts of the 
TMDs have been implicated as part of the pathway of inter-domain communication. 
Firstly, four intracellular helices linking TM2 to TM3 (IH1), TM4 to TM5 (IH2), TM8 
to TM9 (IH3) and TM10 to TM11 (IH4). Secondly, the direct connections between 
TMDs and NBDs, TM6 & 12. These features are highlighted in Figure 1.11. 
 
Figure 1.11: Structural features implicated in coupling ATPase activity and substrate 
translocation in P-gp. The 4M1M structure of murine P-gp is shown in gold. Intracellular 
helices IH1, IH2, IH3 and IH4 are shown in red. IH1 and IH4 are to the left, in close proximity 
to NBD1, while IH2 and IH3 are to the right, in close proximity to NBD2. TM6 and TM12 are 
shown in blue, extending to the point of contact with the NBDs. 
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1.7.1 Contact points between Intracellular Helices and NBDs in P-gp. 
The IHs observed in P-gp structures determined by X-ray crystallography (Figure 1.11) 
have been proposed to mediate communication between TMDs and NBDs by a ball-
and-socket joint (Jin et al. 2012), similar to that observed in ABC importers, and 
bacterial exporter Sav1866 (Oldham, Davidson, and Chen 2008). This conserved 
interface involves the IHs (the ball) lying within a cleft in the NBDs, between the 
helical and RecA-like subdomains (the socket) (Hollenstein, Dawson, and Locher 
2007). A point mutation at the NBD contact point in the human chloride ion channel 
ABC protein CFTR is the principal cause of misassembly, resulting in cystic fibrosis 
(Hollenstein, Dawson, and Locher 2007). Mutations at this interface have also been 
observed to decouple ATPase activity and substrate transport in the human ABC 
antigen transporter complex TAP1/TAP2 (Saveanu, Daniel, and van Endert 2001). It 
has been demonstrated in human P-gp that IH2 and NBD2 are in close proximity, as a 
double mutant containing cysteines introduced into IH2 and NBD2 can be directly 
cross-linked (Loo, Bartlett, and Clarke 2008). 
 The specific roles of the four IHs in human P-gp has been investigated in some 
detail by mutational analysis and cross-linking (Loo, Bartlett, and Clarke 2013; Loo and 
Clarke 2013; Loo, Bartlett, and Clarke 2008). It appears that the IH2/NBD2 interface is 
of greater importance to P-gp function than the IH4/NBD1 interface, as double mutants 
containing point mutations in the former were inactive, while corresponding mutations 
in the latter did not affect activity (Loo, Bartlett, and Clarke 2008). It has also been 
shown that no point mutations in IH1 result in altered maturation of P-gp, or reduced 
ATPase activity, while most corresponding mutations in IH2 result in decreased 
expression, lack of glycosylation and abrogation of ATPase activity (Loo, Bartlett, and 
Clarke 2013). The importance of mobility of these helices in the mechanism of P-gp has 
also been explored. Linking IH1 and IH3 with a short intramolecular cross-linker results 
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in stimulation of ATPase activity, mimicking drug binding (Loo et al. 2012; Loo, 
Bartlett, and Clarke 2010), indicating that the pathway of communication of drug 
binding at the TMDs to stimulate ATP hydrolysis at the NBDs may require proximity 
between the IHs contacting NBD1 and the IHs contacting NBD2. However, the 
stimulation of ATPase activity upon linkage of IH1 and IH4 may simply be a result of 
holding the NBDs in the dimerised conformation. Cross-linking IH2 and IH3, or IH1 
and IH4 inactivates the protein (Loo and Clarke 2013, 2014a). This suggests that 
relative movement between the two IHs at each NBD is necessary over the course of the 
translocation cycle. MD simulations have predicted that the IHs move in concert with 
the NBDs during ATP binding, maintaining contacts between these helices and 
conserved features of the NBDs (Prajapati and Sangamwar 2014). 
The role of the IHs has been further explored by determining the importance of 
the areas in the NBD contacted by the IHs. A homology model of P-gp in the ATP 
bound conformation, based on the structure of SAV1866 (Stockner et al. 2009) 
suggested that the IHs were in close proximity to conserved glutamine containing loops 
in each NBD (NB1: Q475, NBD2: Q1118) (Zolnerciks et al. 2014). These glutamine 
containing ‘Q-loops’ link the F1-core and helical subdomains of the NBDs, and are 
thought to mediate relative movement of these subdomains in a variety of ABC 
transporters (Diederichs et al. 2000; Gaudet and Wiley 2001; Verdon et al. 2003). Q 
loops have also been implicated as a key part of the ATP binding pocket in a number of 
ABC transporters (Sauna and Ambudkar 2007). To investigate the role of Q-loops in 
human P-gp, cells were transfected with WT P-gp, Q475A, Q1118A or a 
Q475A/Q1118A double mutant, and substrate transport was measured. Accumulation of 
fluorescent P-gp substrate BODIPY-verapamil was measured by flow cytometry (Blott, 
Higgins, and Linton 1999; Zolnerciks et al. 2014). Cells expressing no P-gp showed 
high BODIPY-verapamil fluorescence, whilst the wild-type P-gp expressing cells 
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showed very little due to export of the fluorescent substrate by the transporter. The 
single mutants were shown to be able to prevent accumulation to a similar extent, 
however the double mutant could not (Zolnerciks et al. 2014). This indicated that one 
Q-loop was sufficient for the proper function of P-gp. 
The cause of the loss of transport activity in Q475A/Q1118A was investigated 
using conformation-sensitive antibody UIC2 (Zolnerciks et al. 2014), the antibody binds 
to an intracellular loop between TM5 and TM6 only when it is accessible in the inward-
open conformation (Zhou, Gottesman, and Pastan 1999), this was detected by flow-
cytometry. A Walker B motif mutant E1201Q showed very low binding of the antibody, 
this mutant retains the ability to bind, but not hydrolyse ATP (Tombline et al. 2004) and 
becomes trapped in the NBD-dimerised closed conformation, causing the UIC2 binding 
site to be permanently inaccessible.  Conversely the Q475A-Q1118A double mutant 
showed very high binding of the antibody in comparison to WT P-gp and Q475A and 
Q1118A single mutants, indicating it is unable to progress from the inward-open 
conformation to the ATP-bound conformation. The single mutants and WT P-gp 
showed intermediate binding because these functionally competent P-gp isoforms are 
present in a combination the series of conformations sampled during the extrusion of 
substrate (Figure 1.8). These results show that one Q-loop is required for 
ATP/verapamil binding to lead to conformational change.  
Another study analysed the effect of Q-loop mutations in murine P-gp on the 
stimulation of ATPase activity by a variety of drugs (Urbatsch, Gimi, et al. 2000). 
Mutation of either glutamine residue to glutamic acid resulted in a reduction of 
stimulation by vinblastine, verapamil or tetraphenylphosphonium, while a greater 
reduction was observed when the glutamines were replaced by alanines. These effects 
were equal with respect to the two conserved glutamine residues in murine P-gp. This 
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was interpreted to show that the degree to which the hydrogen bonding character of the 
glutamine residue was preserved in either Q-loop was directly related to the degree of 
inter-domain communication.  
Overall, there is significant evidence that IHs and Q-loops play a significant role 
in coupling of ATP hydrolysis and drug export. Specifically, that movement of IHs 
contacting Q-loops in the NBDs permits ATP binding to lead to formation of the 
sandwich dimer, due to the essential role played by Q-loop glutamine residues in ATP 
binding. Formation of the sandwich dimer leads in turn to drug dissociation. This is 
only one part of the bidirectional coupling process however, other researchers have 
identified that TM6 & 12, the direct connections between TMDs and NBDs, are also 
involved in the pathway of inter-domain communication. 
1.7.2 Transmembrane helices six and twelve – The direct connection 
between TMDs and NBDs   
 
The sixth and twelfth transmembrane helices (TM6 and TM12) are the direct connection 
between the TMDs and the NBDs (Figures 1.3, 1.11). This has led many researchers to 
hypothesise that these helices may be involved in inter-domain communication (Storm 
et al. 2007; Crowley et al. 2010; Loo and Clarke 1997; Prajapati and Sangamwar 2014). 
Extensive investigation of the role of these helices has revealed; firstly, that they are 
involved in the recognition of some substrates; secondly, that specific residues of TM6 
and TM12 are essential to the coupling of drug binding to nucleotide hydrolysis, and 
thirdly that the two helices undergo significant and indispensable conformational 
transitions during ATP hydrolysis and substrate efflux. 
As described in Section 1.6.1, P-gp has a number of distinct binding sites 
displaying high affinity for different substrates and modulators, numerous investigations 
have implicated TM6 and TM12 as playing a role in binding of certain compounds. 
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Studies using mutational analysis of TM6 & 12 have indicated that specific residues 
might be important in the recognition of particular substrates (Devine, Ling, and Melera 
1992; Chen et al. 1997; Hafkemeyer et al. 1998). For example, decreased affinity for, or 
total loss of response to vinblastine has been observed in single mutants of P-gp 
containing the substitutions S344C, V345C, A348C, S349C and M986C (Crowley et al. 
2009; Storm et al. 2007; Storm et al. 2008), in comparison to the well characterised 
cysless parent (Taylor et al. 2001). None of these single mutants has a decreased 
response to nicardipine, or a decrease in maximal rates of ATP hydrolysis, confirming 
that the effect of the mutations is to specifically disrupt the binding interaction with 
vinblastine. One mutation in TM12 has been previously shown to have a specific effect 
on nicardipine affinity, G984C (Crowley et al. 2009), while another, V982C, has been 
implicated in the interaction with fluorescent substrate rhodamine 123 (Mittra et al. 
2016). 
Other mutations in TM6 & TM12 have been shown to alter communication 
between TMDs and NBDs in P-gp. This has been deduced in cases where mutations 
result in a changed rates of ATP hydrolysis, but no effect on the affinity of P-gp for 
drugs or ATP. Effects of this kind can be subdivided into: firstly, those which show the 
general conformational changes associated with ATP hydrolysis have been perturbed; 
and secondly those which show drug binding being differently communicated to the 
NBDs. The mutations G346C, Q347C, L976C and V978C lead to a decrease in basal 
and stimulated rates of ATPase activity, thus fall into the first group, as does A980C 
which causes an increase in these rates (Crowley et al. 2009; Storm et al. 2007). The 
second group of residues, involved in inter-domain coupling, show a change in 
stimulated rates of ATPase activity while the basal rate of ATP hydrolysis remains 
unaffected. The mutations V988C and G989C lead to a decrease in nicardipine 
stimulated activity, while the modification Q990C leads to a decrease in both 
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nicardipine and vinblastine stimulated rates of ATP hydrolysis (Crowley et al. 2009). A 
further mutation, G346C resulted in decreased transport of fluorescent substrate 
rhodamine123 in transfected cells, decreased ATPase activity in basal and 
nicardipine/vinblastine stimulated conditions, but did not affect drug binding (Storm et 
al. 2007). These observations demonstrated that specific residues in TM6 & 12 are 
involved in inter-domain communication in P-gp. 
Subsequently, covalent modification of TM6 & 12 with hydrophobic (coumarin-
malemide/CM), hydrophilic (fluorescein-malemide/FM) and zwitterionic (BODIPY-
malemide/BM) probes was used to explore the topography of the two helices (Rothnie 
et al. 2004; Storm et al. 2008; Crowley et al. 2010); binding of these probes was also 
measured in P-gp trapped at different stages of the export cycle, to interrogate 
conformational changes. The first of these studies focused on the extracellular half of 
the membrane-spanning portion of TM6 (Rothnie et al. 2004), showing that all seven 
positions analysed were in a primarily hydrophobic environment throughout the 
catalytic cycle. However, some residues were moderately accessible to covalent 
modification by the zwitterionic probe BM in the basal state, inaccessible in the ATP 
bound conformation and highly accessible in the post-hydrolysis state, demonstrating 
that the helices undergo significant changes in environment. Similar investigations in 
the intracellular half of TM6 (Storm et al. 2008) and along the entire length of TM12 
(Crowley et al. 2010), showed a variety of topographical changes occurring in these 
regions.  
Intramolecular cross-linking (Loo and Clarke 1997, 2001a) and EPR (van 
Wonderen et al. 2014; Verhalen et al. 2017), have also been used to demonstrate that the 
two helices move during the catalytic cycle. Pairs of cysteine residues introduced in 
TM6 & 12 have been demonstrated to form direct cross-links at different stages during 
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the catalytic cycle (Loo and Clarke 1997). Linkage of TM6 & 12 by homobifunctional 
thiol-reactive reagents has also been shown to be perturbed by drug binding, and ATP 
hydrolysis (Loo and Clarke 2001a). Continuous-wave EPR has revealed that the 
solvent-accessibility of residues V331C, F343C, A354C (TM6) and A980C (TM12) 
undergoes significant changes during the catalytic cycle (van Wonderen et al. 2014). 
Double electron-electron resonance EPR (DEER) has been used to show that cytosolic 
portion of TM6 moved closer to the cytosolic portion of TM5 after ATP hydrolysis, 
while a similar decrease in distance was observed between TM12 and TM11 (Verhalen 
et al. 2017). These studies, in combination with the mutational analysis, demonstrated 
that TM6 and TM12 move during the catalytic cycle, as well as having a role in inter-
domain communication. 
These researchers also analysed the effect of covalent modification (Storm et al. 
2008; Rothnie et al. 2005), or intramolecular cross-linking (Loo and Clarke 1997, 
2001a) of TM6 & 12 on the activity of P-gp, in order to determine the importance of the 
movement of these helices. This was first quantified in detail when the activity of TM6 
single mutants was measured after labelling with the hydrophobic probe CM (Rothnie et 
al. 2005). The ATPase activity of P-gp mutant L339C was no longer stimulated by 
nicardipine, vinblastine or paclitaxel (although the basal activity was unaffected), and 
no longer inhibited by XR9576 (tariquidar) when CM was attached. It was shown that 
the ability of the substrates to bind to the protein was unimpaired, as their ability to 
displace tritiated azidopine was unaltered. Attachment of CM to residues S344C, 
G347C and A354C was subsequently demonstrated to cause a similar decrease in 
nicardipine stimulated activity, while the potency of the drug to stimulate ATPase 
activity was unaffected (Storm et al. 2008). Therefore, covalent modification of these 
residues depressed drug response by impairing communication of events between the 
TMDs and the NBDs, possibly due to steric hindrance of local conformational change 
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associated with inter-domain communication. Direct intramolecular cross-links between 
P350C and S993C (Loo and Clarke 1997), and cross-links formed with 
homobifunctional reagents between L339C and V982C (Loo and Clarke 2001a) have 
also been demonstrated to significantly reduce drug-stimulated activity. In summary, 
results from covalent modification (Storm et al. 2008; Rothnie et al. 2005) and 
intramolecular cross-linking (Loo and Clarke 1997, 2001a) strongly suggested that 
inter-domain communication requires relative movement of TM6 & TM12.  
1.8 Project aims and strategy implemented to obtain research 
outcomes 
 
A dynamic structural model for TM6 & 12 will help clarify the conformational changes 
involved in the molecular mechanism of P-gp mediated efflux. The aim of this project 
was firstly to determine the relative position of TM6 and TM12 in the inward-facing 
basal conformation and use this to determine which of the current structure models, if 
any, provides an accurate representation of human P-gp in a lipid bilayer (Figure 1.12). 
Secondly, this project aimed to define how the relative motion of TM6 & 12 is involved 
in inter-domain communication during the translocation cycle of P-gp. To achieve the 
first aim of the project, it was decided to use two techniques (intramolecular cross-
linking by homobifunctional reagents, and DEER) to measure distances between points 
in the two helices. To achieve the second, the different points in the two helices would 
be trapped in their basal positions, and the effect of this on the activity of the transporter 
was to be measured. In order to use the planned techniques a series of functional, 
purified and reconstituted ‘double mutant’ forms of P-gp were required, each with one 
cysteine on TM6 and one on TM12.  
Specific residues were chosen for modification to cysteine on the two helices for 
two reasons. Firstly, this was done to provide a diverse combination of measurements 
  
62 
 
between different parts of the membrane spanning portion of TM6 & 12. Secondly, as 
functionally relevant double mutants were required, residues were selected which had 
previously been modified to cysteine and shown to not perturb function in studies on 
single mutants (Table 1.1). Double mutants were made by introducing one of these 
residues from TM6 and one from TM12 to the previously well characterised poly-his 
tagged cysteine-less P-gp (Taylor et al. 2001). These double mutants were to be 
expressed using the recombinant baculovirus/insect cell system, purified by affinity 
chromatography, then reconstituted into proteoliposomes. The ATPase activity of these 
double mutants was to be measured, to ascertain whether physiological levels of 
function were retained, and the mutants were therefore a representative model of human 
P-gp. Distances between points in TM6 and TM12 were to be measured by 
intramolecular cross-linking and DEER. In order to define which existing structure of  
Residue Position Used 
V331C Top TM6 (Rothnie et al. 2005; Rothnie et al. 2004)*  
F343C Mid TM6 (Loo and Clarke 1997) (Rothnie et al. 2004; Rothnie et al. 2005)* 
A354C Bottom TM6 (Storm et al. 2007; Storm et al. 2008)* 
V974C Top TM12 (Loo and Clarke 2001a)  
A980C Mid TM12 (Crowley et al. 2009)* 
V982C Mid TM12 (Loo and Clarke 2001a, 2002, 2001c) (Crowley et al. 2009)* 
F994C Bottom TM12 (Loo and Clarke 2001a) (Crowley et al. 2009)* 
Table 1.1: Residue positions mutated to cysteine by site-directed mutagenesis of cysless P-gp 
and studies in which they have been previously used. ‘Top’ refers to positions close to the 
extracellular side of the membrane, ‘Mid’ to the central portion of the membrane-spanning 
helix and ‘Bottom’ to the intracellular side of the membrane. *denotes a study in which 
parameters of ATPase activity have been measured and found to be not significantly reduced 
relative to the cysless parent.  
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PDB 
code Origin 
Structure 
determination 
technique 
Resolution 
(Å) State Misc. details 
3G5U Murine X-Ray crystallography 3.8 Basal 
Improper 
residue 
assignment: 
TM3-5  
4M1M Murine X-Ray crystallography 3.8 Basal N/A 
4F4C C. elegans 
X-Ray 
crystallography 3.4 Basal N/A 
6FN1 
Human/ 
murine 
chimera 
Cryo-EM 3.6 Inhibitor-bound 
Altered 
activity/ 
cross-linked 
NBDs/ 
UIC2 antibody 
bound 
6C0V Human Cryo-EM 3.4 ATP-bound N/A 
Figure 1.12: Details regarding selected extant P-gp structures. All P-gp structure 
representations were generated in VMD 1.9.1. The UIC2 antibody in the 6FN1 structure has been 
excluded, while the VDW radii of the two associated molecules of zosuquidar are shown in red.  
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P-gp is the best representation of human P-gp in a lipid bilayer, experimentally 
determined inter-residue distances would be compared to existing murine crystal 
structures (Li, Jaimes, and Aller 2014; Aller et al. 2009) and MD simulations (O'Mara 
2012; O'Mara and Mark 2014). Finally, the ATPase activity of P-gp double mutants was 
to be measured after intramolecular cross-linking at the determined basal state inter-
residue distance. Any effects on activity could then be attributed to the ‘trapping’ of 
specific points of the two helices in the basal orientation, to show the role of relative 
motion between particular areas of the helices. 
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2.1 Materials 
Nicardipine hydrochloride, vinblastine sulphate and disodium adenosine triphosphate 
(ATP) were purchased from Sigma-Aldrich (NSW, Australia). Bismethanethiosulfonate 
(MTS) reagents and MTSL (S-[1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl] 
methyl methanesulfonothioate) were obtained from Santa Cruz Biotech (Texas, USA). 
Q-Band EPR tubes (round bottom) were purchased from Wilmad Lab Glass (New 
Jersey, USA). Analysis grade n-Dodecyl-β-D-Maltopyranoside (DDM) was purchased 
from Anatrace (Ohio, USA). Crude Escherichia coli lipid extract was obtained from 
Avanti polar lipids (Alabama, USA). Ni-NTA His●Bind® resin was obtained from 
Merck Millipore (Victoria, Australia). Disposable PD-10 Desalting Columns, with 
Sephadex G-25 resin were from GE Healthcare Life Sciences (NSW, Australia). EX-
CELL 405 media powder was purchased from SAFC Biosciences, (Kansas, USA), 
liquid media was made according to the manufacturer’s instructions and filter-sterilised 
(0.22μM) before use. Insect Express medium was obtained from Lonza (Victoria, 
Australia). Penicillin streptomycin (10,000 U ml-1 penicillin 10,000 μg ml-1 
streptomycin) obtained from Life Technologies (New York, USA). Foetal Calf Serum 
(FCS) was purchased from Biological Bovogen Ltd (Victoria, Australia). Trypan Blue 
solution (0.4% w v-1) was purchased Sigma Aldrich (Victoria, Australia). 
 PageBlueTM Protein Staining Solution and the Spectra Multicolor High Range 
Protein Ladder were from Thermo Scientific (Victoria, Australia). The anti-His Tag 
HRP-Labelled Mouse Monoclonal IgG1 antibody was purchased from R&D Systems 
(MN, USA). Nicardipine and vinblastine were dissolved in dimethyl sulfoxide (DMSO) 
to a concentration of 50mM and stored at -20°C. Stock solutions of MTS reagents were 
prepared in ≥99.9% anhydrous DMSO (Sigma) at a concentration of 90mM and stored 
pursuant to the manufacturer’s instructions for each molecule. SIMAFASTTM protease 
inhibitor cocktail tablets (EDTA-free) were purchased from Sigma Aldrich (Victoria, 
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Australia); one tablet was dissolved 10 ml distilled H20 to form a 10X stock solution, 
stored at -20°C. Protease Inhibitor Cocktail Set III (EDTA-Free) was obtained from 
Calbiochem. Triton X100 was from Ajax Finechem Pty Ltd (NSW, Australia). 
ProtranTM 0.2μm NC Nitrocellulose Blotting Membrane was purchased from Amersham 
(WA, Australia). SM2 Biobeads, and the Biorad DCTM total protein assay kit were 
obtained from Biorad, Australia. Disodium ATP salt hydrate, Tween®20 and all general 
reagents were purchased from Sigma Aldrich (Victoria, Australia).  
2.2 Tissue culture of Insect cells  
 
Insect cell lines were derived from ovarian tissue of two organisms: Hi5 cells, 
originating from Trichoplusia ni cabbage looper, and Sf9 cells of the fall worm 
Spodoptera frugiperda were maintained in suspension as described previously (Rothnie 
et al. 2004; Taylor et al. 2001). The cells were cultured for a maximum of 25 subculture 
passages, in the presence of penicillin and streptomycin, 100U ml-1 and 100μg ml-1 
respectively. Hi5 cells were routinely grown from a starting density of 5x105 cells ml-1 
in serum-free EX-CELL 405 media and were maintained with orbital shaking until cell 
density was ≥ 3x106 cell ml-1. Sf9 cells were maintained between 1x106 and 6x106 cells 
ml-1 in Insect Express medium containing FCS (10% v v-1). Sf9 cells were also 
maintained in suspension in serum free Insect Express, in this case they were designated 
Sf900.  
2.2.1 Recombinant baculovirus production and amplification 
 
Initial (P1) stocks of recombinant baculovirus containing the 982P-gp single mutant and 
each of the nine double mutants (Table 2.2) were generated using site-directed 
mutagenesis of the cysteine free P-gp (CyslessP-gp) coding sequence by Dr Ian Kerr at the 
University of Nottingham, as previously described (Rothnie et al. 2005; Taylor et al. 
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2001; Mittra et al. 2016). The previously characterised CyslessP-gp was generated by 
substituting the seven endogenous cysteine codons with serine codons, and attaching a 
C-terminal dodeca-histidine tag (Taylor et al. 2001).  
TM6 TM12 Double mutant 
F343C V974C 343-974P-gp 
F343C V982C 343-982P-gp 
F343C F994C 343-994P-gp 
A354C V974C 354-974P-gp 
A354C V982C 354-982P-gp 
A354C F994C 354-994P-gp 
V331C A980C 331-980P-gp 
F343C A980C 343-980P-gp 
A354C A980C 354-980P-gp 
Table 2.2: Identity of the residues mutated to cysteine to generate P-gp double-mutants. Each 
double mutant contained one cysteine introduced in TM6 and one in TM12.  
P1 stocks were stored at -80°C and used to generate derivative working stocks 
by two rounds of amplification in serum-free Sf900 cells. First derivative stock (P2) 
was generated by addition of P1 baculovirus stock (approximately 1*108 plaque 
forming units [pfu] ml-1) to Sf900 cells in suspension at a density of approximately 
2*106 cells ml-1, using a multiplicity of infection (MOI) of 0.1. After 5-6 days of 
shaking at 27°C a sample of cells was counted in the presence of Trypan Blue. When at 
least 70% cell death was observed by Trypan Blue uptake the culture was harvested by 
centrifugation at 4000g for 10 minutes at 4°C to pellet cells for removal. This period of 
infection has been demonstrated to yield a viral titre of 1*108 plaque forming units per 
millilitre (pfu ml-1) in the culture medium (Manual 2011). FCS was added to the 
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supernatant to a concentration of 3% v v-1 and the P2 stock was stored at 4°C for up to 
12 months. A second derivative stock (P3) was generated in the same manner from the 
P2 recombinant baculovirus encoding each of the P-gp mutants; this was stored at 4°C 
for up to 12 months.  
2.2.2 Expression of P-gp in Hi5 cells by infection with recombinant 
baculovirus 
 
P-gp mutants were expressed by infection of Hi5 cells with recombinant baculovirus via 
the method used previously by Callaghan et. al. (Taylor et al. 2001; Storm et al. 2007; 
Rothnie et al. 2005; Crowley et al. 2009). Hi5 cells were suspended in medium to a 
density of 1.5*106 cells ml-1. After approximately 24hrs (when a density of 3*106 cells 
ml-1 was reached) the cells were infected by direct addition of P3 recombinant 
baculovirus. The P3 stock generated in Section 2.2.1 (1*108 pfu ml-1) was added at a 
MOI of 2. After 1 hour incubating at 27°C without shaking, Hi5 cells were diluted with 
EX-CELL 405 media to a density of 1.5*106 cells ml-1. The Hi5/baculovirus culture was 
incubated with shaking at 27°C for a further 72 hours. Subsequently cell viability was 
assessed with Trypan Blue, if approximately 30% cell death was observed the cells were 
harvested by centrifugation at 4000xg for 10 min and cell pellets were stored at -80°C 
for up to 12 months. 
2.2.3 Isolation of crude membranes from Hi5 cells 
 
Crude membranes were isolated from Hi5 cell pellets by high-pressure nitrogen 
cavitation and differential centrifugation, as described previously (Taylor et al. 2001). 
Briefly, a high sucrose buffer (20mM MOPS [3-(N-morpholino)propanesulfonic acid], 
200mM NaCl, 0.2mM CaCl2, 250mM sucrose) containing 1X SIGMAFAST protease 
inhibitor was used to resuspend the Hi5 cell pellet. Cells were burst by four 20 min 
rounds of cavitation at 4°C with 1000psi high-purity nitrogen. Cell debris was removed 
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by centrifugation at 2000*g for 10 min. Membranes were pelleted by a second 
centrifugation step (100,000*g for 45 mins) and resuspended in a second buffer (20mM 
MOPS, 200mM NaCl, 250mM sucrose) before snap-freezing and storage at -80°C for 
up to one year.  
2.3 Production of purified reconstituted P-gp 
2.3.1 Purification of P-gp by metal affinity chromatography 
 
Crude Hi5 membranes were pelleted by centrifugation at 100,000g for 45 mins. 
Solubilisation of proteins from the membrane was achieved by resuspension of the 
crude membrane to 5mg ml-1 total protein by Dounce homogenisation in a 
lipid/detergent containing solubilisation buffer (2% [w v-1] DDM, 4mg ml-1crude E. 
Coli lipid/cholesterol (80:20), 10mM MOPS, 150mM NaCl, 1.5mM MgSO4, 10% [v v-
1] glycerol, pH 6.8) as previously described (Modok, Heyward, and Callaghan 2004; 
Taylor et al. 2001; Rothnie et al. 2004). The membrane/buffer mixture was magnetically 
stirred at 4°C for 90 min. Insoluble proteins were removed by centrifugation at 
100,000*g for 30 min. The solubilised protein mixture in the supernatant was incubated 
with Ni-NTA resin at a volume ratio of 20:1, this was agitated on a windmill for one 
hour at 4°C. Imidazole (10mM) was added to binding of weakly interacting proteins to 
the Ni-NTA resin. Gravity chromatography was done as described previously (Taylor et 
al. 2001). The resin was washed sequentially with a chromatography buffer (0.1% w v-1 
DDM, 1mg ml-1crude E. Coli lipid/cholesterol (80:20), 10mM MOPS, 150mM NaCl, 
1.5mM MgSO4, 10% v v-1 glycerol). Initial wash steps of 10 bed volumes (bv) 
containing low concentrations of imidazole (10, 20mM) at pH 8.0 were done to remove 
weakly-bound contaminants. A final 2mM Imidazole wash (pH 8.0) was performed to 
flush residual contaminants from the prior washes in the retention volume of the 
column. P-gp was eluted from the column in five bed volumes of a high imidazole 
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buffer (250mM imidazole, 1mg ml-1 E. Coli lipid/cholesterol (80:20), 0.1% [w v-1] 
DDM, 10mM MOPS, 150mM NaCl, 1.5mM MgSO4, 10% [v v-1] glycerol, pH 6.8). 
Purity of P-gp preparations was confirmed by SDS-PAGE electrophoresis and PageBlue 
(Thermo Fisher) staining (section 2.5). 
2.3.2 Reconstitution of P-gp into proteoliposomes  
 
P-gp mutants were reconstituted from lipid(1 mg ml-1)/detergent (0.1% w v-1) micelles 
into proteoliposomes using SM2 Biobeads (Biorad, Australia) to selectively adsorb 
DDM (Rigaud et al. 1998). A typical reconstitution would be performed using a 2.5ml 
elution fraction, containing 50μg P-gp (20μg ml-1). Washed biobeads (225 mg ml-1) 
were added to eluted P-gp and the mixture was agitated on a windmill for 2 hours at 
20°C. Reconstitution was confirmed by sucrose density centrifugation as previously 
described (Taylor et al. 2001; Rigaud, Paternostre, and Bluzat 1988). 200μl of 
reconstituted P-gp was mixed 1:1 with 200μl sucrose (60% w v-1) in Triton X-100 
(0.05% w v-1) containing buffer (50mM Tris.HCl, 150mM NH4Cl, 5mM MgSO4, 0.02% 
[w v-1] NaN3, pH 7.4), the mixture (30% sucrose w v-1) was transferred to a centrifuge 
tube and the meniscus was marked on the outside of the tube. Layers of sucrose solution 
were added on top, in decreasing order of sucrose density (20, 10, 5, 0% w v-1 sucrose), 
the meniscus of each layer was marked. The resulting density gradient was centrifuged 
at 150,000g, 4°C for 16 hours. Lipid distribution was visibly observed, the layers of the 
gradient were separately aspirated and the protein distribution was analysed by SDS-
PAGE and Western blotting (sections 2.5, 2.6). Successful reconstitution was defined 
by co-migration of lipid and protein through the gradient.  The concentration of P-gp in 
proteoliposomes was estimated by quantitative densitometry (Section 2.5.1).  
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2.4 Determination of Protein concentration 
 
The Biorad DCTM total protein assay was used to determine total protein concentration 
of lysed cells and crude membrane preparations. Typically, three volumes (2, 4 and 6μl) 
of each sample were analysed against a standard curve (0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10μg) of bovine serum albumin (BSA). For details of the kit see the manufacturer’s 
instructions. Linear regression was used to determine the relationship between 
absorbance at 750nm and BSA concentration. Interpolation of the absorbance observed 
for 2, 4 and 6μl aliquots of sample was used to determine the total protein amount in 
each; these values were used to calculate an average observed protein concentration. 
2.5 SDS-Page gel electrophoresis  
 
Protein samples were analysed by SDS-PAGE using the Biorad mini-
PROTEAN® Tetra system with 7% poly-acrylamide gels (Laemmli 1970). Protein 
samples were prepared in Laemmli sample buffer (LSB), (30mM Tris.HCl [pH 6.8], 1% 
[w v-1] SDS, 6% [v v-1] glycerol, 50mM DTT) and electrophoresed at 100-200 V. 
Subsequently, protein bands were visualised using the PageBlue protein staining 
solution according to the manufacturer’s instructions. Gel images were captured using 
the Molecular Imager® Biorad Gel Doc XR+ system with Image LabTM software. 
Protein molecular weights were determined by comparison with a high range protein 
standard ladder. 
2.5.1 Estimation of P-gp concentration by quantitative densitometric 
analysis 
 
The concentration of purified reconstituted P-gp could not be measured with any 
commercial kit, due to interference in absorbance spectra by imidazole and lipid 
vesicles (Taylor et al. 2001). Consequently, samples of reconstituted P-gp (10, 20, 40μl) 
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were analysed by SDS-PAGE (Section 2.5) against a standard curve of BSA (0.1, 0.2, 
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0μg). Poly-acrylamide gels were stained and images 
captured as in Section 2.5. Densitometric analysis was performed using ImageJ to 
determine the optical density of bands relating to BSA and P-gp. Linear regression was 
used to describe the relationship between protein amount in BSA lanes and the number 
of pixels in the bands. The number of pixels observed in the bands relating to P-gp was 
interpolated to estimate the protein amount in these lanes. 
2.6 Western immunoblotting 
 
Proteins were transferred to nitrocellulose membrane following SDS-PAGE at 
90V for 1 hour (Towbin, Staehelin, and Gordon 1979). Membranes were blocked for 
1hr with 5% w v-1 skim milk powder in PBST (135mM NaCl, 2.5mM KCl, 10mM 
Na2HPO4, 1.75mN KH2PO4, 0.1% [v v-1] Tween20, pH 7.4) and agitated by rocking 
overnight at 4°C with 1: 10,000 Anti-His-Tag antibody. Subsequently, protein bands 
were visualised by chemiluminescence treatment using the Amersham ECLTM start 
western blotting detection reagent, according to the manufacturer’s instructions. 
Chemiluminescence was captured using a GelDoc Vilber Fusion SL 
Chemiluminescence system. 
2.7 Measuring the rate of ATP hydrolysis by P-gp  
 
The rate of ATP hydrolysis by P-gp was quantified by a colorimetric assay detecting 
inorganic phosphate release, as previously described (Chifflet et al. 1988; Taylor et al. 
2001). Proteoliposomes containing 0.1-0.4μg of P-gp were incubated at 37°C for 40 
minutes in an ATPase buffer containing: 50mM Tris.HCl, 150mM NH4Cl, 5mM 
MgSO4, 0.02% w v-1 NaN3. The concentration of DMSO in the reaction mixture was 
kept at 1% v v-1; at this proportion it has been previously demonstrated to not affect 
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ATPase activity (Martin et al. 1997). ATP, in ATPase buffer, was added to a final 
concentration which varied dependent on the parameters of activity being measured. 
The reaction was stopped after 40 minutes had elapsed by addition of SDS (40μl 12% w 
v-1). Inorganic phosphate was detected by a colour change upon addition of an 
ammonium molybdate complex (Chifflet et al. 1988). Absorbance at 750nm was 
measured using an ImarkTM plate reader. 
 Two variations of the ATPase assay were used to determine different parameters 
of P-gp activity. The first type was used to determine the Michealis-Menten parameters 
of P-gp activity in basal (no drug present) or nicardipine-stimulated conditions. This 
was performed with an increasing concentration of ATP (0-1.75mM) and a fixed 
concentration of nicardipine (10μM) to measure stimulated activity, or ATP and DMSO 
to measure basal activity. The Michealis-Menten (Equation 1.) curve was fitted to the 
data by non-linear regression to find the maximal rate of activity (Vmax) and affinity for 
ATP (Km): 
! = #$%&[(](+,-[(]) 
Where V refers to ATPase activity (nmol Pi min-1 mg protein-1) and [A] refers to the 
concentration of ATP (M). The second variation of the ATPase assay was done in the 
presence of a fixed, saturating concentration of ATP (2mM) and a varying concentration 
of drug modulators (nicardipine or vinblastine). This was used to determine the potency 
of P-gp for interaction with the two drugs. Data was plotted as a function of the 
increasing concentration of the drug on a logarithmic scale; non-linear regression was 
used to fit general dose-response curves (Equation 2.): ! = !,/0 + #$%&2	#$45(6-67(89:;<=>?<@[A])) 
Equation 1 
Equation 2 
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 ‘V’ is ATPase activity (nmol Pi min-1 mg protein-1). Where [B] is the drug 
concentration (M), EC50 is the effective concentration of modulator required to achieve 
50% of the observed stimulation from Vmin (minimum rate) to Vmax (maximum rate). 
Overall the two types of ATPase assays can be used to rigorously asses the function of 
P-gp, Equation 1 allows the affinity for ATP (Km) to be determined, while Equation 2 
measures the potency for interaction with drugs (EC50). Both equations measure the 
maximal rate of basal and drug stimulated ATPase activity. 
2.8 Cross-linking P-gp with homobifunctional methanethiosulphonate 
reagents 
 
The distance between cysteine residues introduced in TM6 & 12 was measured 
by intramolecular cross-linking with homobifunctional methanethiosulphonate (MTS) 
reagents. These molecules consist of a saturated hydrocarbon spacer arm, and a 
methanethiosulphonate functional group on either end (Figure 3.8). The functional 
groups react with sulphydryls (SH) to ‘cross-link’ to another molecule. The only 
sulphydryls present in the P-gp double mutants employed in this study are in the side 
chains of the two cysteine residues introduced. If an MTS reagent is of an appropriate 
length to span the distance between the two cysteines introduced, the two functional 
groups may react with the two cysteines, creating an intramolecular cross-link.  
Intramolecular cross-linking can be detected because during SDS-PAGE a 
denatured protein containing a cross-link does not run through a poly-acrylamide gel as 
fast as a protein with no intramolecular cross-link. This happens because the protein 
containing an intramolecular cross-link will be ‘bunched’ by the covalent attachment of 
two distant parts of the primary structure (Figure 2.13). Previous studies have incubated 
double mutants with a range of MTS reagents, and reported the range of lengths of MTS 
reagents which bind as the range of inter-residue distances (Loo and Clarke 2002, 
  
76 
 
2014b, 2001c; O'Mara 2012). One of the major hurdles in this investigation was 
rationalising the observation that the cross-linking reaction never resulted in 100% 
altered migration of P-gp. The key realisation was that the cross-linking reaction 
involves a competition between the attachment of two MTS molecules at the two 
cysteines, and the formation of an intramolecular link by one MTS molecule. Only an 
intramolecular link will cause the bunching of the denatured protein  
 
Figure 2.13: Effect of an MTS reagent on migration of 343-974P-gp through a polyacrylamide 
gel. The upper panel shows the two possible modes of MTS binding, with the formation of an 
intramolecular cross-link on the left. The middle panel depicts the denatured peptide strands. The 
lower panel shows the observed migration though a polyacrylamide gel. MTS reagents are shown 
as red lines, and cysteine residues as blue circles. 
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strand which leads to altered migration through a poly-acrylamide gel.  A reaction 
between a double mutant and the MTS molecule which is the closest in length to the 
span between the two thiol groups will cause the highest proportion of intramolecular 
cross-linking, because this reaction will better out-compete the binding of two 
molecules individually (Figure 2.13). This is unlike treatment with an oxidant such as 
copper phenanthroline, where the proportion of intramolecular cross-linking will 
eventually reach 100% if there is an appropriate distance between two cysteines. The 
oxidant only makes a direct cross-link between two cysteine residues more favourable, 
as such there is no alternative endpoint to the reaction, so no competition. 
In this investigation intramolecular cross-linking was quantified in order to show 
which length of MTS reagent caused the highest proportion of homobifunctional 
attachment. The cross-linking reaction is reversible by treatment with educing agents, so 
all solutions used in cross-linking experiments were free of reducing agents (DTT, 
mercaptoethanol etc.). The MTS reagents were initially made up to a 90mM stock in 
anhydrous DMSO, then diluted to 3mM prior to use. The cross-linkers were added to 
purified reconstituted protein to a final concentration of 30µM, with the amount of 
DMSO kept at 1% of the reaction mixture volume. Reaction mixtures were placed in a 
water bath at 25°C for 2hrs with 30µM MTS reagent. Time point samples of P-gp 
incubated with MTS reagents (10µl) were taken at 0, 5, 10, 30, 60 and 120 minutes, and 
the addition of 3X LSB (5μl), (3.3% w v-1 SDS, 17% v v-1 glycerol, 0.03% 
bromophenol blue, 0.1M Tris.HCl [pH 6.8]) was used to quench the reaction. In order to 
quantify the proportion of cross-linking caused by each MTS reagent, a negative control 
of each mutant was used in each experiment which was treated with DMSO only. This 
was done so that any level of altered migration observed without MTS treatment could 
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be categorised as such and subtracted from the quantification of cross-linking caused by 
MTS reagents 
As noted above, intramolecular cross-linking is detected by altered migration of 
protein through a poly-acrylamide gel. This can be visualised by staining of the gel or 
immuno-blotting, both of which raise potential problems when trying to quantify 
intramolecular cross-linking. PageBlue staining is not specific to P-gp, so appearance of 
a higher weight band after treatment with MTS reagents could be due to intermolecular 
cross-linking between two contaminants in the sample. Total protein staining is also less 
sensitive than immuno-blotting, making small amounts of cross-linking in the earlier 
time points difficult to detect. Immuno-blotting is sensitive and specific, but 
quantitating results is challenging due to potential over- or under-exposure of the blot, 
which may cause less intense bands to either appear more intense than they are or 
disappear entirely. The strategy used to avoid these problems was inspired by previous 
investigations using fluorescent probes (Storm et al. 2008; Crowley et al. 2010). In 
these previous studies a control mutant, known to be 100% labelled, was analysed 
alongside the samples in coomassie stained gels and UV imaging. Using densitometry, 
the relationship between the size of the coomassie band and the fluorescent band 
representing the control was determined. This ratio was then normalised to 100%, and 
the proportion of labelling in the samples could be determined.  
Positive controls for intramolecular cross-linking were used in the present 
investigation. A positive control was made for each double mutant with each cross-
linker, taken from the endpoint of the reaction so as to minimise problems associated 
with the limited sensitivity of coomassie staining. The proportion of altered migration 
for this control was measured by both immuno-blotting (Section 2.6) and staining 
(Section 2.5), so the relationship between the proportions of altered migration observed 
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in the two techniques could be calculated. Immuno-blotting was used to measure altered 
migration in the time point samples, as this is more sensitive to the low levels of cross-
linking seen at earlier time points. The proportion of altered migration observed in the 
blot of the time points was then normalised with the relationship between staining and 
immuno-blot observations calculated for the positive control, to compensate for the 
exposure level. This strategy thus allowed determination of the proportion of cross-
linking that was sensitive, specific and not subject to error from varying exposure 
levels. 
2.8.1 A strategy to quantify the proportion of intramolecular cross-
linking of P-gp by MTS reagents 
 
The positive controls for a double mutant treated with each MTS reagent were subjected 
to SDS-PAGE (Section 2.5) and PageBlue staining alongside the DMSO treated 
negative control for that mutant and a molecular weight marker. The proportion of P-gp 
showing altered migration through 7% acrylamide gels was quantified by densitometric 
analysis using ImageJ. The number of pixels was measured for bands at 140kDa 
(140Pix), which represent native P-gp, and bands at 190kDa (190Pix), which represent 
P-gp cross-linked by MTS reagents. The proportion of cross-linking for the positive 
control sample (XL%True) on the PageBlue stained gel was determined (Equation 3) by 
dividing the number of pixels in the cross-linked P-gp band by the total number of 
pixels for both P-gp bands in that lane: 
BC%EFGH = I 190MNO[140MNO + 190MNO]Q ∗ 100 
The DMSO treated negative control, positive control, and time point samples 
were used together in a second round of SDS-PAGE, this was transferred to 
nitrocellulose film for immuno-blotting (Section 2.6). The apparent proportion of cross-
Equation 3 
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linking in each lane visualised by western blotting (XL%App), was determined (Equation 
4) in the same manner as used for the stained gel:  
BC%STT = I 190MNO[140MNO + 190MNO]Q ∗ 100 
Observations of the proportion of altered migration in the positive control from 
the PageBlue stained gel (XL%True) and the western blot (XL%App) were used to 
calculate (Equation 5) the exposure factor (Efac): 
UVWX = BC%EFGHBC%STT  
As explained in Section 2.8, in order for observations in immuno-blots to be 
quantitated, the exposure level of the blot (Efac) must be corrected for. The Efac, 
calculated from the proportion of cross-linking observed in the positive control, was 
used to convert (Equation 6) the apparent proportion of intramolecular cross-linking of 
P-gp in the time course samples and DMSO treated negative control into a true 
proportion of cross-linking: 
BC%EFGH = BC%STT ∗ UVWX 
The proportion of cross-linking observed in the DMSO treated negative control 
was subtracted from the proportion of cross-linking observed in each of the time course 
samples. At this point the proportion of cross-linking in P-gp caused by the MTS 
reagent is known at each time point, this was used to calculate the maximal extent of 
cross-linking caused by that MTS reagent with that double mutant. The proportion of 
cross-linked P-gp (Y) was plotted as a function of time (X), and the plateau, or maximal 
extent of cross-linking (XLmax) was determined (Equation 7) by fitting a one-phase 
association curve to the data:  
Equation 4 
Equation 5 
Equation 6 
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Y = Y7 + (MZW[\W] − Y7) ∗ (1 − \(2_`)) 
Where Y0 is the percentage of cross-linking when time is zero; the Plateau is the 
proportion of cross-linking after infinite time and K is the rate constant. At least three 
independent experiments were completed to determine the average XLmax for a P-gp 
double mutant with an MTS reagent. This data can be used to determine the distance 
between the two residues, if the lengths of the MTS reagents are known. 
2.8.2 Calculation of the lengths of MTS reagents 
 
The manufacturers of the MTS reagents (Santa Cruz Biochem) do not state the length of 
the molecules; however they reference a paper in which the reagents are used to 
measure distances between cysteine residues (Loo and Clarke 2001c). Loo and Clarke 
do not give any explanation of how the lengths they used were calculated, other than the 
statement that they were ‘calculated from the estimated size of the bonds’, however 
other investigations have used these distances (Loo and Clarke 2001c; Zhu et al. 2016; 
Collier et al. 2014; Moore et al. 2008; Moore and Fillingame 2008; Rothnie et al. 2004). 
This investigation sought to accurately determine the distance between cysteine 
residues, accurate MTS lengths were fundamental to this. Therefore, this study opted to 
calculate the length of the MTS reagents, rather than use the previously used but 
unexplained lengths. This is not done by adding up the lengths of all the bonds in the 
spacer arm, because the bonds of a saturated carbon atom are not oriented at 180° 
angles. Saturated hydrocarbons are commonly represented as a ‘zig-zag’ because the 
bonds are oriented at an angle of 109° (Figure 2.14). Each set of two bonds is an 
isosceles triangle because there are two sides (the two carbon to carbon bonds) which 
are of equal length.  
Equation 7 
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Figure 2.14: A representation of the isosceles triangle formed by two carbon to carbon bonds. 
Carbon to carbon bonds (b) are depicted by solid black lines. The angle between bonds in a 
tetrahedral carbon atom is highlighted in green, where ‘θ’ is the other two equal angles in the 
triangle and is represented in red. The black dashed line marked with an ‘x’ is the unequal side 
of the triangle and is length of the isosceles unit. 
The total length of an MTS reagent can be calculated by adding up the length of 
all the ‘isosceles units’ of two carbon to carbon or carbon to oxygen bonds, then adding 
a further isosceles unit for the length of the two carbon to sulphur bonds. Treating each 
pair of bonds as an isosceles triangle allows calculation (Equation 8) of the length of a 
three atom span using trigonometry: 
O = 2(b) ∗ Xcde 
Where ‘x’ is the length of an isosceles unit in angstroms; this is the third side of 
the isosceles triangle not of the same length as the other two. The length of one bond in 
angstroms is represented by ‘b’, this is the length of one of the two equal sides of the 
triangle. The angle ‘θ’ is the two equal angles of the isosceles triangle. The angle ‘θ’ 
can be calculated separately because the one unequal angle is known, and all angles in a 
triangle add to 180°. The total length of MTS reagents was then calculated (Equation 9) 
by multiplying the length of as isosceles unit by the number of carbon atoms in the 
MTS reagent and adding the length of the two carbon to sulphur bonds: 
Equation 8 
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fgf	hicdd − ZNjkNjl	dmWj	nÅp = 	Oq 	+	rsOt2 u ∗ (g − 1) − v ∗ Ot + v ∗ Ow	x 
 Where ‘y’ is the total number of atoms in the spacer arm of the MTS reagent, ‘MyM’ is 
the name of the reagent (e.g. M1M contains one [carbon] atom in the spacer arm), ‘z’ is 
the number of oxygen atoms in the spacer arm. The term ‘xS’ represents the length of 
the isosceles triangle comprising two carbon to sulphur bonds. As isosceles unit 
comprising three carbon atoms has a span of ‘xC’. The length of the spacer arm is 
represented by the term [(xC/2)*(C-1) - z*xC + z*xO]. The number of carbon to carbon 
to carbon isosceles units is multiplied by the number of carbons, but first it must be 
divided by two because the addition of a new isosceles unit requires the addition of two 
carbons (xC/2). While one must be subtracted from the total number of carbons (C-1) 
because there are no carbon to carbon bonds unless at least two carbons are present in 
the spacer arm. For each oxygen atom in the spacer arm, one carbon-carbon-carbon unit 
is lost (-z*xC), and one carbon-oxygen-carbon unit is added (+z*xO) . 
2.8.3 Determining the distance between cysteine residues from cross-
linking results 
 
Using the proportion of cross-linking of a P-gp double mutant with each MTS reagent 
and the lengths of these MTS reagents, the distance between the two cysteines 
introduced in that double mutant was determined. The average XLmax (as calculated in 
section 2.8.1) for each cross-linker with a particular P-gp mutant was plotted as a 
function of the cross-linking span of that reagent as calculated by the method described 
in section 2.8.2. A Gaussian distribution (Equation 10) was fitted to the data to 
determine the average cross-linking span between the two introduced cysteines: 
Y = yzmZN[]{\ ∗ \(27.}~`2HÄ0qÅ ÇÉ) 
Equation 9 
Equation 10 
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Where Y values are the extents of cross-linking and X values are the lengths of the 
cross-linkers. The Amplitude is the extent of cross-linking (XLmax) at the centre of the 
distribution; Mean is the distance (Å) at the centre of the distribution and SD is the 
width of the distribution. The cross-linking span provides an estimate of the distance 
between the two cysteine residues in the basal conformation of P-gp. 
2.8.4 The ATPase activity of P-gp mutants following covalent 
modification with MTS reagents 
 
To determine the effect of intramolecular cross-linking on the activity of P-gp, the 
double mutants were cross-linked, then ATPase activity measurements were done as in 
Section 2.7. Proteoliposomes containing 0.1-0.4μg of P-gp mutants were incubated for 2 
hours at 25°C, with 1% v v-1 DMSO, or 30μM MTS reagent, as described in section 2.8. 
ATPase assays used a fixed concentration of ATP (2mM) and a varying concentration 
of nicardipine (10-8 to 10-4.5M). Three controls were used to confirm that observed 
effects on ATPase activity were a result of cross-linking. The first was an untreated 
sample of the P-gp mutant, which was not incubated at 25°C prior to use in the ATPase 
assay. The second was the DMSO control, this was incubated for two hours at 25°C 
prior to use in the ATPase assay, but treated with DMSO only rather than MTS 
reagents. The third was the treatment of CyslessP-gp with MTS reagents under the same 
conditions as the double mutants, prior to use in ATPase assays. The rate of ATPase 
activity (nmol Pi min-1 mg protein-1) was quantified for the controls and MTS treated 
double mutants against a standard curve of known phosphate concentrations. Data was 
fitted with the general dose-response equation by non-linear least squares regression, as 
in section 2.7, to obtain the maximum rate of activity and the concentration of drug 
required to elicit a half maximal response (EC50). Any changes in the parameters of 
ATPase activity in the DMSO treated control in comparison to the untreated control 
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would show that these changes are be due to the incubation conditions; while any 
changes in the activity of CyslessP-gp after treatment with MTS reagents would show that 
MTS reagents can affect ATPase activity without covalent attachment to the protein.  
2.9 Attachment of MTSL probes to P-gp for double resonance EPR 
To prepare EPR samples larger scale (100 - 200mg) purifications were done with on-
resin MTSL labelling, as previously described, with a few key modifications (van 
Wonderen et al. 2014). The solubilisation and chromatography buffers were composed 
of the DDM, E.coli lipid and cholesterol proportions detailed in section 2.3.1. MTSL 
was dissolved in ethanol (absolute) to a concentration of 100mM. After solubilisation 
and centrifugation 1ml packed resin was added. The column was washed with 20 bed 
volumes (bv) of 10, 20 and 30 mM imidazole. Resin with P-gp still attached was 
removed from the column in chromatography buffer containing 2mM imidazole (pH 
6.8) and MTSL (100μM). The resin/protein/MTSL mixture was gently agitated by 
rocking overnight at 4°C, before washing with 15 bv of 2mM imidazole 
chromatography buffer (pH8) and 40 bv of 2mM imidazole chromatography buffer 
(pH6.8). P-gp was eluted from the column in two fractions of chromatography buffer 
with an imidazole concentration of 500mM, at pH 6.8, these two elution fractions were 
2.5bv each.  
The second elution fraction was reconstituted into proteoliposomes directly after 
recovery from the column, as in Section 2.3.2. After reconstitution, this second elution 
fraction was used in ATPase assays (fixed concentration of ATP, varied concentration 
of drug as in section 2.7) to confirm the retention of P-gp function. Buffer exchange was 
used to remove imidazole from the first fraction of eluted P-gp as described previously 
(van Wonderen et al. 2014). PD-10 Desalting Columns, containing 8.3ml of Sephadex 
G-25 resin were equilibrated with three bv of gel filtration chromatography (GFC) 
buffer (0.1% w v-1 DDM, 1mg ml-1crude E. Coli lipid/cholesterol (80:20), 10mM 
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MOPS, 150mM NaCl, 1.5mM MgSO4, 5% v v-1 glycerol, pH6.8) this was collected as it 
flowed through the column for re-use. Subsequently, the 2.5ml first elution fraction was 
added to the column and the flow through was discarded. The 3bv GFC buffer was 
reapplied to the column, and the first 10 ml of flow-through was collected in 1ml 
fractions. The second, third and fourth fractions were combined and biobeads were used 
to reconstitute P-gp into proteoliposomes (Section 2.3.2). Proteoliposomes were 
pelleted by centrifugation (20,000g, 20 min) and resuspended in 10mM MOPS, 150mM 
NaCl, 1.5mM MgSO4, 5% v v-1 glycerol, pH 6.8, to a P-gp concentration of ≥10μM (1.4 
mg ml-1). Approximately 15μl of concentrated proteoliposomes were transferred to a Q-
band EPR tube, before flash-freezing and transport in dry ice.  
2.9.1 Determining the distance between MTSL probes in labelled P-gp 
double mutants by DEER 
 
Double electron-electron resonance was used to measure the distance between MTSL 
labelled cysteine residues introduced in P-gp double mutants. DEER spectroscopy was 
carried out by Assoc. Prof. Jeffrey Harmer at the University of Queensland. This was 
done using ‘four pulse’ sequences as previously described for MTSL labelled proteins 
(Bowen et al. 2016; Lovett, Lovett, and Harmer 2012). In simplified terms, the 
fundamental aim of EPR is to align unpaired electrons in a magnetic field with 
microwave pulses, then measure the ‘echo’ microwave signal released as the electrons 
revert to their prior unaligned spins (Stipe et al. 2001). The character of the echo decay 
signal can be used to infer details about the local environment of the unpaired electrons. 
In the case of double-resonance EPR, the two unpaired electrons in the MTSL probes 
may ‘cross-relax’ if they are sufficiently close in three-dimensional space causing 
oscillations in the decay signal (Stein, Beth, and Hustedt 2015). The strength of the 
oscillations is proportional to the distance between the unpaired electrons, so the 
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distance between the MTSL labels can be calculated. These inter-spin couplings can be 
detected up to a distance of 60Å (Jeschke 2012). The four pulse sequence commences 
with a ‘refocused primary echo sequence’, this refers to two microwave pulses, the first 
of which magnetised the unpaired electrons, the second of which ‘refocused’ them in a 
single plane leading to a more coherent decay signal (Mentink-Vigier et al. 2013). 
DEER measurements were done at 55°K, the oscillation of spins [V(t)] was measured 
over a period of 2 µs. The oscillations due to interspin coupling must be separated from 
the background decay signal, this was done by fitting a background function ([1-∆]Bt) 
to the curve after ‘Tdd’ the time when oscillation was decayed (Stein, Beth, and Hustedt 
2015). The experimental form factor, which is the product of all possible interspin 
coupling contributions (Jeschke et al. 2009), was determined by dividing V(t) by B(t), 
thus separating the contribution of the coupling of the two spins from the background 
decay signal. Inter-spin distance was determined by using DeerAnalysis to fit a two-
dimensional simulated form factor representing a distance to the experimental form 
factor. The fit of this curve then allows the calculation of a distance distribution 
between the spins via the Tikhonov regularisation (Schiemann and Prisner 2007). A 
Gaussian curve was fit to the distance distribution to find the average distance between 
the two MTSL probes and the width of the distribution. 
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CHAPTER 3: Production of purified, reconstituted P-gp double 
mutants and functional analysis. 
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3.1 Inter-residue distances between transmembrane helices 6 & 12 in 
current structural models 
 
A key aim of this project was to determine the relative spatial orientation of TM6 and 
12 in the basal state and compare the results to existing models of the structure of P-gp, 
namely the two crystal structures published for murine P-gp (Aller et al. 2009; Li, 
Jaimes, and Aller 2014). Murine P-gp is considered a good model as it shares 86% 
sequence identity and broad functional similarity with the human protein (discussed in 
Section 6.2.1) In this study distances were measured between a series of pairs of 
residues and compared to predictions from the existing structural models (Table 3.3). 
The experimental strategy necessitated that the residues be mutated to cysteine to allow 
attachment of specific probes. Pairs of residues were selected, each comprising one 
amino acid in TM6 and one in TM12. The specific positions of mutations were chosen 
on the basis of their position in the three-dimensional structure of the protein as 
observed in the crystal structures. These selections were strategically chosen to analyse 
topographical detail along the length of the helices. For example, one double mutant in 
which cysteines were introduced in the place of A354 and F994 (354-994P-gp) was chosen 
because these two residues were both predicted to lie on their respective helices near the 
intracellular leaflet of the membrane. A measurement between these would therefore 
determine the extent of ‘horizontal’ separation between the two helices (Figure 3.15).  
Pairs were also chosen which differed ‘vertically’ i.e. the two residues were not in the 
same part of their respective helices. The double mutant 343-994P-gp, for example, was 
predicted to contain one residue in the centre of the membrane spanning portion of TM6 
and one on the intracellular leaflet of TM12. Measurements on a series of double 
mutants with differing vertical position were used to determine whether the helices were 
aligned vertically as seen in the crystal structures. The combination of vertical and 
horizontal measurements was necessary to determine any discrepancy between the 
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distance measurements and the distances observed in the crystal structures (Table 3.3). 
If only horizontal measurements were performed and the results significantly differed 
from the crystal structures, uncertainty would remain as to whether the discrepancy was 
a result of a different horizontal separation or a vertical misalignment of the helices in 
the crystal structures. If vertical measurements correspond to the crystal structures, but 
horizontal ones differ widely, then it can be deduced that the difference is genuinely due 
to a different horizontal separation. Thus, the position of cysteine residues in the double 
mutants was chosen to enable the combination of one dimensional inter-residue distance 
measurements to inform on the three-dimensional structure. 
 
Figure 3.15 A representation of specific positions selected for mutation to cysteine. The 
horizontal span between A354 and F994 is represented by the black arrow. The vertical span 
between F343 and F994 is represented by the orange arrow. TM6 is shown in blue and TM12 in 
red. The structure shown is a section of the 4M1M crystal structure, visualised using VMD 
1.9.1. 
There were some notable differences between the original (3G5U) and refined 
(4M1M) crystal structures. The largest discrepancies previously reported were in TM3, 
A354 
 
F343 
 
F994 
 
Extracellular leaflet 
 
Intracellular leaflet 
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4 & 5 due to an inappropriate assignment of residues in 3G5U (Ward et al. 2013). For 
this study the distance between the Cα carbons of the selected residues in both crystal 
structures was measured (Table 3.3). This revealed relatively little difference in the 
distances between the backbone carbons of most of the residue pairs used in this study 
when comparing 3G5U to 4M1M; the spans 343-974, 343-994, 354-974, 354-982, 354-
994, 343-980 and 354-980 are less than 2Å different. Pairs 343-982 and 331-980 show 
the largest disagreement, at 2.8Å and 2.4Å respectively. However, these measurements 
of the static crystal structures give no insight into the stability of the protein. For this 
reason MD simulations of P-gp were used to predict the variation in the structure over 
time. 
MD simulations were done by a collaborator (Dr Megan O’Mara, ANU) to 
explore the differences between the 3G5U and 4M1M structures, and to see how the 
structures change when introduced into a simulated bilayer environment (O'Mara 2012; 
O'Mara and Mark 2014). The wild-type murine sequence was used in each simulation, 
as this study aimed to measure the accuracy of wild-type structures. This was done in 
three independent 100ns simulations for each starting structure. In this investigation the 
distances between the selected TM6 and TM12 residues were measured over the course 
of these MD simulations, shown in Table 3.3. These measurements will allow 
comparison of the experimental proximity data to a structural model of P-gp in a lipid 
bilayer. The average inter-residue distances in the MD simulations based on the original 
3G5U and refined 4M1M structures were quantified by taking a measurement at 0.1ns 
intervals during the 300ns simulations. The mean and standard deviation were 
calculated for inter-residue distances in 3G5U and 4M1M based simulations. Average 
distances between the residue pairs 343-974, 354-974, 354-994 and 331-980 had a 
disparity of less than two Angstroms when comparing 3G5U and 4M1M based 
simulations. An average disagreement between 3G5U and 4M1M distances of two to 
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three Angstroms was observed for residue pairs 343-994 and 343-980. There were no 
significant differences (ANOVA p>0.05) comparing 3G5U to 4M1M, despite to the 
known errors in the 3G5U structure, although there is considerably more variability in 
the 3G5U based simulations. Route mean squared deviation (RMSD) values for 
residues in the TMDs in simulations based on 3G5U and 4M1M have been 
demonstrated to regularly exceed 4Å (O'Mara and Mark 2014; O'Mara 2012). The 
greatest  
P-gp Mutant 
3G5U Cα-Cα distance (Å) 4M1M Cα-Cα distance (Å) 
crystal MD range MD average crystal MD range MD average 
343-974 24.5 20.7 - 31.4 26.4 ± 2.4 25.9 24.0 - 29.7 26.9 ± 1.0 
343-982 15.5 10.7 - 22.6 16.8 ± 2.5 18.3 15.9 - 22.8 19.9 ± 1.2 
343-994 18.5 18.3 - 28.6 24.0 ± 1.8 17.1 16.0 - 25.8 21.3 ± 1.6 
354-974 39.8 36.6 - 47.1 41.9 ± 2.6 41.0 39.7 - 47.5 43.2 ± 1.5 
354-982 29.2 21.8 - 34.8 28.9 ± 2.9 30.8 28.3 - 37.2  32.7 ± 1.5 
354-994 21.7 16.5 - 30.3 22.6 ± 2.8 21.3 16.6 - 28.0 21.7 ± 2.1 
331-980 22.6 14.6 - 25.9 20.8 ± 1.8 20.2 18.5 - 25.9 22.7 ± 1.3 
343-980 21.7 07.5 - 25.5 18.8 ± 4.8 20.8 17.4 - 24.9 21.4 ± 1.3 
354-980 34.1 19.9 - 39.5 31.7 ± 5.2 34.9 32.5 - 40.9 36.0 ± 1.5 
Table 3.3: Comparison of distances between residues on transmembrane helices six and 
twelve measured in crystal structures and membrane-embedded MD simulations of P-gp. 
3G5U refers to the crystal structure, and derivative molecular dynamics simulation of the 
original  structure of mouse P-gp [1], whereas 4M1M refers to the equivalent of the refined 
structure (Aller et al. 2009; Li, Jaimes, and Aller 2014). All inter-residue distances are in 
Angstroms. The MD range refers to the minimum and maximum distances sampled across the 
course of the 3x100ns simulations. The MD average refers to the mean ± standard deviation of 
the 3000 time points (0.1 ns) sampled during the course of the simulation. Distances were 
extracted using VMD 1.9.1.  
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apparent variations in average distances in the MD simulations were observed for 343-
982 (3.1Å), 354-982 (3.8Å), and 354-980 (4.3Å). Considering the fact that only two 
residue pairs had a disparity of greater than 2Å, and none had a disparity of greater that 
2.8Å when comparing the two crystal structures, It appears that there is greater disparity 
between 3G5U and 4M1M MD simulations than 3G5U and 4M1M crystal structures. It 
is likely that this is a result of the aforementioned errors in the 3G5U structure affecting 
the simulation, but the disparity emphasises the need for the experimental analysis of 
this study. 
The wider disagreement between 3G5U and 4M1M MD simulations was more 
pronounced for residue pairs which include residues in one specific region. All 
distances involving residues in the central portion of TM12 (980 or 982) showed shorter 
distances in the MD simulation based on 3G5U compared to the simulation based on 
4M1M. MD also predicted a wider range of distances in the simulations based on 3G5U. 
All residue pairs had a broader standard deviation of distance in the 3G5U simulation, 
with residue pairs 343-980 and 354-980 showing the most variation, at 4.8Å and 5.2Å, 
respectively. Simulations based on 4M1M predicted only one residue pair with a 
standard deviation of Cα-Cα distances greater than 2Å; namely 354-994 at 2.1Å. These 
predictions suggest that the 4M1M structure is more stable in the TMDs, particularly in 
the central portion of TM12.  
Crystal structures and MD simulations predict a range of distances between 
TM6 & 12 within the range of measurement by intramolecular cross-linking and DEER. 
This study sought to experimentally determine the distances between these residue 
pairs. This was done to elucidate which of the structural models of P-gp, if any, is a 
good representation of human P-gp in a lipid bilayer. The P-gp double mutants were 
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expressed, purified, and assayed for their functional integrity prior to measuring cys-cys 
distances.  
3.2 Production of purified, reconstituted P-gp double mutants and 
verification of functional competency  
3.2.1 Expression of P-gp in Hi5 insect cells and preparation of crude 
membranes 
 
 Recombinant baculoviruses encoding Cys-lessP-gp, one TM12 single mutant and 
nine TM6 & 12 double mutants were generated by Assoc. Prof. Ian Kerr at the 
University of Nottingham as described in section 2.2.1. Each virus was amplified in 
Sf900 (Spodoptera frugiperda) insect cells by two rounds of infection. This generated 
large volume stocks of baculovirus (1x108 pfu ml-1) containing cDNA encoding each of 
the isoforms (section 2.2.1). Viruses were used to infect Hi5 (Trichoplusia ni) insect 
cells as described in section 2.2.2. Successful infection was defined where 30-50% of 
Hi5 cells were unable to exclude the dead cell stain trypan blue; typically, this occurred 
after 72 hours incubation of the Hi5 cells with baculovirus. 
Western blots were used to confirm the presence of P-gp in crude membrane 
samples obtained from Hi5 cells following nitrogen cavitation and differential 
centrifugation (Figure 3.16) (Taylor et al. 2001). The relative P-gp content of samples 
taken from different stages of membrane isolation from a Hi5 pellet containing Cys-lessP-
gp is shown in a representative blot (Figure 3.16 A). The first lane is the mixture 
resulting from the cavitation process, the first low speed centrifugation step separated 
intact cells from burst cells. A fraction of P-gp was lost in the first pellet, but the 
majority was collected in the crude membrane sample, which was separated from the 
cytosolic proteins in a second high speed centrifugation. Western blotting was done 
using equal amounts of protein from each stage of the differential centrifugation 
process.  While the bands show that P-gp makes up an equal proportion of the protein in 
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the intact cells, the total amount of protein in the crude membranes was approximately 
10-fold greater, meaning 90% of P-gp was isolated in the crude membranes. 
 
Figure 3.16: Isolation of crude membranes from Hi5 insect cells following infection with 
recombinant baculovirus containing P-gp.  
Panel A shows the relative P-gp content of fractions from the isolation process. Burst cells refers 
to the supernatant of the first, low speed centrifugation, while intact cells are the pelleted 
material. Cytosolic proteins are the supernatant of the high speed centrifugation, where crude 
membranes are pelleted. The positive control was a sample of crude membranes previously 
demonstrated to contain poly-histidine tagged P-gp. Panel B: Hi5 cells were infected with 
recombinant baculovirus carrying the cDNA for the eleven P-gp mutant isoforms. The relative 
expression level of each isoform of P-gp in the membranes is shown. P-gp expression was detected 
by SDS-PAGE on 7% w/v acrylamide gels and immunoblotting with the monoclonal anti 6x-His 
antibody. The total amount of protein loaded onto each lane was 20μg.  
There were no statistically significant variations in the total membrane protein yield 
from infections with the single mutant or any of the double mutants in comparison to 
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Cys-lessP-gp (Table 3.4). Western blotting analysis confirmed that all eleven mutants were 
expressed in Hi5 cells, however the expression levels varied marginally from 
preparation to preparation and with different batches of virus (figure 3.2B). The total 
quantity (mg) of protein per litre of cell culture was quantified to show whether 
infections with particular mutants or viral batches were deleterious to total protein 
expression. Secondly the amount of pure P-gp (μg) collected per mg of crude membrane 
total protein was calculated to monitor the efficiency of expression and purification of 
P-gp.  The yield of Cys-lessP-gp infections was approximately 450mg total protein litre-1 
of cell culture, or 1μg P-gp mg-1 of total protein in the crude membrane (Table 3.4), 
which closely corresponds to previous observations (Taylor et al. 2001; Storm et al. 
2007; Storm et al. 2008). The crude membrane protein yield was lowest for 343-982P-gp, 
at 321 ± 33 mg total membrane protein per litre of culture medium which is 72% of that 
observed for CyslessP-gp. Membrane preparations for the other mutants all showed greater 
that 75% of the average CyslessP-gp protein yield. All experiments on topography and 
function were done with pure P-gp of known concentration, so the varied expression 
levels in membranes was not problematic. 
3.2.2 Purification of P-gp mutants by affinity chromatography and 
relative yield  
Each P-gp mutant contained a hexa-histidine tag, allowing purification by affinity 
chromatography. The solubilisation of P-gp from Hi-5 membranes using 
dodecamaltoside (DDM) was done as previously described in detail (Taylor et al. 2001; 
Storm et al. 2007; Rothnie et al. 2005). Solubilised P-gp was purified using affinity 
chromatography with Ni-NTA resin. Purity was assessed by SDS-PAGE analysis 
(Figure 3.17). A band at 140kDa corresponding to core-glycosylated P-gp was seen in 
the high imidazole (250mM) fractions at >90% purity. The overwhelming majority of 
the P-gp was eluted in the first 250mM imidazole fraction, with negligible loss in the 
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flow through or wash steps containing low imidazole concentrations. P-gp mutants were 
reconstituted into proteoliposomes by detergent adsorption using SM2 biobeads as 
described previously (Storm et al. 2008; Storm et al. 2007).  
 
Figure 3.17: SDS-PAGE analysis of purification of His-tagged P-gp by Ni-NTA affinity 
chromatography. P-gp mutants were extracted from crude membranes using 2% w/v DDM and 
purified by affinity chromatography as described in Materials and Methods. Fractions collected 
during the purification were analysed by SDS-PAGE on 7% acrylamide gels. The flow through 
of unbound proteins is denoted by FT, the subsequent five lanes show the imidazole wash steps. 
P-gp was eluted with 250mM imidazole as demonstrated in lanes seven and eight. 
The concentration of purified, reconstituted P-gp was estimated by quantitative SDS-
PAGE with densitometric analysis using a range of BSA standards as described in 
section 2.3.2 (Figure 3.18).  
kDa 
mM Imidazole 
  
98 
 
 
Figure 3.18: Determining the concentration of purified P-gp by SDS-PAGE and densitometry 
against a BSA standard curve. P-gp mutants were reconstituted by addition of SM2 Biobeads. In 
order to determine the concentration of the purified, reconstituted P-gp (PR) SDS-PAGE was 
performed on a series of BSA standards (lanes 1 to 9) alongside various volumes of PR (lanes 10 
to 12). Mw denotes the molecular weight marker. The concentration of PR P-gp was quantified 
by densitometric analysis of the gel, against a BSA standard curve. 
The lowest average yield of purified, reconstituted P-gp per milligram of total 
membrane protein (μg/mg) was for 354-974P-gp, 0.63μg/mg, 55% of CyslessP-gp average 
yield. All other double mutants showed a yield of greater than 70% of that of CyslessP-gp, 
Again no variations were found to be statistically significant, therefore the mutations of 
P-gp did not result in a meaningful decrease in P-gp expression or the efficiency of 
purification  relative to the CyslessP-gp parent. 
 
kDa 
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P-gp Mutant 
Membrane protein 
yield  
(mg protein l cell 
culture-1) 
Purified, reconstituted 
P-gp yield  
(μg P-gp mg 
membrane protein-1) 
Cys-less 443 ± 35 1.15 ± 0.15 
982C 343 ± 72 1.49 ± 0.30 
343-974   497 ± 112 0.79 ± 0.22 
343-982 321 ± 33 0.96 ± 0.18 
343-994 349 ± 45 0.85 ± 0.12 
354-974 392 ± 49 0.63 ± 0.14 
354-982 342 ± 98 0.81 ± 0.23 
354-994 360 ± 30 0.91 ± 0.17 
331-980 374 ± 64 1.66 ± 0.27 
343-980 344 ± 44 1.11 ± 0.34 
354-980 415 ± 69 1.22 ± 0.22 
Table 3.4: Yield of total membrane protein and PR. Total protein in membrane preparations 
was determined by the total protein assay. Values represent the mean ± SEM for at least three 
independent membrane preparations. Concentration of P-gp was determined by densitometric 
analysis against a BSA standard curve using ImageJ. Values represent the mean ± SEM for at 
least six independent purifications. No statistically significant variations from the yield of Cys-
less purifications were found using one-way ANOVA and Dunnett’s Multiple Comparison Test at 
the 95% confidence interval. 
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3.2.3 Measurement of ATPase activity of purified, reconstituted P-gp 
double mutants  
Measurement of ATPase activity was used to determine whether the purified, 
reconstituted P-gp mutants retained function (Shapiro and Ling 1994; Taylor et al. 
2001). The rate of ATP hydrolysis and the extent of stimulation by drugs provides a 
stringent measure for the effects of point mutations on the protein (Storm et al. 2007; 
Rothnie et al. 2005). ATPase assays were performed with Cys-lessP-gp and each of the 
double mutants as described in section 2.7. Figure 3.7 provides a summary of the 
ATPase activity of Cys-lessP-gp with a range of ATP concentrations. The rate of ATPase 
activity in response to an increasing concentration of ATP conformed to a hyperbolic 
Michaelis-Menten relationship. The maximal rate of ATP hydrolysis (Vmax), was 
measured in the presence or absence of the known modulator of P-gp activity, 
nicardipine (Figure 3.19).  
The basal Vmax of ATP hydrolysis for CyslessP-gp was 319 ± 79 nanomoles of 
inorganic phosphate liberated per minute per milligram of purified, reconstituted P-gp 
(nmol Pi min-1 mg-1). The presence of the modulator was shown to stimulate an increase 
of the Vmax to 957 ± 208 nmol Pi min-1 mg-1. The affinity constant for the reaction of P-
gp with ATP (Km), was determined to be 0.96 ± 0.27 mM and 0.32 ± 0.06 mM in basal 
and stimulated conditions respectively. These values for Km and Vmax were similar to 
previously published values using CyslessP-gp (Taylor et al. 2001; Storm et al. 2007; 
Rothnie et al. 2005; Crowley et al. 2010).  
The Michaelis-Menten parameters of ATPase activity were determined for each of the 
P-gp double mutants under the same conditions (Table 3.5). One double mutant (354-
974P-gp) showed a significant (p < 0.05) increase (79%) in the stimulated Vmax of ATP 
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hydrolysis in the presence of nicardipine compared to Cys-lessP-gp. However, there was 
no change in the degree of stimulation of ATPase activity for this double mutant,  
 
Figure 3.6: Basal and stimulated rates of ATPase activity of the Cys-less mutant P-gp as a 
function of ATP concentration. ATP hydrolysis by Cys-less P-gp was quantified by a 
colorimetric assay detecting the liberation of phosphate (Pi). The rate of phosphate release was 
measured in the presence of varying concentration of ATP (0-1.75mM). Basal ATPase activity 
was measured in the absence of drug modulator (□) and the stimulated rate in the presence of 
10μM Nicardipine (●). Non-linear least squares regression was used to fit the Michaelis-Menten 
equation to the data using Graphpad Prism 5. Values represent the mean ± SEM of measurements 
from ten independent Cys-less P-gp preparations.  
suggesting that the coupling of drug binding to ATP hydrolysis was unaffected. 
Previous investigations have determined nicardipine-stimulated rates of ATPase activity 
for Cys-lessP-gp and single mutants which also displayed activity above that of Cys-lessP-gp 
(Rothnie et al. 2004). None of the mutants assayed for ATPase activity in this study 
demonstrated a statistically significant (P < 0.05) decrease in the rate of ATPase activity 
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under basal or nicardipine-stimulated conditions. No statistically significant differences 
were found in the affinity for ATP between Cys-lessP-gp and any of the mutants.  
Given the large number of mutations evaluated, a more stringent threshold for statistical 
significance than p = 0.05 may be considered appropriate. As the number of tested 
mutants increases toward 20, the probability that one will produce a p value indicating a 
significant difference, as a result of random chance, approaches 1. While the cut-off at p 
= 0.05 has been in common usage for more than 90 years (Fisher 1926), it is, as any 
chosen point would be, arbitrary and not used due to any intrinsic importance of a one-
in-twenty chance of reaching a false conclusion. Indeed, while many researchers argue 
that using p = 0.01 or p = 0.001 would greatly increase confidence in published 
findings, others contend that p values are intrinsically flawed and should be replaced by 
tests which take into consideration the magnitude of an effect, not only the probability 
of wrongly discarding a null hypothesis (Nuzzo 2014).  
For the purposes of this study, a p value, at 0.05, was used for two reasons. 
Firstly to maintain comparability with related investigations; these measurements were 
done in a context of an already extensively studied protein, in which previous analyses 
of the effects of mutation on P-gp activity have used p = 0.05 (Taylor et al. 2001; Loo 
and Clarke 2014a; Storm et al. 2007). Secondly, in response to the specific context 
necessitating the quantification of mutant activity in this study. P-gp double mutants 
were used here to inform on the structure and function of wild-type human P-gp and the 
activity of the mutants was assayed to interrogate their suitability. In this instance a 
false positive is less misleading to the understanding of the P-gp structure-function 
relationship than a false negative. Using p = 0.001 and failing to identify a change in 
function could have permitted a mutant wrongly considered to be a good representative 
of wild-type P-gp to inform on the structure of the protein. This has a more deleterious 
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effect than viewing with more criticism results derived from a mutant which may be 
have been wrongly considered an unreliable representation of human P-gp due to an 
overly sensitive test of functional modification (p = 0.05). Where all p values are 
arbitrary, a strong argument can be made that the cut-off should be set to render false 
observations as unlikely as possible within reason; in this instance, p = 0.05 is a better 
precaution against reaching an erroneous conclusion than p = 0.001. 
  
Affinity Maximal activity    
 Km (mM) Vmax (nmol Pi min-1 mg-1)   
P-gp mutant Basal Stimulated Basal  Stimulated Fold stimulation 
Cys-less 0.96 ± 0.27 0.32 ± 0.06 319 ± 79    957 ± 208 3.2 ± 0.4 
343-974 0.30 ± 0.12 0.31 ± 0.02  290 ± 24  732 ± 55  2.5 ± 0.0 
343-982 0.28 ± 0.10 0.35 ± 0.05 212 ± 27      807 ± 133  3.8 ± 0.3 
343-994 0.11 ± 0.05 0.46 ± 0.10  138 ± 37   513 ± 16  4.9 ± 1.2 
354-974 1.77 ± 0.78 0.52 ± 0.12 535 ± 16   1712 ± 61 * 3.2 ± 0.0 
354-982 1.53 ± 0.30 0.53 ± 0.10  285 ± 73     958 ± 270  3.8 ± 1.1 
354-994 0.38 ± 0.15 0.32 ± 0.07 411 ± 26   1537 ± 281  3.7 ± 0.5  
331-980 0.97 ± 0.31 0.35 ± 0.12 238 ± 35  711 ± 70  3.1 ± 0.4 
343-980 0.93 ± 0.09 0.26 ± 0.04  215 ± 28   769 ± 127 3.6 ± 0.5 
354-980 1.12 ± 0.41 0.32 ± 0.06  179 ± 50  605 ± 85  4.1 ± 0.9  
Table 3.5: Michaelis-Menten parameters of the ATPase activity of TM6/TM12 double mutants 
and Cys-less P-gp. The Vmax (maximal rate of ATP hydrolysis) and Km (affinity for ATP) values 
were determined by non-linear regression using Graphpad prism 5. The fold stimulation values 
were calculated by dividing the stimulated rate of hydrolysis (Vmax) by the basal rate. Values are 
the mean ± SEM for at least three independent assays on independently prepared PR. Statistically 
significant difference in parameters compared to those of the Cys-less control mutant was 
determined using one-way ANOVA and Dunnett’s Multiple comparison Test (P < 0.05) and is 
denoted by an asterisk (*). 
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3.2.4 Do P-gp double mutants retain the same potency for interaction 
with drugs as the cys-less protein? 
 
Further ATPase assays were done to measure the affinity of the mutants for known 
modulators of P-gp activity, nicardipine and vinblastine, to determine whether the 
mutations had affected the drug-protein interaction. ATPase assays were done on Cys-
lessP-gp and each of the nine double mutants in the presence of a fixed concentration of 
ATP (2mM) and varying drug concentrations (10-8.5-10-4M). Figure 3.20 shows a 
summary of the dose-response experiments for Cys-lessP-gp in the presence of the two 
drugs.  The potency for the interaction of Cys-lessP-gp with drugs, defined as the 
concentration required to stimulate a half-maximal response (EC50), was determined by 
the fit of the general dose response equation to the data (Section 2.7). Potencies 
observed for the interaction of Cys-lessP-gp with nicardipine (2.66 ± 0.59μM) and 
vinblastine (2.63 ± 0.53μM) fall inside the range of previous reports of 1.1 - 3.2μM and 
1.8 - 4.2μM, respectively (Taylor et al. 2001; Mittra et al. 2016; Storm et al. 2007; 
Rothnie et al. 2004). The activity of Cys-lessP-gp was increased 3.3 ± 0.4-fold in the 
presence of nicardipine and 2.1 ± 0.3 fold in the presence of vinblastine. These results 
also fall within the reported range for Cys-lessP-gp with nicardipine (2.0 – 3.6 fold) and 
vinblastine (1.6 – 2.4 fold) (Storm et al. 2007; Taylor et al. 2001; Mittra et al. 2016). 
Table 3.4 shows the potencies of interaction determined for each of the double 
mutants with the two modulators, and degree of stimulation in ATPase activity. All 
double mutants retained comparable potency in response to nicardipine, as none of the 
variations in EC50 were significantly different (ANOVA p > 0.05) to that of CyslessP-gp. 
In contrast, a series of single cysteine mutations (predicted to be in drug binding 
regions) used in a recent investigation resulted in decreases of potency of approximately 
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3 - 18 fold in response to nicardipine and vinblastine (Mittra et al. 2016). The results of 
this study indicate the interaction with nicardipine was unaffected in these double 
mutants. All double mutants showed a degree of drug stimulation of basal activity in 
response to nicardipine in the range 3.0 – 4.7 fold, with no statistically significant 
differences compared to Cys-lessP-gp. The retention of potency for and stimulation 
produced by nicardipine indicates that there is no alteration in the general interaction 
between it and P-gp following mutation. This interaction comprises binding to P-gp and 
the change in conformation leading to ATP hydrolysis (Loo and Clarke 1997). 
 
Figure 3.20: Stimulation of ATPase activity by Cys-less P-gp as a function of modulator 
concentration. ATPase activity was measured in the presence of a range of drug concentrations 
(10-8.5 to 10-4) and a fixed concentration of ATP (2mM). A colorimetric assay was used to detect 
inorganic phosphate (Pi) release. The general dose-response equation was fitted to data for 
nicardipine (●) and vinblastine (○) using non-linear least squares regression. Values represent 
the mean ± SEM for ten independent Cys-less P-gp preparations.  
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  Nicardipine Vinblastine 
P-gp mutant EC50 (μM) Fold Stimulation EC50 (μM) Fold Stimulation 
Cys-less 2.66 ± 0.59 3.3 ± 0.4  2.63 ± 0.53          2.1 ± 0.3 
343-974 2.40 ± 1.20  3.4 ± 0.8  3.00 ± 1.09 2.1 ± 0.5 
343-982 1.50 ± 0.42 3.8 ± 0.6  1.34 ± 0.76 1.4 ± 0.2 
343-994 3.14 ± 0.91 3.0 ± 0.5 ND NA 
354-974 3.69 ± 0.95 3.0 ± 0.4  4.88 ± 1.92 2.0 ± 0.3 
354-982 4.04 ± 1.32 4.7 ± 0.8  3.68 ± 1.46 1.8 ± 0.4 
354-994 1.80 ± 0.50 2.7 ± 0.3  9.59 ± 4.42 * 1.8 ± 0.3 
331-980 2.60 ± 0.76 3.4 ± 0.2  1.62 ± 0.61 2.3 ± 0.4 
343-980 3.49 ± 0.96 4.2 ± 0.9  2.12 ± 0.49 2.9 ± 0.9 
354-980 3.84 ± 1.20 4.4 ± 0.7  9.36 ± 3.26 *    3.4 ± 0.1 * 
Table 3.6: Potency of nicardipine and vinblastine to stimulate ATP hydrolysis by P-gp double 
mutants compared to Cys-less P-gp. The rate of ATP hydrolysis was measured as a function of 
drug concentration in the presence of 2mM ATP. Non-linear regression of the general dose-
response relationship was used to determine the potency and extent of stimulation by drugs. 
Values are the mean ± SEM of assays obtained from at least three independent purifications. ND 
corresponds to ‘no detectable’ response. An asterisk corresponds to a significant difference 
(ANOVA) between the double mutants and Cys-less P-gp (P < 0.05).  
The introduction of two cysteine insertions was observed to have some impact 
on the interaction with vinblastine. For example, 354-994P-gp required 9.59 ± 4.42µM 
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vinblastine to stimulate half-maximal response in ATPase activity, while retaining a 
degree of stimulation comparable to CyslessP-gp (1.8 ± 0.4 fold). The stimulation of 
ATPase activity was increased significantly for 354-980P-gp ATPase activity in response 
to vinblastine, while there was a 3.5 fold drop in the potency of interaction (p < 0.05) 
for this isoform. The effect on 343-994P-gp was more dramatic, since the stimulation of 
ATPase activity by vinblastine was abrogated. These results are not unexpected, given 
the previously observed effects of mutations in TM6 upon potency for interaction of 
vinblastine with P-gp (Storm et al. 2007; Storm et al. 2008). ATPase activity data 
indicate that while certain combinations of mutations affect the affinity of interaction 
with vinblastine, no effects are observed on the affinity for nicardipine or ATP, or on 
the maximal rates of ATP hydrolysis. 
3.3 Summary of P-gp mutant production. 
 Nine double mutants were made in the Cysless P-gp background by site directed 
mutagenesis (Section 3.1). All were expressed to comparable levels using the insect-
cell/baculovirus system (Section 3.2.1). High-pressure nitrogen cavitation was used to 
isolate membranes containing P-gp mutants, with yields equivalent to the parent 
isoform (Section 3.2.1). Yield of purified, reconstituted protein was also comparable 
following DDM solubilisation, affinity chromatography, and detergent adsorption 
(Section 3.2.2). ATPase assays demonstrated that double mutants retained maximal 
rates of ATP hydrolysis (Section 3.2.3), and affinity for nicardipine, while some effects 
were observed on the affinity for vinblastine (Section 3.2.4). Thus, the nine double 
mutants employed in this study are a good model for investigating the structure and 
function of human P-gp. 
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CHAPTER 4: Measurement of inter-residue distances between TM6 
and TM12 
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4.1 Measurement of distances between transmembrane helices 6 & 12 
using homobifunctional cross-linkers. 
The distances between the cysteines introduced in each P-gp double mutant were 
measured at several positions to enable provision of topographical information in the 
TMDs. In the first approach a series of chemical cross-linkers 
(methanethiosulphonate/MTS reagents) was used as molecular ‘rulers’. To determine 
the distance between the two residues, the lengths of the MTS reagents were calculated 
as described in Section 2.8.2 and Figure 4.21. The length of each ruler in the MyM 
series was calculated by viewing each the C-C, C-O and C-S bonds as sides of an 
isosceles triangle, with the two bonds the two sides of equal length (C-C =1.54Å, C-O = 
1.43Å, C-S = 1.82Å). The angle between bonds in a tetrahedral carbon atom is 109°, so 
there is enough information to calculate the length of the third side of the triangle (x) 
with trigonometry. By adding up the x values for each ‘isosceles unit’ of two carbon to 
carbon bonds, and exchanging C-C-C units for C-O-C units where appropriate, the 
maximum length of the space arm is calculated. A further isosceles unit must then be 
added for the two carbon to sulphur bonds at the ends of the molecule to determine the 
total length of an MTS reagent.  The results of this calculation (Figure 4.8) are 0.9-2.6Å 
shorter than previous estimations of the span of MTS reagents (Loo and Clarke 2001c; 
Collier et al. 2014; Moore et al. 2008).  
The calculated spans of the MTS reagents, 3.0 to 22.1Å, are of appropriate 
length to detect crosslinking for most of the predicted distances in Table 3.3. The 
original (3G5U) and refined (4M1M) crystal structures predict that the inter-residue  
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180 = 109 + 2θ 
2θ = 71 
θ = 35.5 
x = 2(b)*cosθ 
 
x = 2(1.82)*cos(35.5) 
 
x = 2(1.54)*cos(35.5) 
 
x = 2(1.43)*cos(35.5) 
x = 2.97 x = 2.51 x = 2.33 
   
MyM Cross-linking span (Å) = 2.97 + [(y-1)*(2.51/2) - z*2.51 + z*2.33] 
 
Figure 4.21: Determining the straight cross-linking span of MTS compounds by 
trigonometry. The rules of trigonometry, with respect to isosceles triangles, were applied to 
estimate the distance spanned by the MTS reagents by the sum of their repeating units of bonds. 
Panel A shows the three models of isosceles triangles required to calculate the relevant 
distances; top left: carbon to sulphur bonds (S-C-S unit), top right: carbon to carbon bonds (C-
C-C unit), bottom centre: carbon to oxygen bonds (C-O-C unit). Panel B shows the method for 
calculating the base angle (θ), using the rule that all angles of a triangle add up to 180°. Panel 
C shows the method for calculating the base lengths (x) for the models, where θ is the base 
angle and ‘b’ is the hypotenuse length, using the relevant cosine rule for isosceles triangles. 
Panel D shows the calculation for the cross-linking span of MTS molecules, in which y 
represents the number of atoms in the spacer arm, and z the number of oxygens. 
b 
A b C C 
C 
D 
B 
O 
1.43Å 
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Cα-Cα distances for 343-982P-gp, 343-994P-gp, 354-994P-gp, 331-980P-gp and 343-980P-gp fall 
within the range of the MTS spans (Table 3.3, Figure 4.22). However, both crystal 
structures predict the Cα-Cα distances for 343-974P-gp, 354-982P-gp, 354-980P-gp and 354-974P-
gp are predicted to be between 4-20Å outside the range of MTS reagents, although this 
is for a static structure. Indeed, MD simulations using 3G5U predict some overlap 
between the ranges of inter-residue distances sampled over the 300ns simulation and the 
lengths of the MTS reagents for 343-974P-gp, 354-982P-gp and 354-980P-gp. MD simulations 
using 4M1M do not predict overlap for any double mutants other than those inter-
residue spans in the crystal structure falling within the range of MTS lengths. However, 
the Cα-Cα distances for 343-974P-gp and 354-982P-gp were observed to narrow to 0.9Å and 
5.2Å longer than the distance spanned by the longest MTS reagent during the course of 
the simulation. MTS reagents were therefore judged to be an effective tool for 
measuring the distance between the residues chosen since only one double mutant (354-
974P-gp) was consistently predicted to have an inter-cysteine distance significantly 
(>10Å) outside of the range spanned by these molecules. The disparity between the 
models (3G5U and 4M1M) also justifies the cross-linking strategy. 
Time course experiments were used to determine the maximal extent of 
intramolecular cross-linking for each P-gp mutant with each MTS reagent. As described 
in detail in Sections 2.8 - 2.8.3, a combined strategy for visualising altered migration 
was used; via western blotting (for specificity and sensitivity) and coomassie staining 
(for quantitation). The time course of cross-linking was determined for each double 
mutant in combination with each cross-linker on western blots. The proportion of P-gp 
cross-linked was quantified by comparison of the densitometry of western blots to 
densitometry of a stained gel via cross-linked samples present on the stained gel and on 
the western blot. Altered migration of P-gp through a 7% w v-1 acrylamide gel was used 
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to demonstrate a cross-link between the two cysteine residues (Loo and Clarke 2001c), 
for 343-974P-gp as seen in Figure 4.23A (red arrow). The intensity of bands 
 
Figure 4.22: Chemical Structures of homobifunctional bismethanethiosulfonate (MTS) cross-
linking molecules and their spanning distances. Structures were created using ACD/Labs 
ChemSketch (freeware) with reference to Santa Cruz Biotechnology. The length of the cross-
linkers was calculated from the length of the individual bonds (carbon to carbon = 1.54Å, carbon 
to sulphur = 1.82Å, carbon to oxygen = 1.43Å) and tetrahedral carbon bond angle (109°) using 
trigonometry. Image adapted from (Loo and Clarke 2001c).  
representing denatured, uncross-linked (black arrow) and intramolecular cross-linked 
(red arrow) P-gp was measured using densitometry. The proportion of cross-linked P-gp 
(XL% True) at each time point was calculated by comparison to the PageBlue stained gel 
in Figure 4.20A (Section 2.8). Cross-linking was rapid, as evidenced by the difficulty in 
stopping the cross-linking reaction at time = 0 despite denaturation in SDS loading 
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buffer after approximately 5 seconds. Samples taken after 2hrs incubation with cross-
linkers were used in the PageBlue stained gels, as at this stage cross-linking had 
invariably reached completion. These values were plotted as a function of time in Figure 
4.23B, and the maximal extent of intramolecular cross-linking for this incubation of 
M11M with 343-974P-gp (XLmax - 27%) was determined by non-linear regression of a 
one-phase binding curve.  
This method was applied to each of the homobifunctional cross-linkers with the 
343-974P-gp isoform. Two independent experiments were carried out for M5M (8.0Å) 
which showed less than 5% cross-linking (XLmax 2.4 ± 1.4%). At least three 
independent experiments were completed for the rest of the MTS reagents. The average 
XLmax for each MTS reagent was plotted as a function of the length of the molecule 
(Figure 4.25B). This revealed a clear relationship between the length of MTS reagents, 
and the extent of homobifunctional cross-linking. Gaussian distributions are commonly 
used to analyse inter-residue distance distributions detected by DEER (Verhalen et al. 
2017; Brandon, Beth, and Hustedt 2012), and MD simulations (Gaieb and Morikis 
2017; Krishnan et al. 2008). As such, non-linear regression was used to fit a Gaussian 
curve to determine the average cross-linking span between the two residues, which 
occurred at the centre of the distribution (see Table 3.7). By applying this strategy to 343-
974P-gp a clear relationship between extent of cross-linking and the length of the cross-
linker was evident, allowing determination of the average cross-linking span at 18.5 ± 
2.3Å (n=3). An important caveat is that while the gaussian analysis enhances cross-
comparability of cross-linking results with DEER and MD analysis of P-gp, it is 
arguably a less appropriate method of interrogation of the cross-linking distance 
distribution. This is due to the limited number and range of distances for which cross-
linking can be tested (a constraint imposed by the availability of MTS reagents) and the 
variability of cross-linking extent detected in repeated measurements. As a result of 
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these limitations, R square values for gaussian fitting varied from 0.597 (354-994P-gp) to 
0.928 (343-982P-gp), indicating some variability in the accuracy of average distance 
determinations. 
 As explained in Section 2.8, the observed varying proportions of cross-linking 
can be used to determine inter-residue distance. The theoretical framework 
underpinning this is that when the length MTS reagent is the best representation of 
inter-residue distance, it will best allow intermolecular cross-linking to out-compete 
separate attachment of MTS reagents at the two cysteines. There is an important critique 
to be made of this proposed theoretical framework, that deriving from the known effect 
of tethering on the local effective concentration of reactants (Mooney and Landick 
2003). Covalent linkage of two proteins via an 11 amino-acid spacer has been 
demonstrated to increase effective concentration, in terms of reaction speed, by six 
orders of magnitude (Robinson and Sauer 1998). Given that the spacer arm of an MTS 
reagent is so much shorter it might be expected that the effect on local concentration 
would be even greater with MTS reagents, making the chances of two MTS reagents 
binding to two cysteines within range of the length of the MTS reagent negligible. In 
this case, all MTS reagents of sufficient length would swiftly produce a population of 
100% intramolecularly cross-linked protein, or, if MTS reagents were becoming 
progressive inactivated in solution over time (via nucleophilic attack by water 
molecules on the thiosulphonate reactive group), this would have an equal effect on all 
MTS reagents of sufficient length to link two cysteines. The latter case would produce a 
cross-linking profile characterised by a group of MTS reagents producing zero 
intramolecular links, and a second group producing an equal amount of cross-linking; 
e.g. M8M-M17M treatment all producing an XLmax of around 50% after 5 minutes. 
However, analysis of the results presented in this thesis strongly support the theoretical 
framework advanced in Section 2.8, in two ways. Firstly, cross-linking distance 
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distributions in Figures 3.25-3.33 show XLmax progressively varying according to the 
length of MTS reagents. Secondly, the activity if P-gp incubated with MTS reagents is 
often changed by a greater extent than the proportion of protein intramolecularly cross-
linked by an MTS reagent, necessitating separate attachment of two MTS reagents in 
the remainder of the population to explain observed changes (further explanation in 
Chapter 5). 
The average cross-linking span equates to the average distance observed 
between the residues using cross-linking, in human P-gp under basal conditions. The 
relationship between extent of cross-linking and cross-linking span was also observed 
for 343-982P-gp (Figure 4.26), 343-994P-gp (Figure 4.27), 354-982P-gp (Figure 4.29) and 354-
994P-gp (Figure 4.30). The average cross-linking span was determined for each of these 
mutants; however, a large discrepancy was seen in the maximal extent of cross-linking 
observed for each mutant. The maximum extent of cross-linking for 343-974P-gp with 
M14M was 13.5%, whereas for 354-982P-gp the maximum extent of cross-linking 
observed was with M17M at an extent of 39.6%. One double mutant, 354-994P-gp (Figure 
4.9), displayed a large proportion of cross-linking without MTS treatment, when 
subjected to SDS page in the absence of reducing agents. This indicates that a 
proportion of 354-994P-gp contains direct cross-links, formed at some point in the 
expression/isolation process, this did not bias data analysis as altered migration in the 
DMSO control was subtracted from that observed after MTS treatment (Section 2.8.1). 
Table 3.7 shows the result of the cross-linking analysis, giving the mean cross-linking 
span where a relationship between extent of cross-linking and cross-linker span was 
observed. 
No altered migration was observed after incubation of CyslessP-gp with MTS 
reagents (Figure 4.24). For double mutants 354-974P-gp (Figure 4.28), 331-980P-gp (Figure 
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4.31), 343-980P-gp (Figure 4.32) and 354-980P-gp (Figure 4.33), cross-linking was minimal, 
and poorly distinguishable form the background. All MTS reagents showed a maximum 
 
 
Figure 4.23: A representative analysis of the time-course of P-gp cross-linking by an MTS 
reagent (M11M) for the 343-974P-gp double mutant using western immuno-blotting. Panel A is a 
representative western blot of cross-linking over a series of time points for 343/974P-gp with M11M. 
The lanes marked DMSO and positive (+) are included for correction of the exposure level in 
data analysis. The position of cross-linked (red arrow) and native P-gp (black arrow) are 
indicated. Panel B shows the proportion of cross-linked P-gp plotted as a function of time; as 
determined by densitometric analysis of Panel A. Non-linear regression was used to fit a one-
phase association curve to the data. The maximal extent of cross-linking of 343-974Pgp by M11M 
was determined from the plateau of the binding curve.  
A 
B 
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attachment less than 10% for these mutants and consequently a Gaussian curve could 
not be accurately fitted to the data to determine the mean cross-linking span. As such, 
results from cross-linking analysis for these double mutants were not considered of 
appropriate quality for interrogation of the quality of structure models. This suggests 
that the residues are too far apart to be measured by MTS reagents, or that the 
attachment of an MTS molecule to both residues was sterically hindered. In order to 
measure a distance between these pairs of residues EPR spectroscopy was used, since it 
can measure longer distances and is less susceptible to forms of steric hindrance unique 
to homobifunctional cross-linking (as discussed in Section 6.1.1). 
 
 
   DMSO    3.0      5.5       8.0      11.4    15.0     18.5     22.1     
Figure 4.24: Migration of CyslessP-gp through a polyacrylamide gel after incubation with 
MTS reagents. This shows western blot of CyslessP-gp treated with a series of MTS reagents. 
The first lane contains the DMSO control, lanes 2-8 contain samples treated with MTS 
cross-linkers, indicated by the span of the cross-linking molecules. 
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Figure 4.25: Proportion of cross-linking of 343-974P-gp with MTS compounds. Panel A shows an 
SDS-PAGE gel for the positive control samples from treatment of 343/974P-gp with a series of MTS 
reagents. The first lane contains the DMSO control, lanes 2-9 contain samples treated with MTS 
cross-linkers, indicated by the span of the cross-linking molecules. Lane 10 contains the 
molecular weight marker. Panel B shows the average extent of cross-linking plotted as a function 
of the cross-linking span. Non-Linear least squares regression was used to fit the Gaussian 
distribution to the data in Panel B in order to estimate the average cross-linking span between 
the residues. Values represent the mean ± SEM obtained for at least three independent protein 
purifications, except M5M (8.0Å) in which case the value represents n=2. 
A 
B 
3.0        5.5         8.0       11.4      14.3      15.0       18.5      22.1 
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Figure 4.26: Proportion of cross-linking of 343-982P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers , at 25°C for 2hrs. Panel A shows SDS-PAGE analysis of 343-
982P-gp with DMSO negative control, M1M (3.0Å), M2M (4.2Å), M3M (5.5Å), M4M (6.7Å), M5M 
(8.0Å), M6M (9.2Å), M8M (11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M 
(22.1Å), DMSO negative control. The lane containing the molecular weight marker is marked 
Mw.  Panel B is a graphical representation of the average maximal extent of cross-linking as a 
function of the length of the MTS compounds. Determined by one-phase binding curve fitting 
analysis of the relevant western blots (data not shown). Values represent the mean ± SEM for at 
least three independent purifications of 343-982P-gp).  
B 
A 
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Figure 4.27: Proportion of cross-linking of 343-994P-gp by MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 343-994P-gp 
with DMSO negative control, M1M (3.0Å), M2M (4.2Å), M4M (6.7Å), M6M (9.2Å), M8M 
(11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The lane containing the 
molecular weight marker is marked Mw.  Panel B is a graphical representation of the average 
maximal extent of cross-linking as a function of the length of MTS compounds. Data was fitted 
with a one-phase binding curve and values represent the mean ± SEM for at least three 
independent purifications of 343-994P-gp. 
A 
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Figure 4.28: Proportion of cross-linking of 354-974P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 354-974P-gp 
with DMSO negative control, M1M (3.0Å), M3M (5.5Å), M4M (6.7Å), M5M (8.0Å), M6M (9.2Å), 
M8M (11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å), DMSO negative 
control. The lane containing the molecular weight marker is marked Mw. Panel B is a graphical 
representation of the average maximal extent of cross-linking as a function of the length of MTS 
compounds. Data was fitted with a one-phase binding curve and values represent the mean ± 
SEM for at least three independent purifications of 554-974P-gp. 
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Figure 4.29: Proportion of cross-linking of 354-982P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 354-982P-gp 
with DMSO negative control, M1M (3.0Å), M3M (5.5Å), M5M (8.0Å), M8M (11.4Å), M10M 
(14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The lane containing the molecular 
weight marker is marked Mw. Panel B is a graphical representation of the average maximal 
extent of cross-linking as a function of the length of MTS compounds. Data was fitted with a one-
phase binding curve and values represent the mean ± SEM for at least three independent 
purifications of 554-982P-gp. 
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Figure 4.30: Proportion of cross-linking of 354-994P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 354-994P-gp 
with DMSO negative control, M1M (3.0Å), M2M (4.2Å), M4M (6.7Å), M5M (8.0Å), M8M 
(11.4Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The lane containing the molecular 
weight marker is marked Mw. Panel B is a graphical representation of the average maximal 
extent of cross-linking as a function of the length of MTS compounds. Data was fitted with a one-
phase binding curve and values represent the mean ± SEM for at least three independent 
purifications of 554-994P-gp. 
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Figure 4.31: Proportion of cross-linking of 331-980P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 331-980P-gp 
with DMSO negative control, M1M (3.0Å), M2M (4.2Å), M3M (5.5Å), M4M (6.7Å), M5M (8.0Å), 
M6M (9.2Å M8M (11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The 
lane containing the molecular weight marker is marked Mw. Panel B is a graphical 
representation of the average maximal extent of cross-linking as a function of the length of MTS 
compounds. Data was fitted with a one-phase binding curve and values represent the mean ± 
SEM for at least three independent purifications of 531-980P-gp. 
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Figure 4.32: Proportion of cross-linking of 343-980P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel A: SDS-PAGE analysis of 343-980P-gp 
with DMSO negative control, M1M (3.0Å), M2M (4.2Å), M3M (5.5Å), M4M (6.7Å), M5M (8.0Å), 
M6M (9.2Å M8M (11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The 
lane containing the molecular weight marker is marked Mw. Panel B is a graphical 
representation of the average maximal extent of cross-linking as a function of the length of MTS 
compounds. Data was fitted with a one-phase binding curve and values represent the mean ± 
SEM for at least three independent purifications of 543-980P-gp. 
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Figure 4.33: Proportion of cross-linking of 354-980P-gp with MTS compounds. P-gp mutant was 
incubated with 30µM cross-linkers, at 25°C for 2hrs. Panel: SDS-PAGE analysis of 354-980P-gp 
with DMSO, M1M (3.0Å), M2M (4.2Å), M3M (5.5Å), M4M (6.7Å), M5M (8.0Å), M6M (9.2Å), 
M8M (11.4Å), M10M (14.3Å), M11M (15.0Å), M14M (18.5Å), M17M (22.1Å). The lane 
containing the molecular weight marker is marked Mw. Panel B is a graphical representation of 
the average maximal extent of cross-linking as a function of the length of MTS compounds. Data 
was fitted with a one-phase binding curve and values represent the mean ± SEM for at least three 
independent purifications of 554-980P-gp. 
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P-gp Mutant Cross-linking distance (Å) 
343-974 18.5 ± 2.3 
343-982 21.4 ± 2.6 
343-994 20.1 ± 3.8 
354-974 ND 
354-982 20.7 ± 5.0 
354-994 19.2 ± 4.3 
331-980 ND 
343-980 ND 
354-980 ND 
Table 3.7: Cross-linking span for the double-cysteine mutants of P-gp. The distance of 
crosslinking was determined from the Gaussian curves in figures 11-19. Values represent the 
mean ± 95% confidence interval of the fit of the Gaussian curves, as calculated with Graphpad 
Prism5. ND refers to a case in which the average cross-linking span was not determined.  
4.2 Measurement of inter-thiol distances by DEER spectroscopy 
Double electro-electron resonance (DEER) is a form of electron paramagnetic 
resonance (EPR) which is commonly used to determine the distance between two 
cysteine residues in proteins (Sahu, McCarrick, and Lorigan 2013). This technique was 
used to validate the strategy of analysing cross-linking results, to measure distances 
longer then the available chemical cross-linkers and in cases where results from cross-
linking and the MD simulations diverge. EPR fundamentally requires unpaired electrons 
to be present in the sample for analysis, these unpaired electrons, when aligned to a 
magnetic field, can move between high and low energy states by absorbing or emitting 
photons. The absorption or emission of energy can be measured and transformed into a  
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Figure 4.34: Dipolar evolution function of DEER measurements. Above are the traces for 354-
982P-gp (A) and 343-980P-gp (B). The resonance signal at t = 0 after the pulse sequence was 
normalised to 1, and the decay measured over a period of 2μs to Tmax (red line). Oscillation caused 
by inter-spin coupling has decayed at time Tdd. The background functions (black line) B(t) are fit 
to the curves between Tdd and Tmax. 
A 
B 
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spectrum to study the environment of the unpaired electrons. Proteins do not normally 
contain unpaired electrons, but these can be introduced by the attachment of thiol 
reactive probes to cysteine residues; in this study S-(1-oxyl-2,2,5,5-tetramethyl-2,5-
dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate (MTSL) was used, which 
contains a nitroxide unpaired electron. The initial round of EPR samples was produced 
by performing purifications, in which resin-bound protein was incubated with 100µM 
MTSL, using conditions with an estimated 100:1 molar excess. The proportion of 
cysteines labelled with the probe in these experiments was not known, however residues 
V331C, F343C (Rothnie et al. 2004), A354C (Storm et al. 2008), V982C and F994C 
(Crowley et al. 2010) have been shown to be highly accessible to covalent modification 
by hydrophobic probe coumarin malemide in the basal state conformation of the 
transporter, while A980C was demonstrated to be moderately accessible (Crowley et al. 
2010). 
A series of dilutions (10, 20, 40µM) were prepared of 982P-gp, 343-982P-gp, 343-994P-gp 
and 354-994P-gp; all produced a very strong continuous wave EPR signal. DEER is a 
‘pulsed’ EPR technique, this means the unpaired electrons are promoted to a high 
energy state by a microwave pulse, or series of pulses. As the unpaired electrons release 
this energy a microwave signal is emitted, this is called the ‘decay’. DEER requires a 
series of pulses at different frequencies to isolate the two unpaired electrons in a double-
labelled protein, these different pulses are called the ‘pump’ and ‘observer’ pulses. As 
the signal decays there may be interspin couplings which cause a delay in the decay. 
The extent of the interspin coupling is proportional to the distance between the unpaired 
electrons (Jeschke and Spiess 2006), meaning this distance can be inferred from the 
decay signal. Four-pulse DEER Measurements were used by our collaborator Dr Jeffrey 
Harmer (University of Queensland) to detect inter-spin coupling and determine the 
distance between the two modified residues of the double mutants. Pump and observer  
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Figure 4.35: Fit of hypothetical form factors to experimental observations. The experimental 
form factor F(t) (red lines) were determined by dividing V(t) by B(t) then renormalisation at T = 
0. The modulation depth (Δ) was quantified and theoretical form factors (black dashed lines) 
corresponding to dipolar coupling patterns fit using DeerAnalysis 2013. Panel A shows the fit 
for 354-982P-gp, while Panel B shows the fit for 343-980P-gp. 
A 
B 
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pulse frequencies and sequences were chosen to best isolate intramolecular spin 
couplings as previously described (Jeschke 2012; Jeschke and Polyhach 2007). The 
strongest interspin signal detected was for 354-982P-gp (Figure 4.34, Panel A). 
Analysis of the initial DEER measurements demonstrated a high proportion of 
background (non-specifically associated probe) that was proportional to the inter-spin 
signal, resulting in a relatively low modulation depth (Δ). The proportion of non-
specific signal was not consistent despite the simultaneous preparation of the samples 
(Table 3.8). The mutant that produced the greatest modulation depth was 354-982P-gp 
(Figure 4.35, Panel A) and the distance distribution for 354-982P-gp is shown in Figure 
4.21. The sample preparation involved washes with 55bv and subsequent buffer 
exchange, further washing was unlikely to resolve this. A second round of samples was 
prepared after incubation with a reduced concentration (20µM) MTSL, in an attempt to 
reduce non-specific association of the probe. Unfortunately, this resulted in a loss of the 
measurable distance signal, but retention of the high background signal. The remaining 
measurements were undertaken with the original 100µM incubation. Results for the 
different double mutants varied in the quality of the distance measurements (Table 3.8), 
an example of a weaker inter-spin signal, that detected in 343-980P-gp, is shown in Panel 
B of Figures 3.34-3.36. The distance distributions of 354-974P-gp and 331-980P-gp were 
indistinguishable from the background signal due to detection of a weak interspin 
signal. Other mutants (343-982P-gp, 343-980P-gp and 354-980P-gp) showed a modulation 
depth of only 0.06 – 0.08, which is low in comparison to the ideal value of 
approximately 0.4 (Jeschke 2012). The distance measurements obtained for 343-974P-gp, 
343-994P-gp, 354-982P-gp and 354-994P-gp were the most reliable because the inter-spin 
signal was more distinct and separable from the background signal, giving modulation 
depths of 0.12-0.33. Furthermore, measurements for 343-974P-gp, 354-994P-gp and 343-980P-
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gp showed a broad distance distribution, with a Half Width at Half Maximum (HWHM) 
of >5Å indicating significant flexibility in these regions. 
 
 
Figure 4.36: Use of Gaussian distance distributions for determining average inter-residue 
distances. The inter-spin coupling distance distribution was determined by approximate pake 
transformation of the form factor [F(t)]. The distributions for 354-982P-gp (A) and 343-980P-gp were 
fitted with a bimodal or unimodal Gaussian curves to determine the mean distance of the principal 
population of dipolar couplings. 
A 
B 
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Distance distributions were fitted to the measurements using unimodal Gaussian 
distributions where appropriate. A split in the distance distribution was observed for 354-
982P-gp and consequently a bimodal Gaussian distribution was fitted, with 76% of the 
population of spins at 26Å. The distance distribution of 354-994P-gp was asymmetric but 
in a single population, so the Tikhonov regularisation was used to determine the peak of 
the distribution for this mutant. The results of DEER measurements are in agreement  
Mutant Mean distance (Å) Half Width Half Maximum (Å) 
Bimodal 
artefact (Å) 
Modulation 
depth (Δ) 
343-974 34 7.5 ND 0.120 
343-982 23 4.0 ND 0.060 
343-994 22 0.5 ND 0.158 
354-974 ND N/A ND N/A 
354-982 26 (76%) 2.0 
47 ± 2.5 
(24%) 0.328 
354-994 20 5.0 ND 0.172 
331-980 ND N/A ND N/A 
343-980 43 6.0 ND 0.076 
354-980 29 2.5 ND 0.068 
Table 3.8: Summary of DEER inter-spin distance measurements for P-gp double mutants. The 
average inter-spin distance was taken from the peak of curves fit to distance distributions. 
Gaussian distributions were used unless otherwise noted. The modulation depth was taken from 
the experimental form factor for each P-gp double mutant. All data analysis was performed using 
DeerAnalysis 2013. ND refers to distances that were not detected. N/A refers to a parameter of 
the signal or distance distribution which is not applicable because no such signal was detected. 
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with previous studies, and the MD simulations, which predict a high degree of 
conformational flexibility for P-gp in the basal state (Wen et al. 2013; Ward et al. 2013; 
O'Mara and Mark 2014; O'Mara 2012). A recently published investigation compared  
DEER measurements between TMDs of P-gp in a series of conformations to structural 
models (Verhalen et al. 2017). The previous investigation used MD simulations based 
on a homology model constructed using MsbA to represent P-gp in the ATP-bound and 
post-hydrolytic states, while distance distributions in the basal state conformation were 
predicted using a rotamer library approach with the 4M1M crystal structure as a starting 
point. The present investigation used significantly different in silico methods for 
predicting inter-residue distances in the structural models, however both studies show 
close agreement between experimental and computational inter-residue distance 
measurements in the TMDs. 
4.3 Summary of distance measurement results 
 
Two distance measurement techniques were used to determine the relative position of a 
series of residues in TM6 & 12 of human P-gp in a reconstituted lipid bilayer. Results 
from the two techniques were compared to one another, to judge the quality of the 
distance measurements, and to existing structure models and MD simulations, to 
determine the accuracy of these as a representation of human P-gp in a membrane. This 
section will proceed through observations on each residue pair, highlighting instances 
agreement and disagreement between experimental techniques and structural models. 
Inter-residue distance measurements for 343-974P-gp and 354-974P-gp are summarised in 
Figure 4.37. The distances between residues F343 and V974 show close agreement 
between the 3G5U (24.5Å) and 4M1M (25.9Å) structures (Figure 4.37 A). The MD 
simulations are also similar, at 26.4 ± 2.4Å and 26.9 ± 1.0Å for 3G5U and 4M1M-based 
simulations respectively. The result of intramolecular cross-linking measurements of 343-
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974P-gp places the distance between the residues at 18.5 ± 2.2Å, significantly different 
(p < 0.05) to both MD averages, however this result falls just outside the range of the 
3G5U MD simulation, closer to the average distance measurement from this simulation 
and the 3G5U crystal structure. In DEER studies 343-974P-gp showed a longer inter-spin 
distance than the cross-linking experiments (34Å), but with a broad distance 
distribution. For the F343 to V974 span, the Cα-Cα distances predicted in the crystal 
structures and MD simulations are 6.0-8.4Å longer than the cross-linking distance, but 
7.1-9.5Å shorter than the DEER measurement. The considerable disagreement between 
experimental observations in this case preclude judgement on which structural model 
best predicted the experimental results in this case. 
The span marked ‘B’ in Figure 4.37 shows the distance between residues A354 and 
V974, from the intracellular section of TM6 to the extracellular section of TM12. The 
crystal structures suggested distances that diverged by only 1.2Å. MD simulations 
produced average inter-residue distances of 41.9 ± 2.6 Å (3G5U) and 43.2 ± 1.5 Å 
(4M1M), also in close agreement. However, these spans are well outside the range of 
measurement for the available intramolecular cross- linking reagents (3.0– 22.1Å). 
Indeed, no distance could be determined between the introduced cysteines of 354-974P-gp 
using cross-linking. In addition, DEER spectroscopy analysis of 354-974P-gp did not 
produce a strong enough inter-spin signal to separate from the background. The lack of 
experimental distance measurements for the A354 to V974 inter-residue distance 
prevents analysis of which structural model was most accurate, however the fact that 
cross-linking was not observed is in support of all structural models in a broad sense, as 
all predicted distances are well beyond the range of cross-linking. 
Residues F343 and V982 (Figure 4.38) lie in the central region of the membrane 
spanning segments of TM6 and TM12, respectively. According to the 3G5U structure 
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A: 343-974 B: 354-974 
 Crystal 
structures 3G5U 4M1M 3G5U 4M1M 
 Distance (Å) 24.5 25.6 39.1 41 
Molecular 
Dynamics 
simulations 
3G5U Average               
(Range) 
26.4 ± 2.4                      
(20.7-31.4) 
41.9 ± 2.6                            
(36.6-47.1)  
4M1M Average       
(range) 
26.9 ± 1.0                                   
(24.0-29.7) 
43.2 ± 1.5                                  
(39.7-47.5) 
DEER 
Distance (Å) 34 ND 
HWHM (Å) 7.5 N/A 
Cross-linking 
Distance (Å) 18.5 ± 2.3 ND 
Extent (%) 13.5 9.7 
F343 
 
A354 
 
V974 
 
A 
 
B 
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Figure 4.37: Comparison of crystal structure, molecular dynamics, EPR and cross-linking 
distance measurements for V974C containing double mutants. The mean ± standard deviation 
and range of distances for MD simulations were extracted from 3x100ns simulations using VMD 
1.9.1. DEER represents distance measurements from double resonance EPR experiments (n=1), 
the breadth of the DEER distance distribution is quantified by the Half the Width of the distance 
distribution curve at Half the Maximum of the Gaussian curve (HWHM). Cross-linking distances 
(mean ± 95% CI) are those determined by the Gaussian distribution, the extent value represents 
the mean percentage of crosslinking for the MTS molecule which caused the highest extent of 
cross-linking. Transmembrane helix six is shown in blue, positions of residues F343 and A354 
shown in pink and salmon respectively. Transmembrane helix twelve is shown in red, with residue 
V974 in black.  
the distance separating these residues was 15.5Å and 18.3Å for 4M1M. The MD 
simulations (3x100ns) of distances predicted a shorter distance for 3G5U, and a wide 
range from 10.7 – 22.6Å for 3G5U and 15.9 – 22.8Å for 4M1M. Intramolecular cross-
linking experiments determined the distance as 21.4 ± 2.7 Å, while the DEER 
measurement produced distance of 23Å, representing close agreement between 
experimental techniques for this mutant. There was no significant difference between 
the cross-linking span and MD averages of either 3G5U (p = 0.0779) or 4M1M (p = 
0.6449). The 3G5U MD average distance is 79% and 73% of the cross- linking and 
DEER distances respectively. The average distance in the 4M1M MD simulation is 93% 
of the crosslinking distance and 87% of the DEER measurement. There appeared to be, 
therefore, less deviation between the average 4M1M distance and the experimental 
measurements than observed with the other structure models. 
The span ‘B’ in Figure 4.38 shows the distance between A354 in TM6 at the 
intracellular leaflet of the plasma membrane, and V982 in the centre of the membrane 
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A: 343-982 B: 354-982 
 Crystal 
structures 3G5U 4M1M 3G5U 4M1M 
 Distance (Å) 15.5 18.3 29.2 30.8 
Molecular 
Dynamics 
simulations 
3G5U Average               
(Range) 
16.8 ± 2.5                      
(10.7-22.6) 
28.9 ± 2.9                            
(21.8-34.8)  
4M1M Average       
(range) 
19.9 ± 1.2                                   
(15.9-22.8) 
32.7 ± 1.5                                  
(28.3-37.2) 
DEER 
Distance (Å) 23 26 
HWHM (Å) 4 2 
Cross-linking 
Distance (Å) 21.4 ± 2.7 20.7 ± 5.0 
Extent 16.4 39.6 
F343 
 
A354 
 
V982 
 
B 
 
A 
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Figure 4.38: Comparison of crystal structure, molecular dynamics, EPR and cross-linking 
distance measurements for V982C containing double mutants. The mean ± standard deviation 
and range of distances for MD simulations were extracted from 3x100ns simulations using VMD 
1.9.1. DEER represents distance measurements from double resonance EPR experiments (n=1). 
Cross-linking distances (mean ± 95% CI) are those determined by the Gaussian distribution, the 
extent value represents the mean percentage of crosslinking for the MTS molecule which caused 
the highest extent of cross-linking. Transmembrane helix six is shown in blue, positions of 
residues F343 and A354 shown in pink and salmon respectively. Transmembrane helix twelve is 
shown in red, with residue V982 in green.  
spanning portion of TM12. The 3G5U and 4M1M crystal structures are in close 
agreement over the distance between the Cα carbons of these residues (29.2Å and 30.8Å 
respectively). MD simulations predict a wide range of distances being sampled between 
the two residues, the shortest distance sampled during the 3G5U simulation was 21.8Å 
and the average distance between the residues was shorter than that in the crystal 
structure. Conversely the MD simulation based on 4M1M predicts a longer distance 
between the residues than the starting crystal structure. Cross-linking experiments with 
354-982P-gp showed 39.6% altered migration, the highest for any double mutant, and 
determined an average span of 20.7 ± 5.0Å, significantly different to the 3G5U MD 
average (p = 0.0469) and 4M1M MD average (p = 0.0095). The DEER measurement of 
354-982P-gp gave an average distance of 26Å, this also had the greatest modulation depth 
of any of the DEER measurements. While 354-982P-gp produced the most reliable 
distance measurements with both techniques, the experimental measurements were 
consistently (2.9-12.0Å) shorter than those predicted in the MD simulations. In this case 
the 3G5U simulation predicted a smaller divergence to distance measurements than the 
other structure models. This inter-residue distance was also consistently variable, the 
cross-linking distance distribution being the widest among the inter-residue distances 
determined with this technique, while the DEER distance distribution was biphasic 
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(Section 4.2). This indicated that there is a significant degree of flexibility in the region 
of the cysteines introduced in 354-982P-gp. 
 Figure 4.39 shows the distances between residues F343 and F994 (A) and A354 
F994 (B). Both crystal structures predicted a 3Å (3G5U) and 4Å (4M1M) shorter 
distance between Cα carbon atoms for A compared to B, suggesting TM12 residue F994 
is closer to F343 than A354. However, the average 343-994 and 354-994 spans were 
predicted to be closer in MD simulations, with a difference of 1.4Å and 0.4Å for 3G5U 
and 4M1M respectively, suggesting that residues F343 and A354 are equidistant from 
F994. In agreement with this, cross-linking analysis determined an average span of 20.1 
± 3.8Å for 343-994P-gp and 19.2 ± 4.3Å for 354-994P-gp. Observations with cross-linking 
were corroborated by DEER spectroscopy, showing distances for A and B at 22Å and 
20Å respectively.  
The cross-linking distance for 343-994P-gp was not significantly different (p = 
0.1924) to the 3G5U predicted distance, or the 4M1M model (p = 0.8021), suggesting 
either model could be a good representation of human P-gp in this case, though the 
4M1M average is far closer to experimental observations. The cross-linking distance for 
354-994P-gp was 85% of the 3G5U MD predicted average distance, and 88% of the 
4M1M MD prediction. There was no significant difference between the 354-994P-gp 
cross-linking span and the predicted distances from the 3G5U (p = 0.3816) or 4M1M (p 
= 0.5637) simulated distances. In summary, the 4M1M simulation more accurately 
predicted the distance between the intracellular section of TM12 and the central and 
intracellular portions of TM6.
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A: 343-994 B: 354-994 
 Crystal 
structures 3G5U 4M1M 3G5U 4M1M 
 Distance (Å) 18.5 17.1 21.7 21.3 
Molecular 
Dynamics 
simulations 
3G5U Average               
(Range) 
24.0 ± 1.8                      
(18.3-28.6) 
22.6 ± 2.8                            
(16.5-30.3)  
4M1M Average       
(range) 
21.3 ± 1.6                                   
(16.0-25.8) 
21.7 ± 2.1                                  
(16.6-28.0) 
DEER 
Distance (Å) 22 20 
HWHM (Å) 0.5 5 
Cross-linking 
Distance (Å) 20.1 ± 3.8 19.2 ± 4.3 
Extent 16.2 24.1 
A354 
 
F343 
 
F994 
 
A 
 
B 
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Figure 4.39: Comparison of crystal structure, molecular dynamics, EPR and cross-linking 
distance measurements for F994C containing double mutants. The mean ± standard deviation 
and range of distances for MD simulations were extracted from 3x100ns simulations using VMD 
1.9.1. DEER represents distance measurements from double resonance EPR experiments (n=1). 
Cross-linking distances (mean ± 95% CI) are those determined by the Gaussian distribution, the 
extent value represents the mean percentage of crosslinking for the MTS molecule which caused 
the highest extent of cross-linking. Transmembrane helix six is shown in blue, positions of 
residues F343 and A354 shown in pink and salmon respectively. Transmembrane helix twelve is 
shown in red, with residue F994 in blue.  
  Three more distance measurements were attempted, from the extracellular 
section (V331), the centre (F343), and the intracellular section (A354), of the membrane 
spanning region of TM6 to the centre of the membrane spanning region of TM12 
(A980). Crystal structure measurements and MD simulations (Figure 4.40) predict that 
the distance between cysteines for 331-980P-gp and 343-980P-gp should be within the range 
of the intramolecular cross-linking reagents (3.0 – 22.1Å). Given that 354-982P-gp 
showed a high proportion of cross-linking it was reasonable to expect that a distance for 
354-980P-gp would be measureable. None of the double mutants referred to in Figure 4.40 
showed a high proportion of cross-linking or an appreciable relationship between the 
extent of cross-linking and the length of cross-linkers. DEER spectroscopy failed to 
produce reliable measurements for these three double mutants, with particularly low 
separation of inter-spin signal from the background, and a very broad distribution for 
343-980P-gp. The inter-residue distances for 343-980P-gp and 354-980P-gp measured by DEER 
fall outside the range of the MTS reagents. Unfortunately, it was not possible to draw 
conclusions about the accuracy of structural models in relation to these three inter-
residue distances, due to the lack of reliable distance measurements.
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A: 331-980 B: 343-980 B: 354-980 
 Crystal 
structures 3G5U 4M1M 3G5U 4M1M 3G5U 4M1M 
 Distance (Å) 22.6 20.2 21.7 20.8 34.1 34.9 
Molecular 
Dynamics 
simulations 
3G5U 
Average               
(Range) 
20.8 ± 1.8                      
(14.6-25.9) 
18.8 ± 4.8                            
(7.5-25.5)  
31.7 ± 5.2                            
(19.9-39.5)  
4M1M 
Average       
(range) 
22.7 ± 1.3                                   
(18.5-25.9) 
21.4 ± 1.3                                  
(17.4-24.9) 
36.0 ± 1.5                                  
(32.5-40.9) 
DEER 
Distance (Å) ND 43 29 
HWHM (Å) N/A 6 2.5 
Cross-
linking 
Distance (Å) ND ND ND 
Extent 0.9 12.7 8.6 
F343 
 
A354 
 
V331 
 
A980 
 
A 
 
B 
 
C 
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Figure 4.40: Comparison of crystal structure, molecular dynamics, EPR and cross-linking 
distance measurements for A980C containing double mutants. The mean ± standard deviation 
and range of distances for MD simulations were extracted from 3x100ns simulations using VMD 
1.9.1. DEER represents distance measurements from double resonance EPR experiments (n=1). 
Cross-linking distances (mean ± 95% CI) are those determined by the Gaussian distribution, the 
extent value represents the mean percentage of crosslinking for the MTS molecule which caused 
the highest extent of cross-linking. Transmembrane helix six is shown in blue, positions of 
residues V331, F343 and A354 shown in yellow, pink and salmon respectively. Transmembrane 
helix twelve is shown in red, with residue A980 in orange.  
For five double mutants (343-974P-gp, 343-982P-gp, 343-994P-gp, 354-982P-gp and 354-
994P-gp) inter-residue distances in the basal state could be determined by both DEER 
and intramolecular cross-linking. For three of these (343-982P-gp, 343-994P-gp and 354-994P-
gp) less than 3Å difference was observed between the results of the two techniques, 
while the results for 354-982P-gp and 343-974P-gp diverged by 5.3Å and 15.5Å respectively. 
Of the three double mutants with experimentally measured distances diverging less than 
3Å, experimental inter-residue distances for two of these double mutants distances were 
closer to the MD simulation based on 4M1M than any other model, where the third (354-
994P-gp) was closest to the 4M1M crystal structure but both experimental measurements 
were less than 2Å different to the MD simulation based on 4M1M. Cross-linking and 
DEER measurements agree in most cases, thereby permitting a high degree of 
confidence in the structural observations of this study. The inter-residue distances 
determined were similar to the existing structural models. None of the models is in 
exact agreement with all experimental distance measurements, but the MD simulation 
based on the 4M1M structure is shown to be the most accurate. The distance 
measurements also support previous observations that the basal, inward facing 
conformation of P-gp is highly flexible. In order to investigate conformational changes 
during drug-stimulated nucleotide hydrolysis, the effect of cross-linking on the activity 
of P-gp was determined. 
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CHAPTER 5: The Effect of homobifunctional cross-linking on the 
ATPase activity of P-gp 
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This study sought to determine what effect constraining the movement of TM6 & 12 
had on the activity of the transporter, using the five double mutants which were 
successfully cross-linked (343-974P-gp, 343-982P-gp, 343-994P-gp, 354-982P-gp and 354-994P-gp). 
The strategy used was to covalently link different regions of the helices, then measure 
changes in the basal and drug stimulated ATPase activity of P-gp. To achieve this, the 
ATPase activity of Cys-lessP-gp and each of the double mutant isoforms was measured in 
the presence of a fixed concentration of ATP and a varying concentration of drugs, after 
incubation with MTS reagents (as in section 3.2.4). This was done to ascertain whether 
alterations in ATP hydrolysis were due to a reduced potency for the drug or a result of 
altered coupling of drug binding to nucleotide hydrolysis.  
No significant differences (ANOVA p > 0.05) were found in any of the dose-response 
parameters between the untreated sample and the DMSO pre-incubated sample in 
experiments with Cys-lessP-gp, or any of the double mutants (data not shown). This 
observation indicates that the conditions of the cross-linking experiment do not 
compromise protein function. Similarly, treatment of Cys-lessP-gp with an MTS reagent 
(M17M) did not alter the parameters of ATPase activity (Tables 5.9 & 5.10). This 
shows that any effect on ATPase activity caused by MTS reagents is due to their 
covalent attachment to the protein. The parameters of ATPase activity were determined 
for the five double mutants which demonstrated intramolecular cross-linking. These 
were also the five for which a relationship could be perceived between the length of 
MTS reagents and the proportion of intramolecular cross-linking (Section 4.1).  Each of 
the double mutants was pre-treated with the MTS reagent which had been demonstrated 
to cause the highest proportion of intramolecular cross-linking for that mutant (Section 
4.1). The activities of 343-974P-gp, 343-994P-gp and 354-994P-gp were determined after pre-
incubation with M14M; while 343-982P-gp and 354-982P-gp were pre-incubated with 
M17M.  
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Mutant Basal rate Nicardipine Stimulated rate Fold stimulation 
 DMSO MTS DMSO MTS DMSO MTS 
Cysless 304 ± 37 299 ± 33 1269 ± 189  1043 ± 51 4.41 ± 0.82 3.60 ± 0.34 
343-974 207 ± 56 81 ± 14  952 ± 211 159 ± 25 * 4.87 ± 0.43 2.06 ± 0.27 * 
343-982 247 ± 18 237 ± 23 630 ± 51 354 ± 19 * 2.58 ± 0.26 1.53 ± 0.15 * 
343-994 189 ± 40 122 ± 52 878 ± 17 309 ± 117* 5.23 ± 0.94 3.18 ± 0.89 
354-982 286 ± 48 43 ± 18 * 1282 ± 77 250 ± 79* 5.03 ± 1.19 9.54 ± 3.76  
354-994 477 ± 124 410 ± 90 1060 ± 185 913 ± 177 2.47 ± 0.32 2.31 ± 0.14 
 Table 5.9: Parameters of ATPase activity in response to nicardipine for P-gp mutants exposed 
to MTS cross-linkers. ATPase activity was measured as a function of nicardipine concentration 
at a fixed concentration of ATP (2mM) for the range of P-gp mutants. Measurements were carried 
out after incubation with DMSO or 30µM MTS cross-linkers linkers on each of the double 
mutants, as well as the Cys-less mutant. Values (nmol Pi min-1mg-1) are the mean ± SEM of at 
least 3 independent protein preparations. An asterisk refers to a significant difference detected 
by one-way ANOVA and Dunnett’s Multiple Comparison Test (p < 0.05) compared to pre-
incubation of that mutant with DMSO.  
Some significant effects following MTS cross-linking were seen on the 
parameters of ATPase activity for four of the five double mutants tested (343-974P-gp, 343-
982P-gp, 343-994P-gp and 354-982P-gp), while one double mutant (354-994P-gp) was 
unaffected. Typically, the magnitude of the effects was greater than the proportion of 
the mutant protein intramolecularly cross-linked. For example, the nicardipine-
stimulated ATP hydrolysis of 354-982P-gp was reduced from 1282 nmol Pi min-1 mg-1 to 
250 nmol Pi min-1 mg-1 after incubation with M17M, a reduction of 74%, while this 
mutant was shown reach an average maximal extent of cross-linking of 39.6% with this 
reagent. This result strongly suggests that the explanation for partial cross-linking 
proposed in Section 2.8 is correct, as the non-intramolecularly cross-linked protein must 
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be contributing to the reduction in activity. Thus, a caveat to all other interpretations of 
the results presented in this section must be highlighted, that activity measurements 
were carried out on a mixed population, composed of P-gp mutants containing 
intramolecular cross-links and protein with two MTS reagents bound to the two 
cysteines.  
Effects on the rate of ATPase activity by P-gp mutants were divided into two 
categories. The first type of effect is characterised by significant decreases in the extent 
of stimulation of ATP hydrolysis by nicardipine, without a decrease in the potency of 
interaction between the double mutant and nicardipine. The basal ATPase activity of 343-
982P-gp was unaffected by cross-linking with M17M, while the stimulated rate was 
decreased from 630 nmol Pi min-1 mg-1 to 354 nmol Pi min-1 mg-1 (Table 5.9). The 
potency for interaction with nicardipine was not significantly different after 
intramolecular cross-linking (Table 5.10). This shows that the decrease in the rate of 
nicardipine-stimulated ATP hydrolysis was not due to an altered ability of the P-gp 
mutant to interact with nicardipine. Rather, it appears that that the coupling of 
nicardipine binding to ATP hydrolysis has been perturbed. The covalent linkage 
between F343 and V982 (and attachment of MTS reagents at both cysteines) may 
prevent movement of TM6 & 12 that is a necessary part of conformational changes 
associated with ATP hydrolysis. The fact that only the nicardipine-stimulated rate of 
hydrolysis, not basal hydrolysis, was affected, indicates that the conformational changes 
associated with the two are different. A similar effect of cross-linking 343-974P-gp on the 
drug stimulation of ATPase activity was observed with an 84% decrease in hydrolysis 
rates. Indeed, the activity was so low that some of the measurements of phosphate 
released were below the range of the phosphate standards. The subsequent extrapolation 
is a caveat, but this double mutant also had a significantly altered potency for 
interaction with nicardipine after cross-linking. However, the observed increase in 
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potency for interaction with nicardipine does not offer reduced nicardipine binding as an 
explanation for the reduction in fold-stimulation of ATP hydrolysis. 
P-gp Mutant 
    Potency or EC50 (μM) 
DMSO MTS 
Cys-less 3.5 ± 0.9 2.0 ± 0.9 
343-974 5.3 ± 1.4   1.4 ± 0.3 * 
343-982 1.1 ± 0.1 1.0 ± 0.1 
343-994 6.1 ± 2.0 0.8 ± 0.3 * 
354-982 4.4 ± 1.4 3.8 ± 2.2 
354-994 1.9 ± 0.3 1.3 ± 0.3 
Table 5.10: Potency of nicardipine to stimulate ATP hydrolysis by P-gp mutants after 2hr 25°C 
incubation with MTS cross-linkers. ATPase activity was measured as a function of nicardipine 
concentration (10-8.5M to 10-4M) and a fixed concentration of ATP (2mM) for the range of P-gp 
mutants. Measurements were carried out after incubation with DMSO or 30µM MTS cross-
linkers on each of the double mutants, as well as the Cys-less mutant. Values are the mean ± SEM 
of 3 or more independent protein preparations. An asterisk refers to a significant difference 
detected by one-way ANOVA and Dunnett’s Multiple Comparison Test (P < 0.05) compared to 
pre-incubation of that particular mutant with DMSO.  
The second type of effect was characterised by a reduction in the rate of basal 
and stimulated ATP hydrolysis; where the degree of stimulation by nicardipine was 
unaffected, and there was also no increase in the concentration of nicardipine required 
to elicit the stimulation. Cross-linking of 343-994P-gp and 354-982P-gp led to a significant 
decrease in maximal rates of hydrolysis but did not affect the ability of nicardipine to 
stimulate an increase in the rate of ATPase activity. For example, the basal rate of ATP 
hydrolysis by 354-982P-gp was reduced 85% after treatment with M17M, while 
nicardipine stimulated activity was reduced by 74% (Figure 5.41). This observation 
indicates that the inherent ATPase activity of P-gp is inhibited by crosslinking of A354 
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to V982, regardless of drug binding. One possible explanation for this is that cross-
linking of these two residues inhibits local conformational changes that are associated 
with basal activity as well as those coupling nicardipine binding to ATP hydrolysis.  
 
Figure 5.41: Effect of homobifunctional crosslinking reagents on the ATPase activity of 354-
982P-gp. The ATPase activity of  354-982P-gp was measured as a function of nicardipine 
concentration at a fixed concentration of ATP (2mM). Measurements were carried out on 354-
982P-gp with no pre-incubation (●), 2hr pre-incubation at 25°C with 1% DMSO (■) and 
incubation with 30µM M17M (□). Points represent the mean ± SEM for three independent 354-
982 purifications. The general dose-response curve was fitted to the data using non-linear least 
squares regression. 
As noted above, the rates of ATPase activity of one double mutant (354-994P-gp) 
were not significantly affected by cross-linking (Table 3.9). This observation may 
indicate that the thiol groups of these two cysteines do not require significant movement 
relative to one another over the course of the translocation cycle. Alternatively, this 
portion of the helices may undergo some form of relative motion that is not prevented 
by intramolecular cross-linking via MTS reagents. The latter explanation is more 
plausible given the effect of cross-linking on the ATPase activity of the other double 
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mutants. The homobifunctional cross-linking reagents are neither rigid nor bulky 
(Figure 4.22) and may therefore bend to accommodate the helical movement. This 
would permit the distance between the two residues to decrease over the course of the 
translocation cycle, but not to increase beyond the span of the MTS reagent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, intramolecular cross-links in 343-982P-gp and 343-974P-gp perturbed 
coupling between nicardipine binding and ATP hydrolysis and cross-links in 354-982P-gp 
V974  
V982 
F994 
A354 
F343 
Figure 5.42: The spatial distribution of intramolecular cross-links and their effect on ATP 
hydrolysis. Cross-links leading to a decrease in nicardipine stimulation of ATPase activity (343-982P-
gp and 343-974P-gp) are shown in orange.  Cross-links leading to a decrease in basal and stimulated 
ATPase activity, but not the degree of stimulation, (354-982P-gp and 343-994P-gp) are shown in blue. The 
cross-link which did not affect ATPase activity (354-994P-gp) is shown in green. TM6 is shown in blue 
and TM12 in red. The structure shown is a section of the 4M1M crystal structure, visualised using 
VMD 1.9.1. 
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and 343-994P-gp inhibited the inherent activity of the transporter, while cross-linking in 
354-994P-gp had no effect. These different observations can best be understood when the 
position of the intramolecular cross-links in the structure of the protein is considered 
(Figure 5.42). Intramolecular cross-links toward the extracellular ends of the helices 
were shown to affect coupling of ATP hydrolysis to nicardipine binding, while those 
toward the intracellular ends affected inherent activity. This suggests two things, firstly 
that both basal and stimulated activity require relative motion between TM6 & 12, and 
secondly that this motion is different in the two cases.  
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CHAPTER 6: Discussion 
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Defining exactly how TM6 &12  communicate events between the TMDs and NBDs is 
a crucial part of the search for a detailed molecular mechanism of P-gp (Callaghan 
2015). Over the last 25 years numerous studies have shown that TM6 and TM12 play a 
pivotal role in the activity of the transporter (Loo and Clarke 1997, 1993, 1994a; Song 
and Melera 2001; Greenberger 1993; Loo, Bartlett, and Clarke 2009); supporting data 
has been provided by mutagenesis and covalent modification, showing that alterations 
at a number of points on these helices can perturb communication between the TMDs 
and NBDs (Storm et al. 2008; Storm et al. 2007; Crowley et al. 2009; Crowley et al. 
2010). The current study determined the relative orientation of the two helices in the 
basal, or resting state of human P-gp and assessed the importance of their relative 
movement during drug translocation. 
A number of double mutants of P-gp were made, introducing cysteines to TM6 
& 12 at positions that have previously been modified in isolation. Residues were chosen 
for mutation at key positions on the ends and centre of the helices. The individual 
mutations have previously been shown to not inhibit P-gp function in the absence of 
covalent modification. We demonstrated that these double mutants retained their 
function and inter-residue distances were measured by homobifunctional cross-linking 
and DEER spectroscopy. These experimental measurements showed that the MD 
simulation based on the 4M1M (refined mouse structure) is the most accurate structure 
model (Section 4.3). Covalent modification of TM6 & 12 double mutants was shown to 
have severe effects on the functional competency of the transporter. Finally, the relative 
movement of TM6 & 12 was shown to be different in conformational changes during 
basal (intrinsic) ATP hydrolysis in comparison to those following the addition of a drug. 
Overall, this investigation provided a topographical description on TM6 & 12, showed 
that their relative orientation is comparable to predictions in the structure models and 
gives key insights into the differing role of the helices in basal and stimulated ATP 
hydrolysis. 
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6.1 Why was homobifunctional cross-linking interpreted in a new way 
in this study?  
 
This investigation aimed to elucidate details of three dimensional structures through a 
combination of strategically placed one dimensional distance measurements, using two 
techniques. One of the techniques used to do this was intramolecular cross-linking with 
MTS reagents of various lengths. For the three-dimensional structural data to be 
reliable, the one-dimensional distance measurements were required to be accurate and 
precise. The way in which homobifunctional cross-linking was done and interpreted in 
this study was designed to provide more precision and accuracy of distances measured, 
in comparison to previous studies.  
Inter-residue distance measurements done in previous investigations using 
homobifunctional cross-linkers have usually reported on a range of spans at which 
cross-linkers bind (Loo and Clarke 2002, 2014b, 2001c; O'Mara 2012). In order for a 
precise distance to be determined, it is necessary to quantify which cross-linkers bind 
best, in comparison to others, and therefore are the best representation of inter-residue 
distance. This could conceivably be done in one of two ways, other investigations have 
quantified which cross-linker is the most appropriate distance by measuring which binds 
fastest (Guan, Murphy, and Kaback 2002), while this study measured which reagent 
caused the highest extent of cross-linking. Some previous works have indicated 
proportional cross-linking by lengths of cross-linkers (Sun and Kaback 1997; Hennon 
and Dalbey 2014). However, these do not compensate for the exposure problems 
associated with western blotting (Section 2.8) so cannot be considered quantitative. 
Some attempts have been made to rationalise why cross-linking with MTS reagents 
might not reach 100% (Ermolova, Guan, and Kaback 2003), but this study is the first to 
identify that the cause as competition between the formation of intramolecular cross-
links and separate attachment of two residues (explained fully in Section 2.8), which 
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was demonstrated to be correct by changes in ATPase activity disproportionate to the 
extent of intramolecular cross-linking (Chapter 5). 
Unlike most previous intra-molecular cross-linking studies this investigation 
used pure protein, making visualisation of cross-linking in coomassie stained gels, and 
thus quantitative analysis, possible (Section 2.8). These quantitative measurements 
made comparison of proportions of cross-linking possible, subsequently allowing a 
precise inter-residue distance to be determined. In order for these precise measurements 
to be accurate, the analysis had to be done with correct MTS lengths. 
6.1.1 How long are MTS reagents? 
 
The effective distance that MTS reagents span is a matter of controversy (Green, 
Reisler, and Houk 2001). There are two hypotheses, namely that the distance 
corresponds to the maximum theoretical lengths of the reagents (the ‘straight’ spans), 
and the second seeks to predict the average distance between the two sulfhydryl reactive 
groups (the ‘bent’ spans). Loo and Clarke state they calculated the span of MTS 
reagents from the total length of the covalent bonds between the constituent atoms (Loo 
2001), other studies have applied these lengths to determine inter-residue distances (Loo 
and Clarke 2001c; Zhu et al. 2016; Collier et al. 2014; Moore et al. 2008; Moore and 
Fillingame 2008). These distances, given in Table 6.11, are the previously employed 
‘straight’ spans. Other groups of researchers have used MD simulations to predict the 
cross-linking span, resulting in a trend in which the longer cross-linkers span a shorter 
distance relative to the number of atoms in their spacer arm (Table 6.11) (Green, 
Reisler, and Houk 2001; Shvetsov et al. 2006). This trend is due to the fact that with an 
increasing number of tetrahedral carbon-carbon bonds there is an increasing chance that 
one or more will adopt a gauche conformation, effectively causing the molecule to 
bend, reducing the distance between functional groups (the ‘bent’ spans). This section 
will explain why straight spans are more applicable to P-gp, and therefore were used in 
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the present study. The reason the previously published straight spans were not used, but 
rather were calculated from first principles, will also be addressed. 
As noted above, the ‘bent’ spans are a prediction of the average distance between the 
two functional groups of the MTS reagent. It could be strongly argued that the best 
strategy for measuring inter-residue distances would be to combine the average length 
of a cross-linker with the average distance between the thiol groups of the cysteines and 
the respective Cα carbons of the two residues on the cross-linking ‘axis’ between the 
two residues. However, this requires the environment of the residues in question and the 
orientation of the side chains, to be known. The extent of bending of each MTS reagent 
is dependent on the environment it is in (Green, Reisler, and Houk 2001), i.e. in an 
aqueous environment, MTS reagents would bend more to reduce the exposure of the 
alkyl chain to the polar environment. The central cavity of P-gp is a tripartite interface 
of protein, lipid bilayer and aqueous cavity, making any prediction of the environment 
of a specific residue subject to error. Secondly, the crystal structures of murine P-gp are 
at a resolution of 3.8Å (Aller et al. 2009; Ward et al. 2013), while atomic resolution 
(<2Å) is required to confidently assign side chain orientations. Any assumption of side 
chain orientation may cause bias in distance measurements. To not assume any side 
chain orientation, it must be assumed any side chain orientation is possible, and that the 
side chains could therefore be facing away or toward each other, giving an average 
contribution to the cross-linking span of zero. The lengths of the side chains were 
therefore not added to inter-residue distances in this investigation. For these reasons, 
straight spans were thought to be more applicable to P-gp and were used in the present 
study. 
This reasoning was supported by the results summarised in Section 4.3. One part 
of the rationale offered for using bent spans is that straight spans may result in over-
estimating the distance between cysteine residues (Green, Reisler, and Houk 2001), 
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however the DEER measurements done in this study do not reveal any instances of 
over-estimating inter-residue distances using straight spans in the cross-linking results 
(Section 4.3). Using the straight spans, in instances where there is more than 3Å 
difference between cross-linking and DEER invariably the cross-linking distance is the 
shorter of the two, due to the limited lengths of MTS reagents available (as explained in 
Section 6.1). Using the shorter ‘bent’ spans would result in a further underestimate of 
these inter-residue distances. 
In the present study the lengths of the MTS reagents were calculated to determine 
whether the previously used ‘straight’ spans were correct, trigonometry was used to 
generate the ‘novel equation’ as described in Sections 2.8.2 and 4.1. When compared to 
the original straight spans quoted in the literature (Loo and Clarke 2001c; Zhu et al. 
2016; Collier et al. 2014; Moore et al. 2008; Moore and Fillingame 2008) the lengths 
determined by our method are similar (Table 6.11). A second equation was derived, 
which produces the lengths used in published works (the ‘original equation’):  
!"!	$%&'' − )*+,*+-	'./+ = 2.6 + (6"27 ∗ 2.6) 
Where Y = the number of atoms in the spacer arm (not including terminal sulphur 
atoms). 
The accuracy of this original equation, in comparison to the novel equation used in this 
study, must be considered to justify our divergence from the previous computation of 
inter-residue distances using homobifunctional cross-linking. As in the final equation 
used, the original contains firstly a fixed figure to represent the two carbon to sulphur 
bonds (2.6). Secondly a term to represent the length of the spacer arm, variable by the 
number of atoms ([Y/2]*2.6). Unlike the final version employed in this investigation, 
this equation contains simplifications which reduce accuracy. Firstly, the term referring 
to the sum total length of carbon-carbon bonds ‘([Y/2]*2.6)’ gives a result  
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 Calculated length of MTS reagents (Å) 
MYM Original Equation 
Loo & 
Clarke 
(Loo and 
Clarke 
2001c) 
Shvetsov 
(Shvetsov 
et al. 
2006) 
Green 
(Green, 
Reisler, 
and 
Houk 
2001) 
Novel Equation 
1 3.9 3.9 5.4 - 3.0 
2 5.2 5.2 - - 4.2 
3 6.5 6.5 - 6.87 5.5 
4 7.8 7.8 7.8 8.07 6.7 
5 9.1 9.1 - - 8.0 
6 10.4 10.4 9.6 10.4 9.2 
7 11.7 - - 11.6 10.5 
8 13 13 12.1 11.5 11.4 
10 15.6 15.6 - - 14.3 
11 16.9 16.9 - - 15.0 
14 20.8 20.8 - - 18.5 
17 24.7 24.7 - - 22.1 
      
Table 6.11: Cross-linking spans of homobifunctional MTS molecules determined by 
trigonometry and MD simulations. MYM refers to the cross-linker with the given number of 
atoms in the spacer arm, M1M, M2M etc. The measurements given by Shvetsov and Green were 
calculated by MD simulations. The ‘Novel Equation’ refers to the equation used to calculate MTS 
reagent lengths in this study: 2.97+[(Y-1)*(2.51/2)-z*2.51+z*2.33]. The ‘Original Equation’ 
refers to that which yields the original straight spans as stated in the literature: 2.6+([Y/2]*2.6). 
greater than zero Angstroms when there is only one carbon present (Y=1), so no carbon 
to carbon bonds. This produces to a bias for overestimating the length of the MTS 
reagents. Secondly, differing lengths of carbon to carbon, carbon to oxygen and two 
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carbon to sulphur bonds are not taken into account. For these reasons data collected in 
this investigation was analysed using the cross-linking spans calculated for the MTS 
reagents by the method described in Section 2.8.2. 
In summary, the present study undertook a rational analysis of how cross-linking 
occurs and how different strategies for calculating MTS lengths are most appropriately 
used. The maximum length of MTS reagents was also calculated in a new way, 
producing moderately different results to MTS spans previously used. This was done to 
allow a precise inter-residue distance to be determined, rather than the range of 
distances reported in previous studies. Straight cross-linking spans were theorised to be 
most appropriate for use with P-gp, and the spans generated by the novel equation used 
in this study are asserted to be more accurate than those used previously. A comparison 
of inter-residue distances determined by cross-linking and DEER supports this 
approach.  In the three instances where the DEER distance measurement was within the 
range of available MTS reagents, there was a disparity of 0.8, 1.9 and 2.6Å. This 
indicates that the quantitative cross-linking strategy used in this investigation was 
precise and accurate, within the range of MTS reagents. 
6.2 The relative positions of TM6 & TM12 in human P-gp 
 
Attempts to determine the structure of human P-gp in the basal inward facing 
conformation have been fraught with challenges and controversy (O'Mara 2012; 
Callaghan 2015) (Section 1.5). Another issue with X-ray crystallography pertains to the 
requirement of taking the protein out of the bilayer environment that is required for 
ATPase activity (Callaghan et al. 1997) and drug binding (Jin et al. 2012; Shukla et al. 
2017). Biochemical data that illuminates the basal structure of human P-gp in a lipid 
bilayer is highly valuable in providing an supporting information to past and future 
attempts to predict the overall structure (O'Mara 2012). This investigation was the first 
to attempt numerous distance measurements in a confined region of the protein, using 
 161 
 
two techniques. As described in Section 3.1 the combination of distance measurements 
in a narrow locality aided interpretation of the results in three dimensions.  
Our investigative strategy involved multiple biochemical and biophysical 
approaches.  The comparison of DEER and cross-linking results revealed strong 
agreement between distance assignments for a number of residue pairs (Section 4.3, 
Figure 6.43). There was less than 3Å divergence between distance measurements for 343-
982P-gp, 343-994P-gp and 354-994P-gp. The agreement in the measurements for these three 
double mutants underscores the reliability of the two procedures. All three double 
mutants displayed avid cross-linking (Section 4.1), while 343-994P-gp and 354-994P-gp 
were characterised by a high-quality DEER signal (as measured by separation of inter-
spin signal from the background, Section 4.2).  
The notable outlier to the trend of convergence between reliability and 
agreement between distance measurements was 354-982P-gp. This double mutant had the 
highest extent of cross-linking and the greatest modulation depth, yet the inter-residue 
distance determined by cross-linking was 5.3Å shorter than the distance measured by 
DEER. This disagreement may be due to the limited lengths of cross-linking reagents 
used. For example, a higher proportion of cross-linking may have been observed with 
an MTS reagent of 26Å; however, there are none of this diameter commercially 
available.  
Distance measurements for 343-974P-gp showed a discrepancy of 15.5 Å between 
the results of different techniques (Figure 4.37). A distance (18.5 ± 2.3Å) was 
determined for this double mutant with homobifunctional cross-linking, but the data 
was obtained with a low extent (13.5% XLMax). The DEER measurement for this mutant 
gave a modulation depth of 0.12 F(t), and a distance of 34 ± 7.5Å. It is plausible that the 
reason for the observed disagreement in this case is flexibility of the helices in this  
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Figure 6.43: Comparison of Cross-linking and DEER distance measurements. TM6 shown in 
blue and TM12 in red, the mutated residues are shown as Van der Walls radii and labelled with 
residue numbers. Above is a ‘front view’ of the TMDs, in which an expanded view of the protein 
would see the NBDs side-by-side, while below is an orthoganol ‘side view’ in which one NBD 
would entirely eclipse the other. Measureable inter-residue distances shown in green where there 
was less than 3Å difference between cross-linking and DEER measurements. The distance 
highlighted in orange showed 5.3Å disagreement between techniques, while the distance in red 
diverged by 15.5Å.  
region or manoeuvrability of the V974C side chain (Section 6.2.3). In addition, the 
DEER value was outside the range of available cross-linker sizes, meaning that cross-
linking detected only the lower range of the highly variable inter-thiol distance, 
resulting in the underestimation of inter-residue distance determined by this technique. 
The weight of evidence strongly indicates that the reason no cross-linking was observed 
in the 354-974P-gp double mutant was due to an excessive distance between the residues 
(Section 3.1). This meant no cross-linker was long enough to bind both cysteines, while 
the inter-spin DEER signal was impossible to separate from the high background signal, 
due to the inherently lower sensitivity for longer distances in measurements using this 
technique (Borbat, Georgieva, and Freed 2013). The remaining three A980C containing 
double mutants will be addressed in Section 6.2.2. Within the range of the available 
MTS lengths (3.0-22.1Å), there was good agreement between cross-linking and DEER 
measurements. Furthermore, where there was agreement between cross-linking and 
DEER, the MD simulation based on 4M1M was a good model of human P-gp in this 
region of the protein (Section 4.3).  
A recently published study (Verhalen et al. 2017) sought to use a combination of 
DEER and computational techniques to probe conformational changes in mouse P-gp 
over the course of the ATP hydrolysis/ substrate translocation cycle. This study used a 
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rotamer library approach to predict inter-spin distance distributions in the 4M1M crystal 
structure; this technique estimates the possible arcs of rotation of the side chains in a 
static structure, as done previously with the Na+/H+ antiporter NhaA (Polyhach, 
Bordignon, and Jeschke 2011). Distance distributions predicted by a rotamer library 
approach with the 4M1M structure were compared to DEER measurements. Inter-
residue distances between the two NBDs were significantly greater in measurements 
using DEER, in comparison to the rotamer library predictions. This result was indicated 
to suggest a more open basal conformation as observed in the C.elegans P-gp crystal 
structure (Jin et al. 2012). Distances were also measured between transmembrane 
helices, TM2-TM8, TM2-TM5, TM9-TM11, TM5-TM11, TM5-TM6 and TM11-
TM12. Most Transmembrane helix-Transmembrane helix (TM-TM) inter-residue 
distance measurements showed close agreement between distance distributions from the 
4M1M rotamer library and DEER (Verhalen et al. 2017). The largest disagreements 
between rotamer library prediction and DEER-observed distances in TM-TM inter-
residue measurements were found in the two double mutants involving a residue in 
TM6 or TM12, suggesting that the position of TM6 & TM12 is not accurate in the 
4M1M structure.  
The findings of this study appear to contradict the findings of the present study, 
which showed very close agreement between the crystal structure and TM6-TM12 
measurements. However the two double mutants involving TM6 and TM12 residues 
employed in the Mchaourab study (Verhalen et al. 2017) only retained approximately 
40% and 65% ATPase activity respectively. In contrast, none of the double mutants 
used in the present study were shown to have a statistically significant loss of ATPase 
activity (Section 3.2.3). The residue pairs used in this previous study (Verhalen et al. 
2017) for TM-TM measurements were located at the ends of the helices near the NBDs, 
whereas the present investigation measured distances within membrane spanning 
region. This difference in location further limits comparability of the two studies.  
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6.2.1 Why did this study use murine P-gp structures 3G5U and 4M1M, 
when there are other inward-facing structures available? 
This study compared results to 3.8Å murine P-gp structures (3G5U/4M1M) and related 
MD simulations despite the availability of the higher resolution (3.4Å) 4F4C structure 
of Caenorhabditis elegans P-gp (Jin et al. 2012). Murine P-gp structures were used 
because mouse P-gp is functionally similar to human P-gp, whereas C.elegans P-gp is 
less well characterised, and furthermore what is known about C.elegans P-gp suggests 
there are meaningful differences in the function of this protein in comparison to human 
P-gp. Firstly, murine P-gp has higher sequence identity (87%) (Taylor et al. 1999) with 
human P-gp in comparison to that of C.elegans P-gp with human P-gp (46%) (Jin et al. 
2012). Secondly mouse P-gp is known to share many characteristics with human P-gp, 
including an equivalent magnitude of basal and stimulated ATPase activity (Taylor et 
al. 1999; Aller et al. 2009). Conversely the basal ATPase activity of C.elegans P-gp is 
an order of magnitude lower than human and murine P-gp, while drug stimulated 
ATPase activity is approximately one fifth of the mammalian proteins (Jin et al. 2012). 
Murine P-gp has been demonstrated to interact with vinblastine (Taylor et al. 1999), 
verapamil (Aller et al. 2009) with a comparable affinity to that of human P-gp. P-gp-
knockout mice have been shown to have increased accumulation of human P-gp 
substrates vinblastine (Schinkel et al. 1994), etoposide, paclitaxel and cyclosporin A 
(Schinkel et al. 1996) beyond the blood-brain barrier (a principle location of 
endogenous P-gp expression) suggesting that murine P-gp is also capable of extruding 
these drugs. While paclitaxel, actinomycin D and valinomycin have been shown to elicit 
stimulation of C.elegans ATPase activity, human P-gp modulators verapamil, 
rhodamine 123, vinblastine, doxorubicin, emetine, etoposide, vincristine, puromycin, 
colchicine and daunorubicin had no effect on ATPase activity (Jin et al. 2012). 
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 Distance (Å) Average Distance (Å) 
 4M1M 4F4C MD (4M1M) Cross-linking DEER 
A: 343-982 18.3 19.1 19.9 22.0 23 
B: 354-994 21.3 25.3 21.7 19.8 20 
Figure 6.44: Comparison of Murine and C.elegans P-gp crystal structures. The upper panels 
depict the TMDs of i) murine (4M1M) and ii) C.elegans (4F4C) structures in gold and black 
respectively in front-view (above) and side-view (below). The span labelled ‘A’ is the distance 
between residues equivalent to F343 and V982 in human P-gp. The span labelled ‘B’ is the 
distance between residues equivalent to A354 and F994 in human P-gp. The lower panel gives 
the inter-residue distance measurements from both static crystal structures to the left, and the 
average distances determined by various techniques in the present investigation to the right.  
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The investigation that determined the structure of C.elegans P-gp (4F4C) 
acknowledged that the conformation of TM12 is significantly different in comparison to 
the murine (3G5U/4M1M) structures (Jin et al. 2012; Li, Jaimes, and Aller 2014). In the 
4F4C structure there is discontinuity of the TM12 helix, resulting in a 4Å difference in 
the distance between residues equivalent to A354 and F994 compared to 4M1M (Figure 
6.44). The significant conformational difference in TM12 and the functional differences 
of C.elegans P-gp indicate that while 4F4C may be a good representation of C.elegans 
P-gp, its relevance to human P-gp is less than that of the murine structures.  
A more recent structure of murine P-gp (Esser et al. 2017), with a higher (3.4Å) 
resolution than 3G5U and 4M1M was also excluded from analysis by MD simulations 
and distance measurements. This was done for two reasons; firstly, the 5KPD was 
produced using a mutant form of murine P-gp, with 34 residues removed from the 75-
residue linker region between NBD1 and TM7. This linker region had previously been 
demonstrated to be required for drug transport and ATP hydrolysis (Hrycyna et al. 
1998). The linker-shortened mutant used to generate 5KPD was demonstrated to have 
no modulation of ATPase activity in the presence of verapamil or cyclosporine A, and 
have dramatically reduced rates of rhodamine123 and Calcien-AM transport (Esser et 
al. 2017). The linker-shortened mutant is therefore, significantly less functionally 
relevant to human P-gp than the wild-type murine P-gp used to generate 4M1M. The 
second reason the 5KPD structure was excluded from our analysis is that it is almost 
indistinguishable from 4M1M with respect to TM6 & 12 (Figure 6.45). As our 
measurements would not permit meaningful interpretation of the relative accuracy of 
4M1M and 5KPD, and 4M1M is the functionally relevant structure, only 4M1M was 
used in our analysis of inward-facing P-gp structures. 
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 Distance (Å) 
Residues 4M1M 5KPD 
A: 343-974 25.6 25.9 
B: 343-982 18.3 18.4 
C: 343-994 17.1 16.9 
D: 354-982 30.8 30.8 
E: 354-994 21.3 19.9 
   
Figure 6.45: Comparison of 4M1M and 5KPD crystal structures. The upper panels depict the 
TMDs of murine i) 4M1M and ii) 5KPD crystal structures in gold and cyan respectively, with 
front-views above and side-views below. The span labelled ‘A’ is the distance between residues 
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equivalent to F343 and V974 in human P-gp. The span labelled ‘B’ is the distance between 
residues equivalent to F343 and V982 in human P-gp. The span labelled ‘C’ is the distance 
between residues equivalent to F343 and F994 in human P-gp. The span labelled ‘D’ is the 
distance between residues equivalent to A354 and V982 in human P-gp.  The span labelled ‘E’ 
is the distance between residues equivalent to A354 and F994 in human P-gp. The lower panel 
gives the inter-residue distance measurements from both static crystal structures. Images were 
generated and inter-residue distances measured using VMD 1.9.1.  
6.2.2 The topography of TM6 & 12 in human P-gp 
The results of this study can be used in combination with existing biochemical data to 
inform on the orientation of amino acid side chains in TM6 and TM12, due to the 
specific steric requirements of intramolecular cross-linking. Successful intramolecular 
cross-linking between two sites has several requirements. For example, attaching a 
bifunctional probe to two cysteines requires that both must be physically accessible, 
also there must not be any other part of the protein blocking the space between the two 
thiol groups. This requirement for ‘line of sight’ means that intramolecular cross-linking 
will be prevented if the side chain of a cysteine residue is facing directly away from the 
other helix. Therefore, a lack of cross-linking between two residues which are close 
enough to cross-link may give insights into the orientation of side chains, if both thiol 
groups are physically accessible. 
No cross-linking distance could be established for any of the A980C containing 
double mutants (331-980P-gp, 343-980P-gp and 354-980P-gp). The TM6 residues V331C, 
F343C and A354C have all been demonstrated to be highly accessible to labelling by 
CM (Storm et al. 2008; Rothnie et al. 2004) and produced an EPR signal after labelling 
with MTSL (van Wonderen et al. 2014). The residue 980C also showed an EPR signal 
after labelling with MTSL (van Wonderen et al. 2014), and has been shown to be 
moderately accessible to covalent modification by CM (Crowley et al. 2010). Thus, the 
lack of 331-980P-gp, 343-980P-gp and 354-980P-gp cross-linking is not due to an inherent 
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inaccessibility of the residues. In contrast, isoforms containing the proximal mutation 
V982C (343-982P-gp and 354-982P-gp) displayed intramolecular cross-linking with MTS 
reagents able to span 11.4-22.1 Å. This strongly indicates that insufficient cross-linker 
lengths are unlikely to be responsible for the failure to observe cross-linking of 343-980P-
gp and 354-980P-gp. A plausible explanation for experimental observations is therefore 
that residue A980C is facing directly away from the internal cavity and TM6 in the 
basal conformation, preventing line of sight (Figure 6.46).  
This interpretation is supported by a consideration of the results of the present 
study, in the context of a-helical geometry. Each amino acid corresponds to a 100° turn 
in an α-helix, therefore the orientation of the side chains of A980C and V982C can be 
predicted to diverge by 200°. As V982C does form intramolecular cross-links with 
TM6, it can be predicted to face roughly toward this helix, while the 200° divergence of 
A980C means this side chain will face away from TM6. This is unlikely to be 
compensated for by changes in orientation of the A980C side chain, as previous EPR 
experiments have shown the movement of a spin label attached to this residue is highly 
restricted (van Wonderen et al. 2014). Further evidence is available in existing 
biochemical data, homobifunctional cross-linking has previously been employed to 
determine the dimensions of the central cavity in P-gp, and has demonstrated residue 
pairs in TM6 & 12 which can, and cannot, be cross-linked (Loo and Clarke 2001c, 
2001a) . These studies generated a model for side chain orientation in TM6 & 12, which 
also concluded that residue A980C faces directly away from TM6 (Loo 2001). Residues 
V982C and A985C (separated by 60° rotation) were cross-linked to L339C or F343C in 
TM6. In contrast, residue G984C, which is separated from A980C by a 20° helical 
rotation, could not form intramolecular cross-links with TM6 (Loo and Clarke 2001c). 
In summary, this collection of biochemical experimental evidence supports the 
interpretation that the A980C side chain is oriented away from TM6. 
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Figure 6.46: Crystal structures and MD simulations show A980 facing away from TM6. Panel 
A shows the 3G5U crystal structure of P-gp, Panel B shows a representative snapshot of the MD 
simulation based on 3G5U. The Van der Walls radii of atoms in the protein backbone are shown 
in silver. Van der Walls radii of side chains (excluding hydrogens in Panel A) of residues proximal 
to A980 are shown in the standard colouring by atom type. Panel C shows the 4M1M crystal 
structure of P-gp, Panel D shows a representative snapshot of the MD simulation based on 
4M1M. The Van der Walls radii of atoms in the protein backbone are shown in gold. Van der 
Walls radii of side chains (excluding hydrogens in Panel C) of residues in TM7 proximal to A980 
are shown in the standard colouring by atom type. Residues F343 and A980 are shown in purple, 
the distance measurement (Å) between the Cα atoms is shown in blue.  
A B 
C D 
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Crystal structures of murine P-gp show the side chain of residue A980 facing 
away from the central cavity and TM6 (Figure 6.46, panels A, C). MD simulations also 
predict the A980 residue faces away from the central cavity (Figure 6.46, panels B, D). 
The 4M1M simulation shows TM7 adopting a position between TM6 and TM12 (figure 
2, panel D), further preventing line of sight between A980 and TM6. The 3.8Å 
resolution of the murine structures of P-gp in the basal, inward facing conformation do 
not provide enough clarity to confidently assign side chain orientations. However, our 
findings combined with previous cross-linking analyses of TM6 & 12 (Loo and Clarke 
2001c, 2001a), suggest that the side chain orientations in the crystal structures and MD 
simulations at least approximately reflect the actual orientation of these side chains in 
human P-gp in a reconstituted bilayer, at least in the central portion of TM6 & 12. 
6.2.3 Conformational flexibility in TM6 & 12 
 
It is widely recognised that P-gp is a highly flexible protein (Wen et al. 2013; Loo and 
Clarke 2000). Small alterations in crystallisation conditions result in widely differing 
structures determined by X-ray crystallography, most notably the distance between 
NBDs has been observed to vary from 13Å (Aller et al. 2009) to 36Å (Ward et al. 
2013). MD simulations of P-gp show rapid and broad conformational changes in 
differing environments (O'Mara 2012) with inter-residue distances predicted to fluctuate 
by up to 11.4Å (4M1M) or 19.6 (3G5U) during simulations (3x100ns) of the crystal 
structures in a lipid bilayer (Section 3.1). The present investigation observed variability 
in inter-residues distance measurements, these indicate specific regions of the TM 
helices that display fixed conformation in the inward facing state and others that are 
subject to variability. 
 The most variable inter-residue distances were those which included residues in 
the intracellular portion of the helices (Figure 6.47). The most flexible inter-residue 
distance predicted, for the pairs measured, with the 4M1M MD simulation was between 
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A354 and F994 (Section 3.1). Both residues are located at the cytoplasmic leaflet of the 
membrane. Cross-linking and DEER measurements determined a broad distribution of 
inter-residue distance measurements for this double mutant (Figure 3.24). The other 
double mutants incorporating these residues in combination with residues in the central 
portion of TM6 or TM12 (343-994P-gp and 354-982P-gp), were amongst the most variable 
distances predicted by the 4M1M MD simulation (Section 3.1). The inter-residue 
distance determined by cross-linking between the extracellular leaflet of TM6 and the 
central portion of TM12 (354-982P-gp) was the most variable determined by this 
technique (Figure 3.23), while the DEER distribution was bimodal (Section 4.2). 
Results of measurements involving the corresponding residues in the centre of the 
membrane spanning portion of the helices, in other double mutants, demonstrate that the 
variability of cytoplasmic leaflet-central portion distances are not due to movement of 
the central portion of the helices. The one double mutant involving two residues in the 
central portion of the helices, for which an inter-residue distance was successfully 
determined (343-982P-gp) was predicted to have amongst the narrowest variability in the 
4M1M MD simulation (Section 3.1). Distance measurements by cross-linking and 
DEER showed relatively narrow distance distributions with this double mutant (Figure 
3.23). Therefore, the variability in distance measurements for 343-994P-gp and 354-982P-gp 
is due to manoeuvrability of intracellular leaflet residues A354C and F994C, not 
residues in the central portion of the helices (F343C and V982C). 
One double mutant (343-974P-gp) contained one residue in the central portion of TM6, 
and one in at the extracellular leaflet of TM12. While the 4M1M MD simulation 
predicted a stable inter-residue distance between F343 and V974, experimental 
measurements using 343-974P-gp produced conflicting results for both the distance and 
variability (Section 4.3). DEER determined an inter-thiol distance 14.9Å greater than 
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Figure 6.47: Comparative inter-residue distance flexibility predicted in the 4M1M MD 
simulation. The most variable inter-residue distance of the nine quantified in Section 3.1 was 
between A354 (TM6) and F994 (TM12) this is represented by the red arrow. The inter-residue 
distances F343 to F994 and A354 to V982 were also amongst the most variable, these are 
represented by orange arrows. The least variable distances of all nine measurements predicted 
were between F343 to V974, and F343 to V982 both of these are represented by green arrows. 
The structure shown is the 4M1M crystal structure. 
cross-linking, while the MD simulation average was between the two. This is likely due 
to differences in the two distance measurement techniques; DEER measurements are 
not subject to two key limitations of the cross-linking molecules. Firstly cross-
relaxation of spins does not require line-of-sight, so EPR can be used to measure 
distanced between residues that have side chains facing away from the other helix. 
Secondly DEER may be used to measure distances in excess of 60Å (Jeschke 2012; 
Jeschke and Polyhach 2007), whereas the longest cross-linker available is 22.1Å 
(Section 4.1). The broad distribution of the DEER Gaussian for 343-974P-gp suggests 
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there is variability in the inter-thiol distance. The disagreement between the results of 
cross-linking and DEER for this double mutant may occur because the 974C side chain 
is highly mobile, but primarily faces away from TM6. DEER detects the average of all 
inter-thiol distances, including those obtained when the 974C side chain is facing away 
from TM6. Cross-linking can only occur when it is facing toward TM6. This 
explanation reconciles the significantly longer DEER distance in comparison to cross-
linking. The MD simulation measures the Cα-Cα distance, which is the centre point of 
the side chain arc of rotation, so not susceptible to the variation of side chain orientation 
which leads to the variation in experimental measurements.  
The results suggest that, in line with the predictions in the 4M1M MD simulation, 
the intracellular portion of the protein is more flexible than the membrane spanning and 
extracellular portions in the basal state. This observation is also in agreement with 
previous results suggesting a highly variable inter-NBD distance (Verhalen et al. 2017; 
Ward et al. 2013; Wen et al. 2013), which would necessitate movement of the 
intracellular portion of the protein. Conversely, the 3G5U based MD simulation predicts 
a higher degree of variation in double mutants involving residues from the central 
portion of TM12 (Section 3.1), however experimental results do not reflect this. This 
shows that the 4M1M simulation provides a more accurate representation of the 
dynamic structure than the 3G5U based MD simulation. The present study thus 
identified MD simulations based on 4M1M as a good model for the structure, 
topography and flexibility of TM6 & 12, the role of these helices was subsequently 
explored. 
6.3 How do TM6 & 12 move during ATP hydrolysis and drug 
transport by P-gp? 
TM6 and TM12 have long been investigated for their role in inter-domain coupling 
because they are the direct connections between TMDs and NBDs, and therefore 
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thought to communicate drug-binding and ATP hydrolysis through conformational 
change (Loo and Clarke 1994a, 1997; Crowley et al. 2009; Rothnie et al. 2004). There 
is extensive evidence that the topography of both helices changes over the course of 
drug translocation, with certain residues exposed to hydrophobic or hydrophilic 
environments depending on the stage of ATP binding or hydrolysis (Crowley et al. 
2010; Storm et al. 2008; Rothnie et al. 2005). It has been demonstrated that certain 
residues in the helices move significantly relative to other parts of the protein (Verhalen 
et al. 2017), and that relative movement of TM6 and TM12 is required (Loo and Clarke 
1997). The recently published cryo-EM structures of human-mouse chimeric P-gp 
bound to two molecules of zosuquidar (Alam et al. 2018) and human P-gp in the 
outward-facing nucleotide bound state (Kim and Chen 2018) show that large changes in 
inter-residue distances between TM6 & TM12, in comparison to the basal state, occur 
only after dimerization of the NBDs (Figure 6.48). There is also evidence that pairs of 
residues in TM6 & 12 engage in different relative movements in response to the binding 
of different drugs (Loo, Bartlett, and Clarke 2003). The full range of conformational 
changes of P-gp is still not known, for example, whether the helices tilt or rotate (Loo 
and Clarke 2001a, 2002), and whether the whole of the helices are involved in 
movements required for basal and drug-stimulated ATPase activity. This study 
examined the relative movement of TM6 & 12, and the importance of this to the activity 
of P-gp, by measuring the effect of restricting parts of the helices to their basal 
orientation. 
This study may have provided more relevant information about the relative 
movement of TM6 and TM12, due to the different way in which this movement was 
restricted. The principal limitation of previous studies looking at the effect of restricting 
relative motion, is that they have all used the formation of direct cross-links by oxidants 
to link cysteine residues (Loo and Clarke 1996a, 1997; Loo, Bartlett, and Clarke 2010). 
As noted in Section 2.8, copper phenanthroline will cause the formation of direct cross-
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links if the thiol groups of two cysteines are sufficiently close. There is no alternative 
endpoint to this reaction, so complete cross-linking will be achieved eventually in a 
flexible protein even if the sufficiently short distance between cysteines is only 
transiently realised. P-gp is highly flexible (Ward et al. 2013; Wen et al. 2013), so the 
formation of cross-links by oxidants does not necessarily mean that such a short 
distance between cysteines is representative of the average structure. This in turn means 
that activity measurements may be being carried out on P-gp restricted to conformations 
not representative of the norm. In contrast, cross-linking with MTS reagents involves 
competition between the attachment of two cross-linkers individually, and formation of 
intramolecular cross-links, this allowed determination of which MTS reagent was most 
representative of the inter-residue distance in the basal conformation (Section 2.8). 
Thus, the ATPase activity measurements in Chapter 5 used P-gp which was trapped in a 
representative basal conformation, where previous investigations may not have done so. 
The location of the residues mutated to cysteine in the double mutants used in this study 
at a series of points furthermore made it possible determine which parts of the helices 
required relative movement. 
This investigation observed significant inhibition of drug stimulated and 
inherent basal activity, as a result of restricting relative movement in different parts of 
the helices. Basal and nicardipine-stimulated activity were affected by intramolecular 
cross-links involving the cytosolic portion of TM6 & 12 (Figure 5.42, blue arrows) 
suggesting that motion in this region is required in basal and drug-stimulated hydrolysis. 
Only nicardipine-stimulated activity was affected by cross-links in the central and 
extracellular portions of the membrane-spanning segments of the helices (Figure 5.42, 
orange arrows), suggesting that motion in this region is required in drug-stimulated 
hydrolysis, but not basal hydrolysis. This suggests that there are different 
conformational changes associated with basal and drug-stimulated hydrolysis. The 
region of the helices which has been demonstrated to be more mobile in the basal state 
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(Figure 6.47) overlaps with the region requiring relative movement in intrinsic ATPase 
activity (Figure 5.42, Chapter 5). On this basis it could be hypothesised that the 
flexibility observed in the basal state involves conformational transitions similar to 
those taking place during intrinsic hydrolysis. A different series of conformational 
transitions in basal and drug stimulated ATPase activity may also explain the different 
rates of hydrolysis under the two conditions. 
 Most attempts to measure or predict conformational or topographical change in 
P-gp during nucleotide hydrolysis have mimicked the nucleotide bound conformation 
using non-hydrolysable ATP analogues, but not drugs (Crowley et al. 2010; Storm et al. 
2008; O'Mara and Mark 2014; Prajapati and Sangamwar 2014; van Wonderen et al. 
2014; Rothnie et al. 2004). While some have looked at these conformational changes in 
the presence of verapamil (Verhalen et al. 2017; Loo and Clarke 1997) and the 
nucleotide bound structure was determined in the presence of vinblastine (Kim and 
Chen 2018), it is not certain that each drug will exert the same influence on 
conformational changes given the distinct binding sites of different substrates (Mittra et 
al. 2016) and the proposed induced fit mechanism of substrate recognition (Loo, 
Bartlett, and Clarke 2003; Martin, Berridge, Higgins, et al. 2000). Future studies should 
therefore investigate conformational changes in the presence of ATP analogues and 
various substrates, to explore the possibility of distinct modulator-induced pathways of 
conformational transition. 
The other notable finding from this investigation was that the ATPase activity of 
354-994P-gp was not affected by intramolecular cross-linking (Figure 5.42, green arrow). 
This was interpreted to show that the residues may be coming closer together, but are 
not moving further apart, as the MTS reagents are flexible and could bend to 
accommodate a decrease in inter-thiol distance, but not stretch to accommodate an 
increase (Green, Reisler, and Houk 2001). This interpretation matches best with the 
 179 
 
large conformational changes known to take place during NBD dimerization and ATP 
hydrolysis in ABC transporters (Dawson and Locher 2007; Ward et al. 2007; Verhalen 
et al. 2017; Rosenberg et al. 2003). A decrease in the distance between A354C and 
F994C is most likely in the context of the nucleotide bound structures of ABC 
transporters MsbA (Ward et al. 2007) and SAV1866 (Dawson and Locher 2007). This is 
the only inter-residue distance of the five analysed for effect of restriction of movement 
on ATPase activity to be at its highest span in the basal structure, in comparison to 
drug- and nucleotide-bound structures (Figure 6.48, Panel D). A 0.5Å decrease in 
A354C to F994C distance is seen in the 6FN1 structure of drug-bound P-gp, followed 
by a further 6.1Å decrease in the 6C0V structure of nucleotide bound human P-gp 
(Figure 4.5). A homology model of human P-gp based on the structure of SAV1866 
crystallised in the presence of ADP (2HYD), predicts a shorter distance between the 
central portion and extracellular ends of TM6 & 12 in comparison to the basal structure, 
while the intracellular portion appears not significantly altered in comparison to the 
basal state (Stockner et al. 2009). 
The observation that cross-linking in 354-994P-gp does not inhibit ATPase activity 
also favours the interpretation of TM tilting (Storm et al. 2008), rather than rotation 
(Loo and Clarke 2001a), during the translocation cycle. Rotation of the transmembrane 
helices has been offered as an explanation for the decrease in affinity for substrates after 
ATP binding, as different residue side chains are exposed to the internal cavity, thereby 
disrupting interactions with the substrate molecule (Martin, Higgins, and Callaghan 
2001). As explained in Section 6.1.1 intramolecular cross-linking requires line of sight 
between thiol groups, so these cross-links are more likely to occur when the side chains 
are facing roughly toward each other. If the side chains of 354-994P-gp are linked by an 
MTS molecule when facing toward each other in the basal state, but the conformational 
changes of the catalytic cycle required the helices to rotate, this would in turn require 
the distance between thiol groups to increase significantly. It
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     Inter-residue distance (Å) 
Residues Basal Drug-bound Nucleotide-bound 
343-974 25.6 27.0 23.0 
343-982 18.3 20.9 12.2 
343-994 17.1 18.5 18.6 
354-982 30.8 32.9 27.7 
354-994 21.3 20.8 14.7 
V974  V974  V974  
F343  F343  F343  
F994  F994  F994  
V982  
V982  
V982  
A354  A354  A354  
A  B  C 
D 
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would therefore be expected that the rate of ATP hydrolysis would be significantly 
depressed after intramolecular cross-linking if the helices are required to rotate, as the 
covalent linkage between A354C and F994C side chains would prevent these from 
rotating apart.  
The structures of drug- and nucleotide-bound P-gp (Figure 6.48) show the 
orientation of A354C and F994C side chains to be unchanged in comparison to the 
basal state, reflecting the interpretation of the present investigation. After nucleotide 
binding (Figure 6.48, Panel C) there appears to be a distortion of TM12 in the central 
portion of the membrane spanning region of the helix, characterised by a tighter angle 
of turn, causing this region and the extracellular end of the helix to rotate. This in turn 
appears to result in a change of orientation of side chains in the central and extracellular 
portions of TM12, in contrast to the intracellular portion. This matches exactly the 
depression in ATPase activity observed only when cross-linking the central and 
extracellular portions of TM6 & 12 (Chapter 5). However, given that 6FN1 and 6C0V 
Figure 6.48: Movement of TM6 and TM12 between basal, drug-bound and nucleotide-bound 
states, and the areas demonstrated to require movement for retention of activity. Panel A shows 
the basal orientation of TM6 and TM12 in the murine 4M1M crystal structure, in gold. Panel B 
shows the zosuquidar-bound orientation of TM6 & 12 in the human-mouse hybrid 6FN1 cryo-
EM structure, the protein is depicted in green while molecules of zosuquidar are depicted in 
grey.  Panel C shows the orientation of TM6 and TM12 in the nucleotide-bound conformation 
6C0V cryo-EM structure, in blue. Panel D tabulates Ca-Ca distances measured in VMD1.9.1 
using Basal (4M1M), Drug-bound (6FN1) and Nucleotide-bound (6C0V) PDB files. Cross-links 
leading to a decrease in nicardipine stimulation of ATPase activity (343-982P-gp and 343-974P-gp) 
are shown in orange.  Cross-links leading to a decrease in basal and stimulated ATPase activity, 
but not the degree of stimulation, (354-982P-gp and 343-994P-gp) are shown in blue. The cross-link 
which did not affect ATPase activity (354-994P-gp) is shown in green. Residues mutated to cysteine 
in this study are shown in Van der Walls radii, the residues cross-linked are labelled with hP-gp 
equivalent residue numbers. 
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structures are resolved to 3.6 Å and 3.4 Å respectively it is not possible to be confident 
in these side-chain orientations. The observed pattern of effects on nicardipine-
stimulated ATPase activity after intramolecular cross-linking, combined with the drug- 
and nucleotide-bound structures indicate that the intracellular portions of TM6 & 12 
approach via tilting but do not rotate during translocation, while the central and 
extracellular portions rotate after nucleotide binding.  
In summary, the measurements of P-gp activity after restricting relative 
movement between TM6 & 12 concurred with the conclusions of previous 
investigations that there is relative movement between these helices, and that it is 
required for the proper functioning of the transporter. Furthermore, the areas of the 
helices requiring movement converged well with changes seen in the recently published 
zosuquidar- and nucleotide-bound P-gp structures; this was interpreted to suggest that 
the helices tilt and rotate in different areas. This investigation is the first to make the 
additional observation that parts of the helices requiring relative movement differed 
between basal and drug-stimulated hydrolysis, suggesting that there may be distinct 
types of conformational changes associated with basal and drug-stimulated hydrolysis.   
6.4	Conclusions	
Cross-linking and DEER have provided a detailed map of orientation, accessibility and 
flexibility of P-gp coupling helices. Areas of controversy were addressed around the use 
of homobifunctional cross-linking molecules; the novel strategy of interpretation and 
data analysis employed in this study yielded results consistent with DEER. The results 
of empirical measurements with reconstituted human P-gp show that previous models 
using crystallographic data from murine P-gp and MD simulations are a good 
representation of human P-gp in a bilayer. This finding, particularly the evidence 
suggesting the current models accurately predict side chain orientation, suggests that the 
current models are a good tool for in-silico prediction of P-gp interaction with drugs, an 
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area of significant research interest in recent years (Dolghih et al. 2011; Prajapati et al. 
2013; Chen et al. 2012; Poongavanam, Haider, and Ecker 2012; Bikadi et al. 2011; 
Subramanian, Condic-Jurkic, and O'Mara 2016) (Section 1.4.3). The structure of P-gp 
was also observed to be highly flexible outside of the membrane embedded portion of 
the helices, providing a likely explanation for the difficulty of crystallising human P-gp 
to high resolution. There are now a large variety of structure models for P-gp from 
different organisms and in different conformational states, but in human P-gp variability 
is constant.   
Investigation of the effects of covalent modification of TM6 & 12 on the activity 
of P-gp has given further evidence of their critical role in transmitting conformational 
change between TMDs and /NBDs. Additionally, the results indicate that the processes 
of basal and drug stimulated ATP hydrolysis involve different conformational changes. 
One way to frame the conclusion of this study of P-gp structure and mechanism 
therefore, is that MD simulations based on 4M1M are an accurate representation of a 
highly variable structure, and the molecular mechanism of P-gp also varies to suit 
conditions. 
6.5	Future	Directions	
 
A molecular mechanism for P-gp transport must explain how TM6 & 12 communicate 
events at the NBDs into conformational change at the TMDs. The basal state orientation 
of the coupling helices determined in this investigation is a key structural detail for 
human P-gp, and a starting point for determining their role in the molecular mechanism. 
Future investigations must elucidate how these helices move over the entire course of 
the translocation cycle, and how changes in the transmembrane regions of these helices 
is transmitted to the intracellular portions and finally the NBDs. This could be achieved 
by repeating the measurements done in this study, after trapping the protein in the ATP 
bound and post-hydrolytic states. Other investigations have shown extensive evidence 
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for the major structural transitions between these points in the translocation cycle 
(Dawson and Locher 2007; O'Mara and Mark 2014; Rosenberg et al. 2001; Loo and 
Clarke 2002; van Wonderen et al. 2014). Measurements on the less well understood 
post-hydrolytic state could show the extent of the conformational changes following 
ATP hydrolysis. There is particular importance in understanding the post-hydrolytic 
state as dinucleotide release is understood to be the rate limiting step in the transport 
process (Callaghan, Ford, and Kerr 2006).  
Another question this experimental strategy could be used to answer is: how can P-
gp bind so many drugs? Most evidence suggests a variety of sites operating via an 
induced-fit mechanism, but as yet the specific conformational changes in the TMDs 
have not been determined (Loo, Bartlett, and Clarke 2003; Dolghih et al. 2011). Cross-
linking and DEER could be used to measure changes in distance between specific points 
in the internal cavity in response to the binding of different drugs. Alongside 
investigations of the specific residues involved in the binding of different drugs, 
knowing how these residues move to form high affinity interactions with substrates will 
in the future allow accurate in-silico screening of therapeutic candidates, so that the next 
generation of anti-cancer drugs evade P-gp mediated MDR.  
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